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Preface 
FDI plays crucial role in bridging the gap between capital required and capital 
available domestically. It has played a significant role in shaping Indian economy 
since the first half of the decades of I980's. Globalization has further emphasized the 
need of FDI in different sectors of the economy to fall in line with the global 
production standards. Most of the countries of the world have evolved their economic 
policies to attract foreign investors creating further pressure for the economy in India. 
Basically. FDI plays multidimensional role in the overall development of the host 
country. It may generate benefits through bringing non-debt creating foreign capital 
resources, technology up-gradation, skill enhancement, new employment, spillovers 
and allocative efficiency effects. It plays a complementary role in over all capital 
formation and filling the gap between domestic saving and investment. At the macro 
level it is a non-debt creating source of additional external finances. At the micro 
level it is expected to boost output, technology, skill level, employment and linkages 
with other sectors and the regions of the host economy. There are also costs and 
benefits for the countries involved both the investing country and the host country. 
There is a fundamental disagreement on what constitutes the costs and benefits of FDI 
from the perspectives of the two countries. This disagreement is indicated by the big 
gap between those holding pro-globalization and those with anti-globalization, views. 
Moreover, sharing the gains of welfare between the host country and the home 
country depends not only on given market scenario, but also on the relative strength 
of the two countries in bargaining over the terms and conditions governing a 
particular FDI project. It is not necessarily an optimal market condition that one 
country's gains must be accompanied by other country's loss. 
Kindleberger (1969) argues that the relationship arising from the FDI process is not a 
`zero-sum game'. For an effective FDI both countries must believe that the expected 
benefits to them must be greater than the costs. Such a trust and confidence are the 
essence of an agreement to be reached to initiate the understanding projects. Of 
course, such an assessment is in its ex-ante sense that often leads to a departure in the 
ex-post torn. This gives the foundation of the present study that tbcuses on the FDI in 
Indian Pharmaceutical Industry. 
v 
Pharmaceutical industry has universally emerged an important driver in the economy 
and this is a `life-line' industry. The importance of this sector is that its products can 
neither be substituted nor replaced. In fact, India is one of few developing countries 
which have comparative advantages in this sector. Pharmaceutical industry currently. 
accounts for nearly 2% of the GDP and 12% of India's manufacturing sector and is a 
leading export sector. The Indian Pharmaceutical Industry today is in the front rank of 
India's science-based industries with wide ranging capabilities in the complex field of 
drug manufacture and technology. It ranks very high in the third world, in terns of 
technology, quality and range of medicines manufactured. Indian pharmaceutical 
sector produces the entire range of medicines from simple headache pills to 
sophisticated antibiotics and complex cardiac compounds; almost every type of 
medicine is now made indigenously. In terms of trade balance it is the only Indian 
sector after apparels that have consistently given positive trade balance and is growing 
around 1.5 to 1.6 times of the country's GDP growth rate and is known as recession 
tree sector. Presently, 70 percent domestic requirement in bulk drugs and almost all 
the demands for formulations are met. Coping well with the rapid changes in this 
sector the world over, the Indian Phannaceutical Industry has done well in the last 
few decades. 
The study has dealt with the role of FDI in pharmaceutical industry for the period 
from 1991-2008. Performances and appraisals of pharmaceutical industry have been 
done in terms of trends in production, investment, profit, export and employment. The 
same parameters have been taken to explore the nature of interrelation between the 
FDIs vis-a-vis trends in production, investment profit, export and employment of 
pharmaceutical sector in India. 
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Introductory Background and Theoretical Approach of the Study 
1.1 	Introduction: 
Most of the present day developing countries of the world have set out a planned 
programme for accelerating the pace of their economic development. In any country 
planning for industrialization and aiming to accomplish a target rate of growth there is 
need for resources. The resources can be mobilized through domestic as well as 
foreign sources. As far as the domestic sources are concerned, they may not be 
sufficient to acquire a certain rate of growth. Generally domestic saving is less than 
the required amount of investment. Besides the very process of industrialization calls 
for import of capital goods which cannot be locally produced. So, there comes the 
need for foreign resources. They not only supplement the domestic saving but also 
provide the host country t with extra foreign exchange to import essentials for 
economic development. Thus foreign resources are craved for filling the saving 
investment gap and foreign exchange gap. They are available to developing countries 
in mainly three types. 
1. Export of goods and services 
2. External aid 
3. Foreign investment 
Export of goods and services contribute to foreign exchange but they can rneet only a 
small fraction of' the total demand for foreign resources. 
External aid from foreign governments and international institution by increasing the 
rate of home savings and removing the foreign exchange gap permits the utilization of 
previously underutilized resources and capacity. But generally aid is tied and distorts 
the allocation of resources. Therefore its use has been on the decline. 
The third type of foreign resources is foreign investment which is of two types. 
1. Foreign Portfolio Investment (FPI) 
2. Foreign Direct Investment (FDI) 
Foreign Portfolio Investment involves (a) purchase of existing bonds and stocks with 
the sole objective of obtaining dividends or capital gains and (h) investment in new 
1 Host country refers to a country that receives an inflow of FD1 while I tome country refers to a 
country that tZenerates an out flow of FI)t. 
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issues of international bonds and debentures by the financial institution or foreign 
government. 
The FDI is an Investment that involves a long term relationship and control by a 
resident entity of one country. in a firm located in a country other than that of the 
investing firm.FDI is assumed to take place when an investor has acquired 100o  or 
more of the voting power of a firm located in a foreign economy (IMF. 2004). 
1.2 	Foreign Direct Investment: 
There is no specific definition of FDI owing to the presence of many authorities like 
OECD, IBRD, IMF and UNCTAD. All these bodies try to illustrate the nature of FDI 
with certain measuring methodologies. Generally speaking FDI refers to capital flows 
from abroad that invest in the production capacity of the economy and are usually 
preferred over other forms of external finance because they are non-debt creating, 
non-volatile and their returns depends on the performance of the projects financed by 
the investors. EDI also facilitates international trade and transfer of knowledge, skills 
and technology. It is also described as a source of economic development, 
modernisation and employment generation, whereby the over all benefits triggers 
technology spillovers, assists in human capital formation, contributes to international 
integration and particularly exports, helps to create a more competitive business 
environment, enhances enterprise development, increases total factor productivity and 
improves efficiency of resource use. Hence, FDI means the transfer of financial 
capital, technology and other skills like managerial, marketing and accounting 
expertise and practices. This relates costs and benefits for the countries involved both 
the home country and the host country. 
Considerable attempts have been made to assess as to what costs are borne and what 
benefits are enjoyed by the two countries. There is even fundamental disagreement on 
what constitutes the costs and benefits of FDI from the perspectives of the two 
countries. This disagreement is indicated by the big gap between those holding free 
market views and those with anti-globalization. Sharing: of the welfare gains between 
the host country and the home country depends not only on given market scenario but 
also on the relative strength of the two countries in bargaining over the terms and 
conditions governing a particular FDI project. It is not necessarily an optimal market 
condition that one country's gain must be accompanied with other country's loss. For 
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an effective FDI both countries must believe that the expected benefits to them must 
be greater than the costs. Such trusts are the essence of an agreement to be reached to 
initiate the underlying project. 
1.3 	Benefits of Foreign Direct Investment: 
One of the advantages of FDI is that it helps in the economic development of the 
particular country where the investment is being made. This is especially applicable 
for the economically developing countries. During the decade of the 1990s FDI was 
one of the major external sources of financing for most of the countries that were 
growing from an economic perspective. It has also been observed that FDI has helped 
several nations when they have faced economic hardships. 
An instance of this could be seen in some countries of the East Asian region. It was 
observed that during the global financial crises of 1997-98 (in East Asian countries) 
the amount of FDI made in these countries was pretty steady, though the other forms 
of cash inflows like debt flows and portfolio equity had suffered major setbacks. 
Similar observations have been made in Latin America in the 1980s and in Mexico in 
1994-95. 
FDI also permits the transfer of technologies. This is done basically in the way of 
provision of capital inputs. The importance of this factor lies in the fact that this 
transfer of technologies cannot be accomplished by way of trading of goods and 
services as well as investment of financial resources. It also assists in the promotion 
of the competition within the local input market of a country. It can also bring in 
advanced technology and skill set in a country. There is also some scope for new 
research activities being undertaken. 
Inflow of FDI also helps in the development of human capital resources through 
training on the operations of a particular business. The profits that are then generated 
can be used for the purpose of making contributions to the revenues of corporate taxes 
of the recipient country. 
Besides all this the other major advantages of FDI are that it helps in the creation of 
new jobs in a particular country, thereby increasing the salaries of' the workers. This 
enables them to get access to a better lifestyle and more facilities in life. 
FDI assists in increasing the income that is generated through revenues realized by 
taxation. due to the development of the manufacturing sector of the recipient country. 
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It also plays an essential role in the context of rise in the productivity of the host 
countries. Their companies get an opportunity to explore newer markets through 
exports that allows them to cash in on their superior technological resources, and 
thereby generate more income and profits. It has also been observed that as a result of 
receiving FDI. the recipient countries can keep their rates of interest at a lower level, 
thus enabling the business entities to borrow finance at lesser rates of interest. The 
biggest beneficiaries of these facilities are the small and medium-sized business 
enterprises. 
However, little evidence is available on the impact of FDI on the rural economy and 
on the poverty. But FDI inflows are associated with higher economic growth, which is 
critically important for poverty reduction. Besides FDI indirectly benefits poor by 
creating better employment and earning opportunities for unskilled labour in the 
developing countries like India. 
1.4 	Costs of Foreign Direct Investment: 
Recent years have seen increased public concern that the benefits of FDI have yet to 
be demonstrated and that, where it exists, they may not be shared equitably in the 
society. The cost of FDI occurs mostly in case of matters related to operation, 
distribution of the profits made on the investment and the personnel. 
The situations in countries like Ireland, Singapore, Chile and China corroborate such 
an opinion. It is normally the responsibility of the host country to limit the extent of 
impact that may be made by the FDI. They should be making sure that the entities that 
are making the FDI in their country adhere to the environmental, governance and 
social regulations that have been laid down in the country. The various cost of FDI is 
understood the most in matters of strategic importance like national security and 
defence. 
It has been observed that certain foreign policies are adopted that are not appreciated 
by the workers of the recipient country. FDI is also disadvantageous for the ones who 
are making the investment themselves. FDI may entail high travel and 
communications expenses. The differences of language and culture that exist between 
the country of the investor and the host country could also pose problems in case of 
FDI. Besides that there is considerable instability in a particular geographical region. 
This causes a lot of problem to the investor. 
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Another. major disadvantage of FDI is that there is a chance that a company may lose 
out on its ownership to an overseas company. This has often caused many companies 
to approach FDI with a certain amount of caution. 
The size of the market, as well as, the condition of the host country also influences the 
FD[. In case the host country does not have good bilateral relations with their more 
advanced neighbours, it poses a lot of challenge for the investors. The government of 
the host country also faces problems over the control of those companies that are 
functioning as the wholly owned subsidiary of an overseas company. This leads to 
serious issues since investor is not completely obedient to the economic policies of 
the country where they have invested the money. At times there have been adverse 
effects of FDI on the balance of payments (BOPs) of a country. As more foreign 
investors invest in the country, the demand for domestic currency rises. Consequently 
the value of domestic currency appreciates. Appreciation of domestic currency causes 
loss of competitiveness of exports as they become costlier. Cheaper imports and 
costly exports further add to current account deficit in BOP. 
1.5 	Economic, Political and Social Effects of Foreign Direct Investment: 
The controversy of expectation and realization would not have taken place if the host 
country had achieved what the classical economist suggested with relation to the 
effects of FDI. They pioneered the positive theories of FDI that stipulates that FDI 
flows are in consequences of mobility of capital towards profit maximization. Since in 
most cases the host countries lack capital which is essential factor of production, such 
inflows are desirable from the point of global efficiency. It is further complemented 
by the surplus and cheap labour that most of these host countries often enjoy, which 
serves the condition of cost minimization vis-a-vis profit maximization. This is the 
argument of classical economists that suffers from over simplification. Market is not 
perfect in nature. the varieties of imperfections are so much that the MNFs 
(Multinational Firms) are able to exploit the host country without their knowledge and 
forcing the host country to adopt protectionist approach. Such worries sometime lead 
to over protectionism. This is a departure from the classical proposition and quite 
often utilised by the multinationals to he even more aggressive. They take their 
protection as well by means of further manipulation of market imperfections in the 
form of transfer pricing, shadow pricing, dumping, monopolistic competitions. At the 
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end, there are welfare losses on the part of host countries in the form of departure 
from efficiency optimality and constant return to scale. Quite often the multinationals 
are encompassed world-wide and have accumulated so much wealth that it become a 
real threat to the stability of the host country. These are often categorized as the 
economic effects of FDI. There are political effects as well which are not really 
isolated from the economic effects. Sovereignty of host countries can be at stake in 
case of taking very protective policies. Instances are there that political government 
had been over thrown while taking nationalization policies of FDIs. The modern 
system of FDI contributing to different political parties of the host countries does 
have political implications as well. These are the political parties having the 
potentials of making governments in future. The social issues are mainly concerned 
with the creation of enclaves and foreign elite in the host country as well as the 
cultural effects on the local population i.e. custom and tastes. Naturally social issues 
are more likely to arise when there are significant economic, social and cultural 
differences between the home and host countries. 
The economic effects of FDI can be classified into macro and micro effects. The usual 
convention in analyzing the macro effects of FDI is to treat it as a rise in foreign 
borrowing if there is unemployment and capital shortage (as it is typically the case in 
developing countries). Such borrowing leads to a rise in output and income in the host 
country. Under these conditions FDI will have a beneficial effect on balance of 
payments but an uncertain effect on the terms of trade (depending on whether the 
impact of increased output falls on imports substitutes or exports). The micro effects 
of FDI concerns structural changes in the economic and industrial organization. For 
example an important issue is whether FDI is contributive to the creation of a non 
competitive environment or conversely to a worsening of the monopolistic or 
oligopolistic elements in the host country. In general the micro effects concern 
individual firms and individual industries. Particularly those that are closely 
associated and exposed to FDI 
Like the theories of FDI there is significant over lapping in the discussion of these 
effects. Like. the provision of capital as performed by FDI overlaps significantly with 
the effect on the balance of payments and the effect on output. Moreover technology 
is believed to be the main channel through which FDI affects growth and productivity. 
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During the past few decades the activities of `MNFs have grown at a phenomenal rate. 
The MNFs perform their business activities which can be broadly classified as direct 
investment including FDI, technology transfer, Mergers and Acquisitions. 
Collaborations, Joint Ventures 10O°'0 subsidiaries and marketing of' financial services. 
However, their main instrumentality of business is primarily through FDI. The 
significance of FDI in the world economy is much less controversial than its influence 
on economic growth, although an overwhelming majority of country's economic now 
explicitly regard FDI as an integral and crucial part of their growth strategy. 
Since India's economic liberalization in the 1990's the role of FDI in the growth and 
development of the developing countries is ever greater and significant. The origin of 
World Trade Organization (WTO) in January 1995 has further given boost these 
economies to go in a long way for more FDI in a varieties of arrangement such as 
joint ventures, technological collaboration etc. 
1.6 	Foreign Direct Investment and Economic Development: 
It has been observed that the economically developing as well as underdeveloped 
countries is dependent on the economically developed countries for financial 
assistance that would help them to achieve some amount of economical stability. 
The economically developed countries, on their part, can assist these countries 
financially by investing in these countries. This financial assistance can be 
channelized into various sectors of the economy. The channelization is normally done 
on the basis of the requirements of particular sectors. 
FDI has a major role to play in the economic development of the host country. Over 
the years. FDI has helped the economies of the host countries to obtain a launching 
pad from where they can make further improvements. This trend has manifested itself 
in the last seventeen years. Any form of FDI pumps in a lot of capital resources and 
technological knowledge into the economy of a country. 
'['his helps in taking the particular host economy ahead. The fact that the foreign direct 
investors have been able to play a significant role vis-a-vis the economic development 
of the recipient countries has been due to the fact that these countries have changed 
their economic stances and have allowed the foreign direct investors to come in and 
improve their economies. 
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It has been observed that the FDI has been able to improve the infrastructural 
condition of a country. Besides that the private sector companies are not always 
interested in undertaking activities that help in improving the infrastructure of the 
country. This is because the gains from these infrastructural activities are made only 
in the long term; there are no short term benefits as such. So as infrastructural sector 
is one of the most crucial and capital intensive sector but due to insufficiency of 
domestic capital FDI play an important role. 
It can also assist in helping economically underdeveloped countries build their own 
research and development bases that can contribute to the technological development 
of the country. This is a very crucial contribution as most of these countries are not 
able to perlbrm these functions on their own. These assistances come in handy, 
especially in the context of the manufacturing and services sector of the particular 
country, that are able to increase their productivity and ultimately advance from an 
economic point of view. The health sector of many a recipient country has been 
benefited by the FDI through availability of financial and technological and marketing 
skills. 
Besides infusion of capital FDI could also be provided in the form of technology. This 
is an indirect way in which FDI plays an important part in the context of economic 
development. Another important contribution of FDI is in the field of educational 
sector. It can help in assisting the host countries to set up mass educational programs 
that help them to educate the disadvantaged sections of the society. Such assistance is 
often provided by the non-governmental organizations in the form of subsidies. 
The standard of living of the general public of the host country could be improved as 
a result of the FDI made in a country. Thus it may be said that it plays an important 
role in the overall economic and social development of a country. 
1.7 	Effects of Foreign Direct Investment: Theories and Approaches: 
The significance of FDI is being recognized globally since it has accelerated 
remarkably in the last decades and many of the major corporations of most developed 
countries have taken their production of goods and services to many diverse parts of 
the world. Investments are more often to take place where locational and comparative 
advantages are present and FDI is usually concentrated in the regions where the 
industry in question will perform most efficiently. In order to compete in foreign 
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markets, multinational MNCs (Multinational Corporations) take advantage of their 
firm-specific resources, such as technological and marketing skill (Blomstrom & 
Kokkv,1997) 
There are several reasons for a firm to undertake FDI. It can be market- seeking 
(horizontal) or resource- seeking (vertical) FDI. Market- seeking FDI takes place when 
a MNC invests because of domestic market size, prospects for market growth, 
transportation costs and the need to be close to potential customers. Resource- seeking 
FDI seeks comparative advantages such as access to raw material, cheap input and low 
cost of labour. 
To analyze the determinants and effects of FDI a large number of studies have been 
conducted till now. In a land mark study, Agarwal (1980) examined the different 
aspects pertaining to FDI theories under perfect market conditions. The study used 
different variables such as differential rate of return, the portfolio diversification and 
the market size. He also examined the theories under imperfect market conditions. 
Similar kind of discussion has also been organized in other alternative ways. For 
example Boddcwyn (1985) souped the theories according to conditions and 
participating circumstances for FDI. Kojima and Ozawa (1984) differentiated between 
micro and macro model of FDI. The following theories pertaining to FDI have been 
critically appreciated. 
1.7.1 Theories of Foreign Direct Investment under Perfect Market Condition: 
1. Differential Rate of Return 
2, Portfolio Diversification Theory 
3. Output and Market Size Approach 
According to the differential rate of return approach, FDI is the result of capital 
flowing from the countries having higher returns. the evaluation of investment 
decisions is done by comparing the marginal return with the marginal cost of capital. 
If the marginal return is higher in other countries than at home and assuming that the 
marginal cost of capital is the same for both types of investment then the investment 
decision will be in favour of other countries rather than home country. In the late 
1950's this theory gained popularity when the FDI in manufacturing sector from USA 
increased sharply in F.urope. At that time after tax fate of returns of US subsidiaries in 
manufacturing were above the rate of return on US domestic manufacturing. 
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However, this relationship did not last long. During the 1960's US FDI in Europe 
continued to rise oven when the rate of return were high in domestic manufacturing 
(Hufbaur. 1975). These hypotheses have been tested in many ways. Some authors 
even tried to find a positive relationship between the ratios of firm's FDI to its 
domestic investment and the ratio of its foreign profits to its domestic profits. Others 
tried to relate FDI and the rate of foreign profits usually after allowing for a certain 
time lag. Another approach was to examine the relationship between relative rates of 
return in several countries and the allocation of FDI in these countries (Lizondo, 
1991). 
Agarwal (1980) argued on the validity of these empirical studies as it did not provide 
strong supportive evidence mainly due to difficulties in measuring anticipated profits. 
In most cases reported profits were used to represent anticipated profits. However 
reported profit may differ from the anticipated profits. Besides it does not explain 
some aspects of FDL Since this theory argues that capital flows from countries with 
low rate of return to countries with high rates of return which is assumed implicitly 
that there is a single rate of return with in a country. Thus the theory failed to explain 
why there are some countries experiencing simultaneous inflows and outflows of 
FDIs. Thus the theory of differential rates of return failed to explain the determinants 
of FDI flows. 
The theory of portfolio diversification provides a useful foundation for explaining the 
nature and causes of FIN flows. It emphasized that the role of risk in choosing among 
the various available projects should also be taken into consideration. FDI across 
countries takes place due to the goals of risk diversification. Hence FDI decisions are 
guided by assessment of anticipated returns and risk diversification. This follows the 
theory of portfolio diversification of not putting all the eggs in the same basket. It has 
been seen empirically that some of the highly profitable MNCs concentrates in few 
regions rather than going for wider diversification. This contradicts the theory of 
diversification. The theory however is an improvement over the differential rates of 
return theory because of the inclusion of risk factor. Of course an individual investor 
can reduce risk even by means of making his own portfolio diversified rather than the 
firm itself goes for diversification. The other point that remains unexplained by this 
theory is that it does not explain about the concentration of FDI in some industries 
than in others. 
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The `output approach' takes into consideration the variable of output (sales), while the 
market size approach considers the host country's Gross Domestic Product or Gross 
National Product as the proxy for sales potential. The relevance of output for FDI can 
be derived from the neo-classical model of domestic investment theory whereas the 
relevance of host country's market size has generally been postulated rather than 
derived from a theoretical model. Despite the lack of explicit empirical backing the 
market size model has been very popular and a variable representing the size of the 
host country appears in a large number of empirical studies. 
1.7.2 Theories of Foreign Direct Investment under Imperfect Market 
Condition: 
Theories under imperfect market condition are reviewed as follows: 
1. Industrial organization. 
2. Internalization theory. 
3. Product cycle theory. 
4. Eclectic or OU theory. 
5. Oligopolistic Reaction Theory. 
6. New Trade Theory. 
Rymer (1976) was the first researcher who pointed out that the structure of market 
and the specific characteristics of firm play an important role in explaining the FDI. 
He advocated that the existence of MNFs depends on market imperfections. 'there are 
two important types of market imperfections namely structural imperfections and 
transaction cost imperfections. Structural imperfections help the MNF in increasing 
its market strength through economies of scale, advantages of knowledge, distribution 
network, product diversification and credit advantages. While the transaction cost 
imperfection makes profit for the MNFs to substitute on internal market for external 
transactions. The study of structural imperfections led to the industrial organization 
theory of FDI whereas the study of transaction cost gave rise to the internalization 
theory of FDI (Graham & Krugman, 1989). The Industrial organization theory argues 
that a MNF faces a number of disadvantages in case of competition with domestic 
firms. These difficulties include the problems of managing operations, dealing with 
different cultures, legal system, languages, customer preferences. technological 
standards etc. Despite these disadvantage a MNF enjoy some firm specific advantages 
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with respect to domestic firms. The merits of MNF are their brand name, patent, 
protected superior technology, marketing managerial skills, cheaper sources of 
financing, preferential access to market and economics of scale. However, it is 
observed that the industrial organization theory is not complete as it did not explain as 
to why the competition must take the form of FDI. 
The Internalization theory (Buckeye & Casson, 1976) states that the existence of FDI 
as a result of firms replacing market transaction with tormal transactions. This is a 
way of avoiding market imperfection for intermediates inputs. Modem business 
follows many activities in addition to the daily activities of producing goods and 
services. These other activities include marketing, R & D and training of labour which 
are related with the flow of intermediate goods mostly in the form of knowledge and 
expertise. However the market imperfections make it difficult to price some of the 
intermediate goods (Coase, 1937). The main characteristics of this theory is treating 
markets on the one hand and firms on the other as alternative modes of organizing 
production. The internalization of markets beyond national boundaries leads to the 
formation of MNFs which result in FDI. This process continues till the equalization of 
costs and benefit from internalization is complete. This is also known as general 
theory of FDI. Ruwnan (1980) opines that most of the hypotheses for FDI are the 
particular cases of the internalization theory. The theories of imperfect condition arc 
attributed to three basic elements i.e. industrialization in a country, internalization in a 
country and presence of location factor. The central theme of this theory is that FDI 
would be attracted by favourable supply conditions which have their origin in those 
factors underlying industrialization, internalization and location. It does not call into 
question the demand conditions for an integrated plan of FDIs. 
Vernon (1966) introduced the product cycle theory to explain the nature and causes of 
FDI. According to this theory direct foreign investment is a natural and climatic stage 
in the life cycle of a new product introduced to the market by oligopolistic firms. The 
product first appears as innovations and ultimately become completely standardized. 
Innovation can be the result of reacting with more severe competition or can be 
outcome of exploiting new profit opportunity. Vernon's theory viewed "direct foreign 
investment as diffusive mechanism or solution to the problem of intensifying 
competition at both home and abroad. The perfect example illustrating the Vernon's 
theory is the manufacturing of electronics. 
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The Eclectic theory of FDI also known as the Ownership Location and Internalization 
(OLI) paradigm of FDI was first propounded by Dunning (1977, 1979, and 1988) 
which combined three theories of FDI namely industrial organizational theory, 
location theory and internalization theory. According to him three conditions must be 
satisfied if a firm wants to be a MNF. Firstly, the firm must have some ownership 
advantages with respect to other firms. Secondly, it should have other advantages like 
sell or lease to other firms. Lastly, the firm must be more beneficial to use these 
advantages with some inputs located in other countries. It also postulates that 
advantages of this theory are not likely to be uniform since all countries, industries, 
enterprises and are likely to change over a period of time. However, the Eclectic 
theory does not consider the risks associated with the trade groupings, floating 
exchange rate and the super structure of global credit system (Dunning, 1979). 
Knickerbocker (1973) gave the `Oligopolistic Reaction theory'. This theory explained 
that the FDI by one firm will lead to propogate the other tines to do the same in order 
to maintain their market share (Graham, 1978). In this perspective Hufaur (1975) 
contradicted that "due to increased industrial concentration, the competitors compete 
among themselves to achieve cost or marketing advantages over each other. But this 
increases in industrial concentration between different products of MNFs with their 
expenditure on R&D. An important implication of this theory is that the process of 
FDI by MNFs in self limiting due to increased concentration in home and other 
market the competition will increase amongst them and this will reduce the intensity 
of Oligopolistic reaction. A major criticism of this theory is that it does not recognize 
FDI as one of the several methods of foreign investment and it has also failed to give 
reasons for the start of foreign investment process. 
Helpman and Krugman (1985) developed the `new trade theory of FDI in response to 
the failure of classical trade theories of incorporating concepts observed in actual 
flows of international trade such as intra-industry trade. The new trade theories 
contributed by constructing general equilibrium trade models which could include 
increasing return to scale. imperfect competition and product differentiation. The 
main assumption in these theories was about single plant national firms, which limited 
the usefulness of these models explaining FDI. But the earlier trade theory failed to 
incorporate together MNCs and FDI. However during the eighties and nineties, 
Markusen (1995) and other researchers modified the new trade models to allow for 
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inclusion of MNCs and FDI. An important contribution of new trade theory models 
incorporating MNCs is that they can be used to analyze a firm's decision between FDI 
and exports. The decision between foreign production and exports revolves around the 
"Proximity concentration trade-off', where MNCs compare trade costs to the costs of 
producing at several locations. The proximity concentration trade off' has resulted in 
the idea of two primary forms of FDI, i.e. horizontal and vertical. 
The above discussions dealt with some important theories related to the nature and 
causes of FDI flows in the world. An attempt has been made here to concentrate on 
the nature of FDI flows in India. 
1.8 	Locational Factors that Influence Foreign Direct Investment Inflows in 
India: 
1. Market Size: 
Market size is one of the most important considerations in making investment 
locational decisions. The attractiveness of large market is related to large potential for 
local sales, because domestic sales are more profitable then exports especially in 
larger countries such as India where economies of scale can be eventually reaped. 
Also such countries offer more diverse resources which make local sourcing more 
flexible, India is one of the largest markets with a huge growing affluent middle class 
(300 million). According to IMF (2011) in terms of Purchasing Power Parity India 
ranked the third largest in the world, with a gross domestic product of US $ 4.46 
trillion while in USD exchange-rate terms, it is the 13Lh largest in the world, with a 
GDP of US $ 800.8 billion. Furthermore. India is the second fastest growing major 
economy in the world, with a GDP growth rate of 9.2% at the end of the first quarter 
of 2007- 2008. The higher GDP, the better is the country's economic health and better 
is the prospects that the direct investment will be profitable. Hence GDP has a 
positive influence on direct investment from abroad. 
2. Economic Stability of the Country: 
Monetary and fiscal policies determine the parameters of economic stability such as 
the interest rates, tax rates and the state of external and budgetary balances which 
influences the investment rates, as described below: 
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a) Interest rates: 
Interest rates affect the cost of capital in a host country, directly affecting one of the 
determinants of the investment decision. The effects of interest rates on FDI are 
smaller than on domestic investment because MNCs normally have a greater choice 
of sources of financing. It was 4.25 percent in the year 2009. 
b) Level of External Indebtedness: 
It is expected to have a negative impact on FN inflows. The level of indebtedness 
shows the burden of repayment and debt servicing on the economy thus making the 
country less attractive for foreign investor. India's external debt stood at US$221.2 
billion in 2008 which was 18.8 percent of GDP (Economic survey 2007-08). 
c) Debt Service Ratio: 
This is represented by total debt service as a percentage of total income of the 
country. The higher this ratio, the higher will be the burden of the country to service 
the debt out of the income of the country. '[he FDI inflows are expected to increase 
with a small debt service ratio. Thus this variable is having negative correlation with 
FDI in flows. It was 4.4 percent in the year 2008 (Economic survey 2009-10:143). 
d) Foreign Exchange Reserves: 
The higher the level of foreign exchange reserves (FERs) in terms of import cover 
reflects the strength of external payments position and helps to improve the 
confidence of the investors. Hence a positive relationship is expected between the 
FERs and the inflow of FDI. It was USS254.6 billion in 2008. 
e) Exchange Rate Regime: 
Exchange rate represents the investment climate in the country. High exchange rate 
will erode the profitability of foreign investment, increase the cost of production and 
introduce distortions in the host country's economy. Hence a negative relationship can 
be expected between the exchange rate and the flow of foreign capital. Exchange rate 
of the Indian rupees vis-a-vis the SDR, US dollar, Pound sterling and Euro were 68.6, 
43.4, 80.2 and 63.7 respectively in 2008. 
I) Inflation Rate: 
A high rate of inflation is a sign of internal tension and of the inability of the 
government and the central hank to balance the budget and to restrict the supply of 
money. As a rule, the higher the inflation rate, the less will be the FDI inflows. A 
negative relationship is expected. Recently it is very high (9.9 % in 2009). 
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g) Deficit in the Balance of Payment: 
A large deficit in Balance of Payment indicates that the country lives beyond its 
means. The danger increases that free capital movement will be restricted and that it 
will be more difficult to transfer the profit from the direct investment into the home 
country. Hence a negative relationship can be expected. In the year 2008 it has US$ -
118.4. 
3. Availability of Human Capital: 
The continued expansion of MNCs in the past was a response of differential 
availability of factor endowments in different countries. Cheap and productive labour 
reduces the cost of production and yields high profitability. Low wage rates and 
higher labour productivity thus is expected to have a positive effect on FD[ inflows. 
India has 16 percent of world population with 402 million (2001) labour force. 
Besides India has a large pool of trained manpower, with 700,000 science graduates 
and engineers qualifying annually. This includes 122000 chemists around 50,000 
pharmacists, 150,000 chemistry post graduates and chemical engineers and 
approximately 1500 Ph.D. 
4. Availability of Natural Resources: 
The availability of natural resources (raw material) for manufacturing is one of the 
most important factors in investment decision making. If the resources are available 
locally the cost of production remains low, as the cost of transportation is saved. It is 
the sustained availability of the resources which matter in the investment decisions. 
Nature has bestowed upon India a number of mineral resources. Ample deposits of 
coal, iron, bauxite, mica, manganese, gypsum, chromate and limestone are found in 
Indian territory. 
5. Economic Policies of the Host Country: 
Economic policies includes the industrial policies, trade policies, tax structure, the 
intellectual property protection regime, bilateral investment treaties, regional 
integration frameworks, multilateral investment framework and so on of a country. 
Government policies are possible determinants of FDI since the government considers 
FDI flows as a means to fight unemploytnent and increase national growth rate. 
6. Infrastructure Facilities: 
The establishment of industry requires a highly developed infrastructure. The 
developments of roads, rail, electricity and communication system are important 
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inti'astructural facilities which are essential for the development of the industry. These 
factors are responsible for the attraction of FDI and the lack of which becomes a 
hindrance. 
7. Agglomeration Effects: 
Agglomerations also have significant effects on attracting FDI_ Agglomeration 
economies arise from the presence of other firms, other industries, as well as from the 
availability of skilled labour force. It correspond to positive spillovers form investors 
already producing in this area. This gives rise to economies of scale and positive 
externalities, including knowledge spillovers, specialized labour and intermediate 
inputs. Thus high FDI today implies high FDI tomorrow. 
1.9 	Importance of Foreign Direct Investment for Growth and Development in 
India: 
After independence it was realized that the economy was in a bad condition and in 
need of massive reconstruction. There was shortage of capital, productive facilities 
manpower and entrepreneurs. The infrastructure of the country inherited was not 
compatible for production. The technological know- how was poor. Policy makers at 
that time realized the importance of foreign capital and technology to furnish the 
needs. The political leadership of "Swadeshi" at that time was rather sceptic due to 
the bitter experiences of British rule. They by- passed the real need of foreign capital 
and technology in the forms of restrictive policies. Through these policies provided 
the country with a foundation of local technology in the manual form backed by low 
capital. That created enough employment opportunities for the poor economy of India 
but compared to the global development of technology the indigenous technology 
lacked efficiency. By 1950s the policy makers felt the importance of foreign capital 
and technology in the country. The first five year plan introduced to allow foreign 
investment at least in the agriculture sector. I lowever during 1960s and 1970s there 
were a number of collaboration with Russia particularly in the power. petroleum. Coal 
mining, steel and Iron. drugs and pharmaceutical sectors. But the country was vet to 
accept the investment of capitalist countries in view of their nature of exploitation. 
The congress party in the 1980's made the economy more liberalized by permitting a 
number of sectors including telecommunication, infrastructure, banking and 
information technology open for foreign investments. It was observed that the initial 
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experiences were not bad as the locally protected tirms availed the opportunity of 
becoming more competitive at the global standards. 
In India the lure of non-debt creating FDI flows has galvanized successive 
governments since 1990-91. Now the government talks about ensuring S25 billion 
FDl flows into India as the minimum consideration for achieving the economic 
growth target of 8 percent per annum. Because the sustained flow of FDI would give 
the economy a smooth ride to banish the twin dangerous of endemic poverty and huge 
un-employment and cope with the vast investment requirements of maintaining the 
rickety infrastructure and creating more facilities. 
Therefore, in the line of globalization foreign capital and technology was realized as 
an urgent need for the development of the economy. Consequently in 1991, the 
government of India introduced new economic policy' with policy of liberalization. 
Most of the sectors were allowed for foreign investment except very few like defence 
and strategic sectors. The emergence of the WTO made these a kind of obligation. 
The commitment of the country with the WTO and the IMF made official 
withdrawals of all restrictive policies in favour of investment climate of global 
standards. Now India is committed to provide one of the best investment opportunities 
of FDI i.e. ranked second position according to Global Business Policy Council 
(2005). Within a span of about 18 years FDI in India has increased nearly 165 times 
from 1991 to 2008 and attracted more than 1 billion US dollar per year. Except 
defence and strategic sectors all the sectors of the economy are now ready for FDI. 
The statistics highlight the role of FDI in the growth and development of the Indian 
economy. 
The pharmaceutical industry of India has also observed a transition during this period. 
The technology of the sector observed a tremendous development and the quality of 
output improved remarkably. The sector now contributes 90 percent of domestic 
consumption and a sizeable figure to the export of India. This indicates that the 
intensity of production and promotion of FDI inflows in the sector have increased 
significantly. It may be argued that the development of pharmaceutical industry in 
India is an outcome of the flow of FDI in the sector. 
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1.11) 	Conclusion: 
FDI play multidimensional role in the o\ erall development of the host country. It may 
generate benefits through bringing non-debt creating foreign capital resources, 
technology upgradation, skill enhancement, new employment. spillovers and 
allocative efficiency effects. It plays a complementary role in over all capital 
formation and filling the gap between domestic saving and investment. At the macro 
level it is a non-debt creating sources of additional external finances. At the micro 
level it is expected to boost output, technology, skill level, employment and linkages 
with other sectors and the regions of the host economy. Thus FDI acts as a catalyst for 
domestic industrial development and considered to be an important vehicle for 
economic development. According to Chaturvedi (201 1) the value of Karl Pearson 
correlation is found to be +0.89 means a high degree correlation between FD1 and 
economic development. While FDI has many disadvantages also like increased 
market concentration, foreign interference, damages to the nations customs and 
culture etc. The major factors that attract FDI in India are huge market size, low cost 
and skilled labour, sound macroeconomic development, abundant natural resources 
etc. 
A theoretical review on FDI has revealed that the different theories have led emphasis 
on varied micro and macro factors, which as a result, influence the foreign investment 
in an economy. It is therefore inappropriate to assess the role of FD1 through the 
application of single theory and what is needed in the present globalizing economy of 
the world is to blend and combine the indigenous and exogenous factors impinging 
upon the decision for inviting foreign investment in an economy. 
In the succeeding chapter an attempt is made to review the literature on the subject 
matter of FD1 in different sectors of the economy with special reference to 
pharmaceutical industry. The study has further presented the statement of the 
problem, objectives, scope and scheme of chapterisation. Research design and 
methodology suitably carved out keeping in mind the hypotheses formulated to 
critically examine the role of FDI in promotion of pharmaceutical industry in India. 
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Review of Literature and Research Design of the Study 
	
2.1 	Introduction: 
India resorted to liberalization regime by opening the economy and paving the way 
for foreign investment. During the post liberalization period since 1991 different 
issues emerged as regard to inflow of FDI in India. 
As India suffered technological backwardness and institutional rigidities in such a 
scenario pharmaceutical industry was the only potential to the beneficiary of 
economic liberalization through FDI. However, this is the optimistic part of the 
consequences. There is a pessimistic part not ignorable either. Economists quite often 
belong to either of two view points. 
The pessimistic group led by Charles Kindlebcrgcr (1992) viewed FDI as a source for 
exploitation for the host countries by multinationals. Such exploitation ranges from 
inappropriate technology, labour exploitation, transfer pricing etc. to high repatriation 
and economic exploitation. The optimistic group, led by the famous development 
economist Michael Todaro (1999) opines a careful scrutiny of the host country to 
ensure capital formation, technological development, employment generation and 
promotion of living standards. FDI in pharmaceutical industry in India had not been 
informed of this consequence and the present study aims to analyze these. 
2.2 	Statement of the problem: 
The advent of FDI in the Indian economy has given birth to a number of interesting 
and noteworthy problems which are discussed below: 
I) The entry of FDI would give rise to economics of scale and higher 
productivity by the use of latest technology. It is well known that FDI brings 
with it latest technology that is being used in the developed countries. So the 
host country gets the advantages of the use of latest technology. Besides FDI 
brings novel concepts of managerial skills. 
2) FDI generates more employment. With the inflow of FDI in a developing 
economy, the investment process gets boost and a large number of projects 
start that lead to the generation of employment in almost every sector of the 
economy. It also provides an opportunity to the idle work force of the host 
countries. 
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3) FDI paves the way to have large volume of foreign exchange. It helps in 
enhancing exports tor the host country. So the increase will directly influence 
the foreign exchange of the host country, which consequently helps it to 
maintain large volume of lareign exchange and improve its BOP position. 
4) Another significant issue which has cropped up in the wake of FDI is the 
development of social sector. The Indian industries are predominantly labour 
intensive. Human capital in terms of quality was not a big problem in India 
due to its huge population added emphasis must be laid on the quality and 
efficiency in work by MNCs. FDI also enhanced our educational system. 
Since 2003, the Indian government has been allowing 100% FDI in education, 
which means that foreign schools, colleges and universities can set up wholly 
subsidiaries in India. 
The pharmaceutical industry has been chosen for research for many reasons. First this 
sector play an important social role for it is directly concerned with the health of the 
people which is a basic need of every citizen. Second is that the contribution of the 
pharmaceutical companies in the spheres of production, earning foreign exchange and 
investment in Indian economy has been quite significant. Third, this industry is a 
research based one. R&D activity is one of the basic needs of the industry. 
The role of FDI is an important consideration for the fast growing pharmaceutical 
industry as FDI always helped in boosting exports with the setting up of the state-of-
the art infrastructure facilities and latest technological skills, which further helps the 
export industry to stay afloat in the international competitiveness and sustained 
growth which, emergence of the pharmaceutical industry as one of the fastest Bowing 
among all the industries, especially in terms of exports. Therefore by taking into 
consideration all these it is inferred that FDI has a very important role play in the 
development of economies like India, which is lagging far behind in growth and 
development as compared to other developed countries. 
2.3 	Review of literature: 
A lot of research has already been done across the globe for analyzing the various 
aspects of FDI. In the development literature, well reflected in the international as 
well as the Indian discourse, there has been a lot of debate generated about inflows of 
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FDI for different sectors and their impact. Some of the major works are reviewed 
here. For simplification purpose the studies have been divided into two categories. 
The Global Perspective: 
Bransteeter or al. (2007) in their study of "Intellectual Property Rights, Imitation and 
FDI: Theory and Evidence" tried to analyses the effect of strengthening Intellectual 
Property Rights (IPRs) on the level and composition of industrial development in the 
developing countries. They developed a North South Product cycle model in which 
Northern innovation, Southern imitation and FDI are all endogenous variables. The 
study predicts that IPR reform in the South leads to increased FDI from the North as 
the Northern firms shift production to the Southern affiliates. This FDI accelerates 
Southern industrial development. Resides as the production shifts to the South, the 
Northern resources will be reallocated to R&D, driving an increase in the global rate 
of innovation. The study finds that MNCs expand the scale of activities in reforming 
countries after the IPR reforms. 
Analyzing the influence of strengthening IPRs on FDI inflow, Glass and Saggi (2000) 
in their paper "Intellectual Property Right and FDI" developed a product cycle model 
with endogenous innovation, imitation and FDI and determined how stronger 
intellectual property rights protection in South affects innovation, imitation and FDI. 
They find that stronger IPR protection keeps multinational safer from imitation, but 
no more so than Northern firms. Hence FDI decreases with strengthening of Southern 
IPR Protection because an increase in the list of invitation crowds-out FDI through 
tighter southern resource scarcity. 
A study carried out in an edited volume by Narula and Lall (2006) `Understanding 
FDI Assistant Economic Development" emphasizes the factors that led to an 
optimization of the benefits from FDI for the host country. Despite the diversity of the 
countries covered and the methodology used in the study, it points to a basic paradox. 
"With weak local capabilities, industrialization has to be more dependent on FDI. 
However, FDI cannot drive industrial growth without local capabilities." They clearly 
show that market forces cannot substitute for the role of the government and argue in 
favour of a proactive industrial policy. Therefore FDI per se does not provide growth 
opportunities unless the domestic industrial sector exists which has the necessary 
technological capacity to profit for the externalities from MNC activity. 
Blourstrom and Kokko (2005) in their study "The Economics of Foreign Direct 
Investment" suggest that the use of investment incentives to attract more EDT is 
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nonnallv not an efficient way to raise national welfare. The strongest theoretical 
motives for financial subsidies to attract investment are spillovers of foreign 
technology and skills to local industry. They argue that these benefits may not be an 
automatic consequence of foreign investment. The potential spillover benefits are 
realized only if the local firms have the ability and motivation to invest in absorbing 
foreign technology and skills. To motivate subsidization of foreign investment, it is, 
therefore necessary at the same time to support learning and investment in local firms 
as well. 
Haskel et al. (2004) in their study "Does Inward FDI Boost the Productivity of the 
Domestic firms" tried to find out whether there are any productivity spillover from 
FDI to the domestic firms and if so, how much should the host countries be willing to 
pay to attract FDI to their countries. Using plant level panel covering U.K. 
manufacturing during 1973-1992 they estimate a positive correlation between 
domestic plants, Total Factor Productivity (TFP) and the foreign affiliates share of 
activity in that industry. The study suggest that a 10 percent point increase in foreign 
presence in the UK industry raises the TFP of that industry's domestic plants by about 
0.5 percent. These estimates are used to calculate the job value of these spillovers. 
And calculated values appear to be less than per job incentives that the government 
has granted in some cases. 
In the study on "Human capital formation and FDI in Developing Countries, Lyamoto 
(2003) has taken a view of the complex linkages between the activities of the MNCs 
and the policies of host developing countries. The study indicates that a high level of 
human capital is one of the key components for attracting FDI as well as for the host 
countries to get maximum benefits from these activities. He finds that one way to 
improve human capital formation and attract more FDI is to provide a strong 
incentive for MNCs and investment promotion agencies to participate in formal 
education and vocational training for workers employed with domestic firms. Besides 
FDI promotion activities can target high value added MNCs that are more likely to 
bring new skills and knowledge to the economy that can be tapped by the domestic 
enterprises. 
In an interesting article "Intellectual Property Rights. Technology and Economic 
Development: Experiences of Asian Countries" Kumar (2003) critically examined the 
role of intellectual property protection regime with reference to Asian countries. The 
study indicates that the top 10 countries account for 84 percent of global resources 
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spent on R&D activity with controlled 94 percent of the technological output in terms 
of patent taken out in the US and receive )l percent of global cross border royalties 
and technology license fees annually. Therefore it affects the prices of a large number 
of important drugs and thus affects the health systems in poorer countries and lead to 
income transfer from poorer to richer countries. Besides, it will adversely affect the 
manufacturing activity in developing countries and may increase their imports but 
does not guarantee increased FDI inflows, access to technological R&D investment in 
tropical diseases. He suggests that developing countries should build adequate 
provisions for compulsory licensing in their IPR legislation in order to safeguard them 
from possible abuses of monopoly power obtained by patent owners. Government 
may impose regulation of prices of essential drugs to protect the poor masses from the 
price increases and provides increased technical assistance and R&D funding to local 
enterprises to help them in building up their local capabilities. 
Kumar (2001) in his study entitled "Infrastructure Availability, FDI Inflows and their 
Export Orientation: A Cross Country Exploitation" analyses the role of infrastructure 
availability in determining the attractiveness of countries for FDI inflows for export 
orientation of MNCs production. He posits that the investment by the governments in 
providing efficient physical infrastructure facilities to improve the investment climate 
for FDI. The estimates corroborate the fact that infrastructure availability does 
contribute to the relative attractiveness of a country towards FDI by MNCs, holding 
other factors constant. He suggested that infrastructure development should he an 
integral part of the strategy to attract FDI inflows in general and export-oriented 
production from MNCs in particular. 
In an important article "Do stronger patents induce more innovation? Evidence from 
the 1988 Japanese Patent law reforms" Sakakibara and Branstetter (2001) examine the 
impact of patent right expansion on the inducement of innovative effort by firms. 
They find no evidence of a statistically or economically significant increase in either 
R&D spending or innovative output that could plausibly be attributed to these 
reforms. They conclude that Japanese firms changed the structure of their patent 
applications to exploit the new law, but it failed to induce discernible increases in 
R&D or innovative output. 
Aitken and Harrison (I 999) in their article "Do Domestic firms Benefits from FDI?" 
estimated the impact of FDI on productivity growth and spillovers using panel data 
for Venezuelan Manufacturing firms during 1975-1989. The study liiund foreign 
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firms exhibited higher labour productivity. After controlling for size and capital 
intensity, the foreign firms are found to be higher in import and export intensity and 
paid higher wages than their domestic counterparts, and also that the foreign tines are 
found to be a higher contributor to the foreign exchange earnings compared to their 
domestic counterparts. The most important conclusion of the study is that although 
results strongly support the relation between increased foreign equity participation 
and individual firms' performance, but this increase in foreign ownership variable has 
a significant negative impact on domestically owned firms, suggesting that an 
increase in foreign investment decreases the productivity amongst domestic firms. 
Thus, productivity improvement as a result of technology gains is only limited to the 
firms that are directly linked to the foreign firms (Joint Venture firms). 
De Mello (1999) in his article "Foreign direct investment-led growth: evidence from 
time series and panel data" has conducted time series as well as panel data estimation 
for a sample covering 15 developed and 17 developing countries for the period 1970-
90 of the relationships between FDI, capital accumulation, output and productivity 
growth. The study suggests that effect of FDI on growth or on capital accumulation 
and total factor productivity (TFP) varies greatly across countries. The panel data 
estimation suggests a positive impact of FDI on output growth for developed and 
developing country sub-samples. However, the effect of FDI on capital accumulation 
and TFP growth varies across developed (technological leaders) and developing 
countries (technological followers). FDI has a positive effect on TFP growth in 
developed countries but a negative effect in developing countries but the pattern is 
reversed in case of effect on capital accumulation. He infers from these findings that 
the extent to which FDI is growth-enhancing depends on the degree of 
complementarily between FDI and domestic investment. The degree of 
substitutability between foreign and domestic capital stocks appears to be greater in 
technologically advanced countries than in developing countries. Developing 
countries may have difficulty in using and diffusing new technologies of MNEs. 
Mansfield (1994) in his study of "Intellectual Property Protection FDI and 
Technology Transfer" provided a new insight into the IPR-FDI linkage. His analysis 
based on survey data indicates that IPR regimes are relevant for some but not all types 
of FDI decisions. He found that IPR protection is much more relevant about 
investment in R&D facilities than for FDI in sales and distribution outlets. 
Furthermore, he found sharp differences in the perceptions of industries about the 
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importance of' IPR regimes in their decisions about FDI. The pharmaceutical industry 
4 
	
	 reported that IPRs played a major role in their decisions about Investment in joint 
ventures abroad. 
Analyzing the influence of IPRs in encouraging FDI Maskus (1998) in his study "The 
Role of IPRs in Encouraging FDI and Technology Transfer In strengthening IPRs in 
Asia: Implications for Australia". tinds that while there is evidence that strengthening 
IPRs can be an effective means of inducing additional FDI inflow, it is only one 
component among a broad set of factors. Emerging economies must recognize the 
complementary relationship amongst IPRs. market liberalization and deregulation, 
technological development policies and competition regimes. He suggests that given 
the complexity and trade offs for market participants, governments and emerging 
economies should devote considerable attention and analysis of the strategies to 
achieve net gains from stronger IPRs. 
Kirim (1985) in his study "Reconsidering Patent and Economic Development: A case 
study of the Turkish Pharmaceutical Industry" presents a weak interrelation in 
between patent protection and FDI. The study argued that the rate of new drug 
introduction in the Turkish market did not decline after abolishing patent protection 
i.e. after 1961. He concluded that inspite of the elimination of patents, investments 
continued to flow into Turkey's Pharmaceutical Industry. Hence no simple causal link 
can be made between patents and FDI. 
Another interesting article "Regulation of Pharmaceuticals in Developing Countries 
Legal Issues and Approaches" conducted by Jayasuriya (1985), provides a much 
needed introduction to some of the important legal issues concerned with the 
regulation of pharmaceuticals in developing countries and describes some possible 
approaches to establishing a manageable regulatory framework. He argues that 
consideration ought to be given to the administrative and operation mechanism 
needed to translate the laws into action. The study traces the laws and experience of a 
number of the developing countries to assist the policy makers and to show what can 
he done with limited resources in the context of conditions prevailing in the 
developing countries. 
hall (1974) in his thought provoking article "International Pharmaceuticals Industry 
Op 	 and LDCs: Il-Costs and alternatives" analyses the characteristics of the international 
pharmaceutical industry. The study highlighted that LDCs gain little or nothing and 
may even lose from granting patents on inventions developed, published and worked 
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abroad and it increases the monopoly power of foreign investors. I-ie pointed out that 
LDCs would face the problem of internally processing and marketing of drugs, but it 
is the sensible distribution system that would be able to deliver the pharmaceutical 
goods at prices far below. Thus this study suggests the best ways to deal with the 
various long-run problems. Like LDC to move towards a socially owned indigenous 
pharmaceutical industry and copy foreign technology brand names and market the 
product through official agencies. 
The Indian Perspective: 
Duperon and Cinar (2010) in their recent article `'Global Competition Versus 
Regional Interest: FDI and Pharmaceuticals in India" has shown that there is trade-off 
between the ability of nations to attract FDI and moderate the price of drugs to levels 
conducive for widespread distribution. Furthermore, there are additional concerns for 
the impact of FDI on domestic industries relative to the displacement of domestically 
held equity as foreign firms entered the marketplace. They predicted that emerging 
markets will account for sales equal to those in US and the top five European Union 
markets combined by 2017. The study highlighted that India provides one of the most 
conducive environments for firms looking to establish Knowledge Process 
Outsourcing (KPO) operations. Infrastructural developments and policy revisions 
have spurred substantial economic growth in India over the last decades, and it's 
uniquely desirable labour force enhances the viability of profits for foreign 
knowledge-based firms. India holds roughly three percent of the global market for 
outsourcing. According to them corruption is one of the major barrier that could 
potentially disrupt the inflow of FDI via the inherent risk of illegitimacies. The study 
suggested that transparent policies are essential to attract long term investments. 
Rai (2009) in his study on effect of TRIPs on inflows of FDI particularly in 
pharmaceutical sector titled "Effect of the TRIPs — Mandated Intellectual Property 
Rights on FDI in developing countries: A case study of Indian Pharmaceutical 
Industry" tried to find out impact of strong patent regime on the technology transfer in 
the developing countries. "I'he study found that simply enhancing patent protection 
may not necessarily result in a corresponding increase in FDI in the Indian 
pharmaceutical sector. It indicates that the "gravity" type variables, "agglomeration 
benefits" like rapid growth in GDP. huge market size, accelerating economic reforms 
and opening up of the economy and a well developed pharmaceutical sector were the 
dominant determinants of FDI in the pharmaceutical sector. He suggested that India 
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needs to provide incentives for foreign investors and remove the barriers to foreign 
investment and technology transfer into India and to further improve its investment 
environment condition such as political and legal factors to absorb ioreign capital and 
advanced technology. 
Mathiyazhagan and Sahoo (2008) in their study "Do FDI Inflows Benefits the Major 
Sectors in India?" analyses the impact of FDI at the sectoral level on the Indian 
economy. The study used panel co-integration model test of the nine core-sectors 
namely, power & fuel, electrical equipment, transport, chemicals, food processing 
industries, metallurgical, drugs pharmaceuticals, textiles and industrial machineries 
with four variables i.e, FDI, export, gross output and labour productivity from 1991-
92 to 2004-05. The study revealed that the only sector in India that has enjoyed a 
positive relation between export and FDI is drugs and pharmaceutical. It may be due 
to the attraction of many global drug majors to source their production from India. 
Also due to more numbers of Greenfield investment projects which have expanded 
their exports through overseas affiliates by the parent companies. They conclude that 
the advent of FDI has not helped to yield a positive impact on the Indian economy at 
the sectoral level. Further, they suggested the opening up of its export oriented sectors 
so that a higher growth of the economy can be achieved through the growth of these 
sectors. 
Aditya and Nigam (2007) in his work "Globalization in the Indian Pharmaceutical 
Industry — FDI spillovcrs and implications on Domestic Productivity: 1991-2007", 
made an attempt to analyze and study the impact of globalization in the 
pharmaceutical industry and FDI spillovers in various forms to the domestic 
pharmaceutical industry in terms of domestic productivity and competitiveness etc. 
The study reveals that the spillover effects have had a manifold impact on the Indian 
pharmaceutical industry, with the new WTO patent regime introduced in 2005, the 
foreign players have found greater security in operating in India and due to the 
spillover effects of a competitive environment, the domestic players have 
substantially increased their productivity, probability and hence compete on stronger 
footing with the incoming pharmaceutical firms. 
Another important article presented by Bergman (2006) entitled "FDI and Spillover 
Effects in the Indian Pharmaceuticals Industry' analyses the impact of FDI on Indian 
domestic pharmaceutical industry. The study shows that there has been positive 
impact from FDI in the pharmaceutical industry and the MNCs in India have 
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positively contributed to the growth and development of the industry. Spillover effects 
through imitation. industrial management skills and competition were explicitly 
observed in the industry. Such effects were generated not only in product 
development, but also in marketing and documentation techniques. The foreign firm's 
presence has indirectly encouraged domestic firms to increase their managerial efforts 
and to adopt some of the marketing techniques used by MINCs. Further the presence 
of foreign tines has intensified competitive pressure in the industry and stimulated 
domestic firms to use accessible resources more efficiently. The study emphasized 
that the presence of FDI in the pharmaceutical industry does not mean automatic 
spillover effects. It depends on the development of the domestic firms and the efforts 
of domestic firms to invest in learning and imitation. The study suggested that in 
order to promote FDI and maximize future spillover effects, policies should be 
investor friendly with a clear developing strategy. The policies that India should 
encourage are for the domestic firms to invest more in R&D and technology 
upgradation, especially the small firms. Public investment in higher education, 
preferably sciences based are necessary for future progress in innovative research and 
also in order to attract more FDI. 
Kumari (2007) in her study "Liberalization, TRIPs and Technological Behaviour of 
Firms in Indian Pharmaceutical Industry" tried to identify the factors determining 
technology imports for firms in the Indian Pharmaceutical sector. The study is based 
on firm level data for the period 1995-2004 with variable firm's growth, export 
intensity, size of firms, profitability of firms, foreign equity participation, research & 
development intensity and age of the firms. It is found that firms' capability has been 
very important for motivating technology imports to take advantage of liberalization 
policies and free challenges under TRIPs. The study revealed that larger, older and 
firms with foreign equity participation have been importing more technology. Profit is 
not a significant determinant of technology imports. Due to lack of product patent and 
risk of copycat by domestic firms, foreign firms usually preferred intra-firm 
technology transfer. A complementary relationship has been found between foreign 
technology acquisition and R&D intensity. Further, she suggested that smaller finns 
should also take advantage of new technology by growing larger through mergers, 
acquisitions or partnership with either large domestic or foreign firms. 
Pradhan et al. (2006) in their study "Export-orientation of foreign manufacturing 
affiliates in India: Factors, tendencies and implications" tried to estimate the export 
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contribution of foreign affiliates in Indian industries and analyzed the factors that 
determine the propensity of foreign affiliates to undertake export activities. The 
studies found that volume of exports by tbbreign affiliates have grown significantly 
across industries with rising export intensities. Their export's propensities are more 
sensitive to the size of the domestic market. In a liberalizing, host country like India 
foreign firms export intensity is strongly dependent on the domestic firms because, 
domestic firms' exports activity has a strong positive impact on foreign firms. they 
also found that foreign affiliates in India have significantly lower export intensities in 
R&D and advertising — intensive industries and local competition seems to have 
played a negative role in the export orientation of foreign affiliates. Foreign firms are 
likely to focus more on domestic market when they are faced with rising local 
competition. 
Jha (2007) in his interesting article "Options for Indian Pharmaceutical Industry in the 
Changing Environment" has focused on the factors that are influencing the structure 
and growth of the Indian Pharmaceutical industry in the new scenario. The study used 
sample of 15 companies (9 domestic and 6 MNCs) since 1995 with respect to their 
export orientation, import dependence, investment, option of bulk drugs versus 
formulations and stimulus to R&D. The study showed that although India has become 
a net exporter of pharmaceuticals, import dependence of bulk drugs has steadily 
increased over the last decades. As far as the Indian affiliations of the multinational 
pharmaceutical companies are concerned, their shares of both the bulk drugs and 
formulation are declining and their investment preferences have shifted towards 
financial securities. In the field of R&D no Indian pharmaceutical company has been 
capable of taking a potential drug from the investigation stage to the stage of final 
market launch and collaboration with NINCs is the norms. It results in biases in the 
choice of therapeutically areas towards lifestyle-related diseases. Further, he suggests 
that in India the role of government is of utmost importance. The break-through drugs 
typically come out of government funded laboratories. Therefore, government funded 
research organizations have to expand their role by partnering with private sector, 
A recent study entitled "FDI and Growth of Manufacturing sector: An Empirical 
study in Post-reform India" conducted by Sahoo (2005) presents an analytical view 
for the impact of FDl on total factor productivity of six core manufacturing industries 
namely, food products, chemicals, drugs and pharmaceuticals, general engineering, 
electrical and electronics in India with a number of variables such as output, labour, 
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capital, net sales etc. the study argued that FDI would help in augmenting the 
domestic production via various spillover effects to the domestic fines. FDI is one of 
the effective routes of technology diffusion in the host country especially for the 
developing countries perspective. Besides. economic reforms in terms of releasing 
various growth inducing forces would have helped the domestic fuzes more than the 
foreign firms because reforms unleashed a comparative environment for the domestic 
firms to move in terms of greater modernization and expansion drive. The study has 
further emphasized that at manufacturing sector level, domestic fines have registered 
a marginal positive Total Factor Productivity (TFP) growth as compared to foreign 
firms. Moreover domestic firms have performed exceedingly well in drugs and 
pharmaceuticals industry with maximum TFP growth of above 7 percent. It is only in 
the drugs and pharmaceutical and electronics sector that the presence of foreign firms 
has been helpful for the domestic firms to experience a reduction in dispersion of 
productivity. His suggestion is to encourage FDI in these two sectors i.e. drugs and 
pharmaceutical and electronics which will have more beneficial effects on domestic 
firms operating in these sectors. 
In a different study titled "WTO Regime, Host Country Policies and Global Patterns 
of MNE Activity: Recent Quantitative Studies and India's Strategic Response" Kumar 
(2001) analyzed the role of structural, geopolitical and policy factors in shaping the 
patterns of MNEs activity and focus on the role of host government policies and on 
the implications of the emerging WTO regime in their light. He was of the opinion 
that a more restrictive FDI policy regime affects the investment climate in general but 
it may improve the quality of inflows that come. On the other hand his findings have 
stressed that IPR regime does not affect the investment climate in a host country. 
Strengthening of IPR regime is in tune with TRIPs Agreement's obligation in India 
and has the prospect of adversely affecting the domestic R&D activity especially in 
the chemicals and pharmaceuticals industry by choking the domestic industry's access 
to knowledge spillovers from the R&D activity in other countries in the form of 
product development which formed the basis of process innovative activity of Indian 
enterprises. The study emphasized that FDI provides only necessary conditions and 
are effective only in the presence of responsive local entrepreneurship that is willing 
to complement imported knowledge with extensive in-house technological effort on 
absorption, adaptation continuous updating and eventually on innovation. Further, he 
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suggested restricted use of foreign brand names for domestic operative and encourage 
national enterprises to develop local brand names. 
Chaudhuri (2005) in his book "The WTO and India's Pharmaceutical Industry: Patent 
Protection. TRIPs and Developing Countries" focuses on an interesting fact that while 
the technology gap between Indian and foreign firms was non-existent before the 
therapeutic revolution around 1940, it started increasing later when foreign firms 
began investing in R&D while the Indian firms concentrated on developing alternate 
processes for known drugs. He concludes that since the mid 1990s the Indian private 
sector has started investing in R&D for new drugs. A number of new chemical entities 
have also been developed which are at different stages of development, but none of 
the Indian companies is engaged in the entire process of drug development, because 
they do not yet, have all the skills and the funds required. The model that the Indian 
companies have adopted is to develop new molecules and license out the molecules to 
the MNCs at early stages of clinical development. As a result the Indian companies 
are not targeting neglected disease effectively, but diseases of MNCs interest. 
Another important article presented by Lalitha (2002) "Indian Pharmaceutical 
Industry in WTO Regime: A SWOT analysis". The study revealed an insignificant 
relationship between Patent Protection and location of R&D activity emerges. The 
study emphasized that less focus on tropical diseases, dumping, slow pace of research 
in the field of biotechnology, delays in processing of the patent application, lack of 
understanding of various clauses under the TRIPs agreements among the industry 
members, lack of quality standards, high mergers and acquisitions etc. are the major 
problems of Indian Pharmaceutical industry. Study further, suggests that Indian 
Pharmaceutical industry should adopt various strategies such as producing off 
patented products, new patented products by acquiring compulsory licensing, 
collaborate with multinationals not only in R&D and manufacturing but also in 
marketing new patented products and improving the standards of production to widen 
the export market. 
Pradhan (2002) in his paper "FDI spillovers and local productivity growth: evidence 
from Indian Pharmaceutical industry" has shown that although FDI might generate 
development process by competitive effects, human capital effect, demonstration 
effect and linkages effect, but it may also lead to crowding-out of local capabilities 
and market credit rationing for small size local firms by reducing their access to 
capital or raising costs of borrowing. Further. the presence of foreign fines per se may 
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not he important for productivity growth in the domestic sector. It is only when 
domestic firms have already grown large or have been engaged in innovative 
activities that the FDI spillover `corks. The study suggests that the policy efforts 
should be directed towards encourage R&D and concentration of the size of domestic 
firms in the industry. This will be more desirable than passively liberalizing the FDI 
policy. The policy incentives should he towards indigenous technological capability 
building and ensuring the firms easy access to new technology from overseas which is 
crucial for enhancing efficiency of domestic enterprises. 
Feinberg and Majumdar (2001) in their paper "Technology Spillovers from FDI in 
Indian Pharmaceutical Industry", has shown the average size of MNC. is more than 
twice the size of the average Indian firms in terms of total sales. Yet, the average 
wage bill to total production ratio for MNC is approximately the same as that of 
Indian firms. Besides MNC were more profitable than Indian firms. However MNCs 
and Indian firms are equally raw materials intensive. Further. Indian firms are more 
R&D intensive with 0.34 percent than NINCs with 0.22 percent. Further, it concludes 
that only MNCs gained from each other's R&D spillovers while Indian firms gained 
nothing. 
In another article "Manufacturing Drugs without TNCs: Status of the Indigenous 
Sector in India" Chaudhuri (1984) found that out of the 63 TNCs in the drugs industry 
only 32 firms produce bulk drugs. As far as quality of drugs concerned the study show 
that it is not true that TNCs never manufacture and sell sub-standard drugs. Because 
the fact is that the TNCs do not operate in India as independent entities and depend on 
the indigenous sector for bulk drugs and formulations. Thus the sale of drugs of 
proper quality by the TNCs reflects not only the capability of the TNCs but also that 
of the indigenous sector to produce such drugs. He concluded that, the TNCs may not 
produce in India at the lowest cost at which they are capable of doing due to over 
pricing of imports. Technology would not he a bottleneck for undertaking the task of 
replacing most of the manufacturing activities of the TNCs, but there may be other 
constraints, financial, entrepreneurial etc. 
Singh (1985) in his book "Multinational Corporation and Indian Drug Industry" tried 
to examine issues arising out of the activities of MNCs in the pharmaceutical industry. 
The major findings of the study are that pharmaceutical MNCs enjoy tremendous 
market power in India. This is reflected in their monopolistic and oligopolistic hold on 
various sub-drug market of the country. Drug MNCs in India have not only raised 
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funds locally but also exported huge funds by way of remittance and due to the 
regulated Indian drug market, MNCs have also diversified their activities towards 
more profitable areas of production. 
Johari (19t 3) in his study "Business Strategies of MNCs in India: A case study of 
Drugs and Pharmaceutical Industry" tried to analyze the business strategies of drug 
multinationals in India. The sample of the study includes 24 multinationals based in 7 
countries. The study indicated that the majority of the companies have been affected 
by controls on prices of drugs. Further that the policies pursued by the drug 
companies are based on certain quantitative indicators which could lead to wrong 
conclusions being drawn. 
Basu et al. (2007) in their paper "Foreign Direct Investment in India: Emerging 
1-lorizon". focused on to study the qualitative shift in the FDI inflows in India as in- 
depth study of in the last fourteen odd years. It reveals that the country is not only cost 
effective but also hot destination for R&D activities. The study also finds out R&D as 
a significant determining factor for FDI inflows for most of the industries in India. 
But it also reveals strong negative influence of corporate tax on FDI inflows. 
Gakhar (2007) in her book "FDI in India 1947 to 2007: Policies Trends and outlook" 
analyses various determinants and deterrents that influence FDI inflows in India. The 
study revealed that although India has one of the most transparent and liberal FDI 
regimes among the developing countries with strong macroeconomic fundamentals, 
its share in FDI inflows is dismally low. The country still suffers from weakness and 
constraints in teens of policy and regulatory framework, which restricts the inflows of 
FDI. The study pointed out that the present policy of FDI is applicable in all the 
sectors of the economy but there is a need to have a selective approach to the entry of 
foreign capital in various sectors. The study has listed eleven internal and eight 
external determinants of FDI amongst which foreign investment policy and procedure 
ranks first and is the most important determinant in India. This is followed by 
Industrial Policy environment, financial market, foreign exchange regulation and so 
on. On the other hand bureaucratic delays and wide spread corruption, poor 
infrastructure facilities, pro-labour laws, high corporate tax, political rise and weak 
intellectual property rights etc. are the major deterrents of FDI inflows in India. 
Further she suggests measures such as empowering the state governments with regard 
to FDI, developing fast track clearance system for legal disputes, developing basic 
infrastructure and improving India's image as an investment destination. 
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Aggrawal (2007) in the paper "the influence of labour markets on FDI: Some 
empirical explorations in export oriented and domestic market seeking FDI across 
Indian states" has shown that there are wide variations in the FDI inflow across the 
states of India. Only seven states namely Andhra Pradesh, Tamil Nadu, Maharashtra, 
Gujarat. \ est Bengal, Uttar Pradesh and Kerala accounted for over 97 percent of the 
total amount of export-oriented FDI and 83 percent of total FDI approvals during 
1991-2001. The presence of EPZs was found to be a relevant pull factor in attracting 
export-oriented FDI. Further, while explaining the sensitivity of FDI to labour market 
conditions, the study revealed that labour market rigidities and labour costs are more 
pronounced for export oriented FDI than for domestic market seeking FDI. 
Infrastructure and regional development are found to be key factors in attracting 
higher FDI, both in the export and domestic market seeking sectors. 
In order to provide foreign investors a latest picture of investment environment in 
India, Hu (2006) in his study "India's suitability for FDI" analyses various 
determinants that influence FDI inflows to India including economic growth, 
domestic demand, currency stability, government policy and labour force availability 
against other countries that are attracting FDI inflows. Analyzing the new finding it is 
interesting to note that India has some competitive advantage in attracting FDI 
inflows, like a large pool of high quality labour force which acts as an absolute 
advantage against other developing countries like China and Mexico. In consequence 
this study argues that India is an ideal investment destination for foreign investors. 
In another study "Liberalization FDI flows and Development: Indian Experience in 
the 1990s" Kumar (2005) has shown that although the magnitude of FDI inflows has 
increased but in the absence of policy direction much of the FDI has gone into 
services and soft technology consumer goods industries bringing down the share of 
manufacturing and technology intensive industries. This is in sharp contrast to the 
East Asian countries: in terms of technology and R&D the manufacturing affiliates of 
MNEs in India seem to be spending a relative small proportion of their turnover on 
R&D activity after controlling for extraneous influences. The study came out that 
overall economic performance continues to exercise a major influence on the 
magnitude of FDI inflows by acting as an indicator device for foreign investors about 
the growth prospects for the potential host economy. So, paying attention to 
macroeconomic performance indicators such as growth rates of industry through 
public investments in socio-economic infrastructure and other supportive policies and 
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creating a stable and enabling environment is essential. Investments made by 
governments in building local capabilities for higher education and training in 
technical disciplines, centers of excellence and in other aspects of national innovation 
systems would crowd-in FDl inflows. 
Johnson (2004) in his work "The Effects of FDI Inflows on Host Country Economic 
Growth" discusses the potential of FDI inflows to affect host country economic 
growth. The paper argues that FDI should have a positive effect on economic growth 
as a result of technology spillovers and physical capital inflows. The empirical part of 
the paper finds indications that FDI inflows boost economic growth in developing 
economies but not in developed economies. He has assumed that the direction of' 
causality goes from inflow of FDI to host country economic growth. However, 
economic growth could itself' cause an increase in FDI inflow. Economic growth 
increases the size of the host country market and strengthens the incentives for market 
seeking FDI. This could result in a situation where FDI and economic growth are 
mutually supporting. However, for most of the developing economies growth is 
unlikely to result in market seeking FDI due to the low income levels. Therefore, 
causality is primarily expected to run from FDI inflows to economic growth for these 
economies. 
Aganval (1980) in his interesting paper "Determinants of FDI: A Survey" found that 
factors such as comparative labour costs, size of the country, the nature of exchange 
rate regime and political factors including political instability are the general 
determinants of FDI in less developed countries. Further he also stressed about the 
capacity of' the developing country to absorb investment, which largely depends on 
the amount of population and skills in the country. 
In the light of the above literature reviews we conclude that most of studies conducted 
so far indicate that the key factor which affects economic growth is technology. FDI 
is one of the effective routes of technology diffusion in the host country particularly 
from the developing countries perspective. Economic reforms would have helped the 
domestic firms more than the foreign firms because reforms unleash a competitive 
environment for the domestic firms to move in terms of greater modernization and 
expansion drive. Although foreign firms cannot work In vacuums, domestic firms 
provide the environment in which they nourish. Therefore. FDI for economic 
development does not mean automatic spillover effects. It depends on the 
development of domestic firms and their efforts to invest in learning by watching and 
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doing. the level of FDI also plays an important role, because whenever it is relatively 
low, an insignificant result will be the outcomes and vice-versa. 
Similarly almost all the reviews have revealed that there has been a positive impact 
from FDI in the pharmaceutical industry. These MNCs in India have positively 
contributed to the growth and development of the industry. Huge population, cheap 
and skilled labour force, large english speaking people, well developed chemical 
industry; low cost for developing new drugs, liberalized policy regime are the major 
pull factors for attracting FDI in pharmaceutical industry. While weak IPRs, poor 
social and economic infrastructure, price control, corruptions, pro labour laws etc are 
the major hindrance in the smooth inflow of FD in Indian pharmaceutical industry, 
However, not much study has been done focusing particularly on the impact of FDI 
on Indian pharmaceutical industry, investment, foreign exchange earnings (exports) 
profits and employment. 
2.4 	Research Cap: 
FDI has received considerable attention from academics with respect to its role and 
implications in India. Studies are also available on the FDI inflows for different 
sectors, such as telecommunication, fast moving consumer goods and capital goods, 
information technology, infrastructure and services. Comparative studies for different 
regions are also available. However. it is found that there is limited organized study 
on the FDI inflows in pharmaceutical industry in India. The industry has experienced 
considerable changes over last few decades. Initially, the sector was based on 
endogenous technology, but now the era of technological development has emerged 
and our economy has been opened to new areas and challenges and totally new global 
scenario. 
During the last new decades, the pharmaceutical sector has been experiencing a 
remarkable growth pattern. Charges have also taken place in respect of teelmology. 
Such changes are largely attributed to the inflows of FDI in India. The present study 
deals with pharmaceutical sector in relation to the FDI inflows in this sector. 'I he 
study aims to emphasis the linkages between the inflow of FDI in pharmaceutical 
industry and its growth and development after the initiation of economic reform. 
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2.5 	Scope of the Study: 
FDI has grown considerably in its importance In Indian economy. After liberalization 
its role has changed significantly. Earlier the amount of FDI was low conforming to 
some selected sectors, but now the inflow of FDI has grown tremendously and almost 
in all the sectors of the economy. The proposed study is therefore directed towards 
examining the varied aspects of the inflow of the FDI in the Indian economy general 
and pharmaceutical industry particular since 1991. It also tries to highlight the 
problems hindering the smooth inflow of FDI in India. The study has also dealt with 
the problems and the future prospects of the growth of pharmaceutical industry. 
2.6 	Objectives of the Study: 
The study aims to assess the nature of FDI inflows in India's pharmaceutical industry 
since the initiation of economic reforms in 1991 and attempts to seek its effects on 
certain aspects of development. In the light of the research gap, this proposed study is 
designed to cover the following objectives: 
1) To examine the significance and assess the various aspects pertaining to 
performance of the FDI in India viz-a-viz sector-wise, country-wise, state-
wise and year-wise during pre and post reform period. 
2) To analyze the growth and development trend of Indian pharmaceutical 
industry and its contribution to Indian economy. 
3) The study will further focus on the inflow of FDI in Indian pharmaceutical 
industry since economic reforms. 
4) To highlight the dynamic potential and future prospects of FDI inflow in 
the Indian pharmaceutical industry. 
5) To analyze the future dynamic potential of the pharmaceutical sector with 
further FDI inflow in India in the era of new WTO regime. 
6) Finally, to come out with the findings and conclusion of the study and to 
otter some pragmatic suggestions for increasing FDI inflows in India to 
benefit the whole economy in general and pharmaceutical sector in 
particular. 
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2.7 	Hypotheses of the Study: 
\1 ith the advent of the economic liberali ation in India the FDI has undoubtedly 
increased manifold as compared to the pre-liberalization period. Under the liberalized 
regime pharmaceutical industry has been accorded special attention by the 
government of India to attract FDI. Accordingly various incentives and plans have 
been launched. Against this background the following hypotheses have been set: 
1) The changes in the policy and development strategy may not maximize the 
gains from FDI after the initiation of new economic reforms. 
2) It is hypothesized that the opening of the economy and liberalization of 
investment policies has non-beneficial influence on the pharmaceutical 
sector. 
3) There is no significant relationship between the inflows of FDI in 
pharmaceutical industry in India and growth and development of 
pharmaceutical sector in India. 
4) It is further hypothesized that, there is no significant evidence of increase 
in production, employment, profit, investment and exports of drugs with 
an increase in the inflow of FDI in pharmaceutical industry. 
2.8 	Source of Data: 
The present study relies mainly on secondary data (Published and unpublished). The 
sources include World Investment Report, World Development Report, World Health 
Report published by World Health Organization. International Trade Statistics 
published by World Trade Organization (WTO), FDI Data Cell, Department of 
industrial policy & promotion (DIPP),New Delhi, Reserve Bank of India Bulletin and 
annual reports, Handbook of Statistics on the Indian Economy, Statistical Abstract in 
India, Secretarial of Industrial Approval newsletter (SIA),CDSCO (Central Drugs 
Standards Control Organization), CMIE (Centre for Monitoring Indian Economy), 
BDMA (Bulk Drug Manufacturers Association). OPPI (Organization of 
Pharmaceutical Producers of India), IDMA (Indian Drug `ianufacturers Association), 
DGCIS (Directorate General of Commercial Intelligence and Statistics)., CDRI 
(Central Drug Research Institute), Department of Pharmaceuticals etc. and different 
publications of different ministries such as ministry of chemicals and fertilizers, 
ministry of commerce. Articles published in the Journals and Periodicals of national 
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and international repute will be made good use of in order to study the ditferent 
aspects of the FDI in pharmaceutical industry Annual Report of the selected 
pharmaceutical companies is also utilized. 
2.9 	Span of Tine of the Study: 
The period of the study under consideration is from 1991 to 2008. The rationale 
behind the choice of the period is that FDI has played an important role in Indian 
economy since the economic liberalization. 
2.10 Research Methodology: 
In the light of the above objectives and the hypotheses formulated, an attempt has 
been made to analyses the impact of FDI inflows in pharmaceutical industry with 
respect to production, exports, employment, sales, investment and profitability during 
the period from 1991 to 2008. 
Methodology is a way of systematically solving the research problems. It may be 
understood as a science of studying how research is done scientifically. The study 
frequently makes use of to the statistical tool like CAGR, Mean, Standard Deviation 
(SD), Coefficient of Variance (CV), Minimum & Maximum values of variables. Both 
correlation and regression techniques are used as well developing on the nature of 
relation between and among variables. The classical Regression technique of 
Ordinary Least Square (OLS) method is used for the linear approximation of the 
relation. The time series analysis of regression equation takes the following forms: 
Y= a-ht 
Where, Y', is the estimated value of the concerned variable. 
`a' is the constant part of the variable. 
`b' is the annual change of the least square method and 
`t' is the year varying from 1991 to 2008. 
The study will evoke a multivariate regression comprising the lagged and time 
ariables in consideration as well. For the test of hypotheses the standard t-test is done 
to find out whether the coefficients and intercepts are statistically significant or not at 
5° 0 level. The regression estimators are tested by F-test at 5%% level. 
42 
('lull)/('/' - 2 
the oodne» of fit has been hNpothetical by above 50%, as the rule in general R- 
%\ith hi1-Iher values \\iII indicate stronger dependence of' dependent variables on the 
FDt t10 	in pharmaceutical sector in India. 
Durbin-\\ atson (d) test is used for finding auto correlation among t the variables: 
Lt 2(ut — Gt-1)L 
~ 1=1 ut 
It is imhk the ratio ut'the sum of'squared differences in successive residuals to the 
residual ,um of squares its Value must lies in hct ecn ()-d=4. When. d-0>2 it 
indicates positive first order autocurreiatiun. When d=O it indicates no auto correlation 
and \\ hen d-21-4 it indicates nest ative correlation. 
2.11 	Design of the Study : 
the ,tuj\ i, di \ ided into six chapters. The first chapter deals \\ ith the introductory 
background and theoretical approach of the study. The second chapter is concerned 
ith the re 10 of literature and methodological issues. Chapter third is devoted to the 
mcralI scenario of' the economic policy changes of the Indian economy in the pre- and 
post reform period. An over ie%\ of pharmaceutical industry in India since economic 
liberalization \\ill be the focuses in chapter tour. Chapter lire \ill be a statistical 
analysis t 1 test of h\pothesis) \\ith regard to the role of FDI iii f1cnrs in 
pharmaceutical sector in India. Finally chapter six is by \\a\ of conclusions and 
suggestions 
2.12 	limitations of the Studs: 
Since all the economic or scientific studies are faced with various types of limitations 
and this stud\ is also no exception. During, the compilation of the present thesis work, 
researcher found and faced a number ot'difficulties. Some of thcnl are as ti Ilows: 
I. 	\Ithough enough data on FDI 	as available \v ith 1(131, 1)1 PP. \'l iii istry of' 
Commerce& Industry. UNC'l'AD. but there \\as no consistenc\ and similarity 
in the data \\hlch effected conlparahiliu. 
'. I I)I in the post liberalization period 	as easily and up-to date available but 
consistent and continuous FDI data on pre-liheraliiation period as dil'ficuIt to 
find as no organization has made eft'rts to compile it till date. 
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3. Due to inadequacy of time series data from related agencies, and insufficient 
homogenous data from different sources, the time series data is used for 
certain variables and the averages are used at certain other occasions. 
Therelore. the trends, growth rates and estimated regression coefficients may 
deviate from the true ones. 
4. Department of pharmaceutical under ministry of chemical & fertilizers 
separately originated since 2008 therefore; there was dearth of detailed FDI 
data availability on this sector. The only source of data was FDI data cell, 
DIPP New Delhi. In addition there was inconsistency in the year-wise data on 
pharmaceutical sector and the pre-liberalization period of this sector. 
5. Since this research relies on secondary sources so it has to be taken with all its 
limitations. 
2.13 Conclusion: 
The present chapter provided some reviews of literatures and research design of the 
study. The methodological issues related to the source of data, rationality of the 
selection of time period, method of statistical interpretation are given. Hypotheses are 
also presented. The next chapter deals with the liberalization policies that play a vital 
role in the inflow of FDI in India and growth trends of FDI in India. 
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Economic Liberalization and Foreign Direct Investnment Policies in India 
3.1 	Introduction: 
Liberalization moves of developing nations in eighties in general and adoption of 
liberal trade policy regimes for attracting FDI in particular have driven global regional 
FDI inflows to these countries. Apart from the evident benefits of capital inflows such 
as, supplementing domestic savings and investments and creation of employment and 
income, it is transfer of new technology and management expertise from parent firms 
to the foreign affiliates in the host country, which probably stands as the most 
justifiable and legitimate ground for initiation of a liberal policy towards FDI. It is in 
this backdrop that an enabling policy framework, put in a broad and transparent 
manner and its effective implementation play an essential role not only in attracting 
FD1 but also reaping maximum benefits from it in terms of enhancing the efficiency 
of resource use and economic growth and therefore the overall development of the 
national economy. 
The country is endowed with rich natural resources including minerals, forest, vast 
agricultural land and a large pool of manpower. It has largest reservoirs of the 
technical and skilled manpower in the world; hence FDI is not a new phenomenon in 
India. The MNCs with their variety of arrangements such as FDI, technology transfer, 
joint ventures and subsidiaries were present even at the time when India attained 
independence. Industrial Policy Resolutions of 1948, 1956 and subsequent policies 
have accorded special emphasis on the considerably increasing role of foreign funds 
in India. 
The policy towards foreign investment in India has undergone substantial changes, 
from a more restrictive FDI policy to a liberal FDI, since the introduction of the 
economic reforms in July 1991. The New Industrial Policy (NIP) announced on July 
24, 1991 marks a historic change in India's economic mindset towards industrial 
development and liberalization of FDI policy. There were numerous incentives 
including industrial estates EPZs (Export Promotion Zones), Export Processing Units 
(EN. s) and recently developed technology parks have attracted considerable 
attention. In addition, a broad spectrum of financial incentives in the form of tax 
holidays, business services are offered by central and other state authorities to 
encourage economic development. 1lence the policy statement has clarified India's 
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stand on liberalizing the FDI policy, while emphasizing the importance of FDI in 
increasing efficiency in all sectors through several attendant advantage that the FDI 
brings in forms of technology transfer, marketing expertise, introduction of modern 
management techniques and new possibilities for promotion of exports. The FDI 
policy statement under NIP thus clearly underscores the relative merits of FDI in 
promoting India's economic growth and development. 
3.2 	Global FDI Trends and Pattern of Flows: 
The importance of FDI as an instrument of economic development and growth was 
felt immensely after world debt crisis of eighties. Gradual decline of non-equity 
sources of foreign capital gave further impetus to non-debt creating foreign capital 
which comes in the form of equity investment viz. FDI and foreign portfolio 
investment. In addition, most important drivers of the FDI and internationalization of 
production network owes to the increasing globalization of firms resultant on the 
liberalization moves most of the countries, especially developing nations and the 
advent of information and communication technology. 
3.2.1 Trends of Global Fl)! Flow: 
Global regional flows of FDI have witnessed manifold growth during the period from 
1991 to 2008, representing a more than ten-fold increase from a level of US $ 158.94 
billion in 1991 to US $ 1697.0 billion in 2008 (Table 3.1). 
The major share of FDI flow of about 62 percent during 1991-98 was towards the 
developed countries, leaving nearly 34 percent to developing countries. The share of 
developing countries has shown a steady improvement during this entire period, 
which increased from about 26 percent in 1991 to a high of 41 percent in 1994 
(LT'CTAD 2001). The decline in the developed countries share of FDI inflows during 
the same period could be attributed to locatiomal shift of the business activities of 
TNCs to developing countries. The implications of decreasing share of FDI inflows 
into developed countries and its resultant increase of FDI flows to developing 
countries was far-reaching and more desirable from the viewpoint of convergence of 
economic growth across countries. 
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Table 3.1: Trends in Global Regional Inflows of FDl (1991-2008). 
(In US S billions) 
Year 	Total Inflows 
Developed 
Countries 
Developing 
Countries 
Share of 
Developing 
Countries 
1991 158.9 114.8 41.7 26.2 
1992 175.8 120.3 51.1 29.1 
1993 219.4 133.9 78.8 35.9 
1994 256.0 145.1 104.9 41.0 
1995 331.1 203.5 113.3 34.2 
1996 384.9 219.7 152.5 39.6 
1997 477.9 271.4 187.4 39.2 
1998 690.9 472.6 194.1 28.1 
1999 1086.8 828.4 231.9 21.3 
2000 1388.0 1108.0 252.5 18.2 
2001 817.6 571.5 219.7 26.9 
2002 678.8 489.9 157.6 23.2 
2003 559.6 366.6 172.0 30.7 
2004 N.A. 396.0 N.A. N.A. 
2005 959.0 611.0 316.0 33.0 
2006 1411.0 941.0 413.0 29.3 
2007 1979.0 1248.0 500.0 27.3 
2008 1697.0 962.0 621.0 37.0 
Notes: (a) Classification of developing countries is as per the UNCTAD. 
(b) Percentage share may not sum up to 100 due to reporting errors. 
Source: Compiled from UNCTAD. world investment report, United Nations (various issues). 
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Figure 3.1: 
Trends in Global Regional Inflows of FDI (1991-2008) 
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The TNCs which function as the major source of the carriers of the cross—border 
investment the increasing trend of FDI inflow from developed countries to developing 
countries could serve to a greater extent in closing the `objects and ideas gaps' that a 
developing nation might have in the process of economic development, thus, 
facilitating convergence of economic growth and bridging the gap between developed 
and developing countries (Romer, 1993: 543-573). There has been improvement in 
the shares of developing nations from about 21 percent in 1999 to 31 percent in 2003. 
There after due to financial and economic crisis, global FDI inflows fell from a 
historic high of US $ 1979 billion in 2007 to US$1697 in 2008 (14 percent decline) 
(Table 3.1). In 2009 inflows fell further to 44 percent as compared with their level in 
2008 (UNCTAD, 2009: 3). A slow recovery is expected in future. 
The crisis also changed the investment landscape, of developing and transition 
economies. The share of developed and developing countries in the global FDI inflow 
was 57% and 37% respectively in 2008. FDI flows to developing countries when 
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compared with all other capital flows, constituted a major component, accounting for 
more than 72 percent of all resources flows (UNCTAD. 2004). It is interesting to note 
that while global FDI inflow increased more than ten times, the increase for 
developed and developing nations was more than eight and fifteen times respectively 
during 1991-2008. As tar as compound annual growth rate (CAGR) are concerned 
for the total FDI inflows, and to developed and developing countries was 22.76%. 
17.87% and 24.28% respectively during 2005-08. 
Within the developing countries, FDI flows to Asian countries remained dominant 
throughout the period which rose from a mere US S 23 billion in 1991 to a high level 
of US S 146 billion and thereafter it registered a slowdown to US $ 107 billion in 
2003. Several micro, macro and institutional factors were responsible for the 
continued decline in inward FDI flows during 2001-2003 (UNCTAD 2003). In this 
entire period the growth prospects for many countries remained uncertain including 
the performance of major stock markets, which stayed below from the peak of 2002. 
At micro level, lowered profitability coupled with high debt equity ratio continued to 
force large companies to downsize their operations. 
China emerged as the top recipient of FDI inflows in Asian countries with a 
percentage share of 17.4 percent in developing countries total FDI inflows in 2008. 
Other Asian countries such as Hong Kong and Singapore received 10.1 percent and 
3.7 percent respectively. However India's share in developing countries total FDI in 
the region was lower than the above mentioned countries but higher than the 
Philippines and Taiwan with 6.7%, 0.2% and 0.9% respectively in 2008 (Table 3.2). 
The success of Asian countries in attracting FDI lies in an investment climate 
characterized by growing markets and favourable regulatory framework (UNCTAD, 
1995). India and China share many similarities in terms of market size and 
advantageous cheap skilled labour force permeated with huge potential for future 
growth. 
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Table 3,2: Share of Fill Inflos's in Developing Countries: Selected Asian Countries (1991-2008). 
(In percent) 
S. 
No. 
Developing 
countries 
1991 1992 1993 1994 1995 1996 1991 1998 1999 2000 2001 2002 2003 2004 2005 2006 .'007 2008 
I, China 10.5 21.8 34.9 	32.2 31.6 26.4 23.6 23.4 17.4 16.1 21.3 33.5 31.1 22.0 21.7 16.8 l5. 17.4 
2.  1lung Kong 4.1 4.0 4.6 7.S S.S 6.9 6.1 7.6 10.6 24.5 10.8 6.1 79 12.4 10.7 10.4 10.3 10.1 
3.  Indonesia 1.8 3.5 2.5 2.0 3.8 4.1 2.5 -0.1 -0.8 -1.8 -1.4 0.1 -0.4 0.7 1.6 II 1.3 1.3 
4.  Korea 
Republic 
1.1 1.4 0.8 1.0 1.6 1.5 1.5 2.6 4.1 3.4 1.7 I.9 2.2 2.8 2.2 1.1 	0.5 1.2 
. 	11alaysia 3.9 10.1 6.4 4.4 5.1 4.8 3.5 1.4 1.7 1.5 0.3 2.0 1.4 1.7 1.2 1.4 	1.6 1.3 
6. Philippines 1.2 9.5 1.6 1.5 1.3 1.0 0.7 1.1 0.7 0.5 0.5 	1.1 	0.2 0.3 0.3 	0.7 0.6 0.2 
7. Singapore 8.6 4.3 6.1 8.2 7.8 6.8 7.0 4.1 7.0 6.8 6.8 	3.6 6.6 5.4 6.0 	6.4 6.0 3.7 
8. Taiwan 2.5 1.1 1.2 1.3 1.4 1.2 1.2 0.1 1.3 2.1 1.9 	0.9 0.3 0.7 0.5 	1.7 1.5 0.9 
9.  Thailand 3.2 4.1 2.3 1.3 1.8 1.5 2.0 3.9 2.6 1.3 1.7 0.7 1.1 0.5 I.I 	2.2 2.1 1.6 
10.  India 0.4 0.5 0.7 0.9 1.9 1.7 1.9 1.4 0.9 0.9 1.6 2.2 2.5 2.0 2.0 4.7 4.7 6.7 
Note: Classification of developing counties as per the UNCTAD. 
Source: Compiled from UNCTAD, World Investment Report, United Nations (various issues). 
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Figure 3.2: 
Share of FDI Infows in Devebpirg Countries 	Selected Asian Coflries (1991.2008) 
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3.2.2 National Regulatory Changes Introduced by Countries of the World: 
National laws and regulations related to FDI shows that 110 new FDI related 
measures were introduced by a total of 55 countries in 2008 (Table 3.3). Of these 85 
measures were more favourable to FDI as compared to 1991, where only 35 countries 
changed their investment regime, of which 80 measures were more favourable to 
attract foreign investment. 
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Table 3.3: National ReQulatoiv Changes (1991-20081. 
Year 
Countries that 
changed their 
investment regime 
Number of 
regulatory changes 
Number of 
regulatory change 
that made FDI more 
favourable 
1991 35 82 80 
1992 43 77 77 
1993 56 100 99 
1994 49 110 108 
1995 63 112 106 
1996 66 114 98 
1997 76 150 134 
1998 60 145 136 
1999 65 139 130 
2000 70 150 147 
2001 71 207 193 
2002 72 246 234 
2003 82 242 218 
2004 103 270 234 
2005 92 203 162 
2006 91 177 142 
2007 58 98 74 
2008 55 110 85 
auuj~c. t,umpIicu irurn ur i Au, woria inves meni Keport, 2UUI and 1UU5. 
Figure 3.3 : 
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A survey conducted b\ UNC'TAD fbr finding the ten most attractive destinations for 
FDI by factor favourin investment during, 2007-2009 revealed that China is the most 
preferred investment location with respect to percentage of respondents (52 percent) 
followed by India (41 percent). USA (36 percent), Russian federation (22 percent) 
Brazil (12 percent), Vietnam (1 l percent). ['K (10 percent), Poland (7 percent). 
Germany (7 percent), and Australia (6 percent). The two leading host countries for the 
locational FDI inflow are India and China. In fact two-third of the companies that 
participated in the survey, had plans to invest in either or both of these two nations. 
Although as regards to investor's preference the two nations enjoy the same 
advantages in terms of labour cost, size and growth of market but India ranks higher 
in terms of skilled labour and second largest english speaking country. But still certain 
constraints are there in these two countries such as government ineffectiveness and 
low access to capital market, un-suitable investment environment, low access to 
natural resources, government ineffectiveness etc. 
3.2.3 Comparing Performance and Potential: 
Comparing the two indices a four-told matrix can be drawn up of inward FDI 
performance and potential. 
FDI Performance 
High Low 
High Front Runners Below Potential 
Low Above Potential Under Performers 
P 
Front Runners: Countries with high FDI Potential and Performance. 
Above Potential: Countries with low FDI potential but strong FDI performance. 
Below Potential: Countries with high FDI potential but low FDI performance. 
Under Performers: Countries with both low FDI potential and pertorriance. 
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Based on the above matrix, the result for the year 2006 is given below. Though FDI in 
India is showing increasing trends it is still ranked as an under performer, when the 
performance and potential is compared with other countries in the world (Box 3.1). 
Important reasons for the low levels of FDI inflows registered until recently are low 
GDP per capita, low literacy rate, poor social and economic infrastructure, uncertainty 
about government, high tax rates and huge corruption, rigid labour laws etc. 
Box 3.1: Matrix of Inward FDI Performance and Potential (2006). 
HIGH PERFORMANCE LOW PERFORMANCE 
Front Runners Below Potential 
Azerbaijan, 	Bahamas, 	Bahrain, Algeria, 	Argentina, 	Australia, 
Belgium, 	Brunei, 	Darussalam, Austria, 	Belarus, 	Brazil, 	Canada, 
Bulgaria, 	Chile, 	Croatia, 	Cyprus, China, Denrnark, Finland, France, 
the Czech Republic, the Dominican Germany, Greece, Ireland, Islamic 
Republic, 	Estonia, 	Ilong 	Kong Republic 	of 	Iran, 	Italy, 	Japan, 
y (China), 	Hungary, Iceland, Israel, Kuwait, 	the 	Libyan 	Arab 
Jordan, 	Kazakhstan, 	Lativa, Jamahiriya, 	Vlaxico, 	Norway, 
Lithuania, Luxembourg, Malaysia, Portugal, 	Qatar, the Republic 	of 
Malta, Mongdia, the Netherlands, Korea, 	the 	Russian 	Federation, 
Newzealand, 	Oman, 	Panama- Slovenia, 	Spain, 	Switzerland, 
Poland, 	Romania, 	Saudi 	Arabia. Taiwan 	Province 	of 	China. 	the 
Singapore, 	Slovakia, 	Sweden, United 	State and the 	Bolivarian 
Thailand, 	Trinidad 	& 	Tobago, Republic of Venezuela. 
Tunisia, 	Ukraine, 	United 	Arab 
Emirates and United Kingdom 
Above Potential Under-Performers 
Albania, Armenia, Botswana, Angola, Bangladesh, Benin, 
Colombia, Cango, Costa- Rice, Bolivia, Burkina Faso, Cameroon, 
Egypt, Ethiopia, the Gambia, Coted'Ivoire, the Democratic 
Georgia, Guinea, Guyana, Republic of Congo, Ecuador, El 
Honduras, Jamaica, Kyrgyzstan, Salvador. Gabon, Ghana, 
Lebanon, Moldova, Namibia, Guatemala, Haiti, India, Indonesia, 
V Nicaragua, Nigeria, Peru, Sierra Kenya, Madagascar, Malawi, Mali, e Leone Sudan. Tajikistan, the FYR ' Morocco, Mozambique, Myanmar, 
i of Macedonia, Togo, Uganda, the Nepal, Niger, Pakistan, Papua, New 
y°  Republic of Tanzania, Uruguay, Guinea, Paraguay, Philippines, 
o Vietnam and Zambia. Rwanda, Senegal, South Africa, Sri 
Lanka, Suriname, the Syrian Arab 
Republic, Turkey Uzbekistan, 
Yemen and Zimbabwe. 
Source: Compiled from UNCTAD, World Investment Report, 2008. 
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3.2.4 Inward FDI Performance Index: 
The inward FDI Performance index of the UNCLAD is an instrument to compare the 
relative performance of countries in attracting FDI inflows. This measure ranks 
countries by the FDI they receive relative to their economic size'. It is the ratio of a 
country's share in global inward FD( tlows to its share in global GDP`'. There are a 
large number of other variables, which influence the FDI inflows to an economy, but 
these factors influence may vary under varying degree of openness and regimes. 
Under similar conditions the size of the economy can be a major determinant of FDI. 
The value of index which ranges between greater and lesser than one indicates 
countries power of receiving higher amount of FDI relative to its size and countries 
receiving lesser amount of FDI relative to its size respectively. However a negative 
value of the index which is an infrequent occurrence can mean the disinvestment by 
MNCs during the year. 
It is evident that India has an index that is significantly lower than other Asian 
countries like Singapore, Malaysia, Indonesia and Korea since its index value is 
below one. Now it has shown a gradual improvement over subsequent periods from 
0.066 during 1988-90, to 0.155 during 1998-2000 and upto 0.215 during 2001-02 
(Table 3.4). India ranked 112 in a total of 141 selected countries considered for FDI 
Performance index computation during 2005-07 (UNCTAD, 2008). This 
improvement shows that the policy regime in India must be slowly moving towards a 
more open economy by shedding the protectionist economic policies. However, India 
also shows deterioration in terms of the ranking of the Indices. If India has to compete 
strongly for more FDI than larger reforms are required at the macro-economic front. 
l . 	I he inward FIN Perti)nnance index is shown for a three year period to offset annual 
fluctuations in the data. This indices covers 141 economies for as much of the period as the 
data permit. however some countries could not be ranked in the early years for the lack of 
data. 
2. 	The inward FDI performance index methodology is given as: INDi 	[(FDIi) (FDIW)] 
[(GDPi) / (GDPw)l where 'I' is the country and 'w is the world and 'INDi' is inward FDI 
performance index of the i' country as given in World Investment Report. 
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Tahle 34: Inward FDI Performance Index of some Selected Countries. 
1988-1990 
Country 
1998-2000 2000-2002 2003-2005 	2005-2007 
Rank Index Rank Index Rank Index Rank Index Rank Index 
China 46 1.033 51 1.198 50 1_331 53 NA 75 NA 
Hong 
Kong 
3 5.292 2 6.033 2 6.508 6 NA 2 NA 
India 98 0.066 119 0.155 121 0.215 115 	NA 112 NA 
Indonesia 56 0.794 137 -0.570 121 -0528 127 NA 104 NA 
Republic 
of Korea 
81 0.369 91 0.587 107 0330 116 NA 124 NA 
Malaysia 4 4.355 49 1,248 70 0.923 71 NA 69 NA 
Philippines 30 1.689 87 0.641 90 0.618 109 NA 101 NA 
Singapore I 13.599 7 3.737 6 4.755 5 NA S NA 
Thailand 17 2.562 44 1.375 80 0.753 66 NA 56 NA 
United 
States 
41 1.115 78 0.805 92 0.589 118 NA 116 NA 
Note: 	I he data shown for the three years periods moving average. 
NA: 	Refers to not available- 
Source: Compiled from UNCTAD, World Investment Report (various issues). 
3.2.5 Inward FDI Potential Index: 
The inward FDI potential index3 of the UNCTAD is an instrument to compare the 
relative potential of different countries in attracting FDI inflows on the basis of the 
selected 12 socio-economic variables apart from market size affecting inward FDI 
flows. Countries are ranked by value of the index computed through a composite 
score. The USA remained in the first place throughout the period 1988-2006 
(UNCTAD, 2008). India improved its rank to 84 h` position during 2004-06 with its 
value of the index featuring a continuous improvement from 0.120 during pre-reform 
period (1988-90) to 0.159 during 2000-02 in the post reform period (Table 3.5). 
China, the largest recipient of FD[ in the developing world, was positioned 31 during 
2004-2006 by the FDI potential ranking. While China's FDI inflows were higher than 
USA in recent years in terms of potentiality index, USA still remained the top FDI 
3. 	The inward FDI potential index is shown for the three year period moving average to offset 
annual fluctuations in the data The index covers t41 countries for the period covered. For 
methodology see www.unctad.org. 
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destination by various socio-economic variables. As compared to its economy's size 
India lags behind many countries such as Singapore, Hong Kong and Korea. 
Table 3.5: Inward FDI Potential Index of some Selected Countries. 
Country 
1988-1990 -- 1998-2000 2000-2002 2003-2005 2004-2006 
Index Rank Index Rank Index Rank Index Rank Index Rank 
China 0.176 45 0.255 42 0.273 39 NA 32 NA 31 
Hong Kong 0.355 17 0.426 13 0.413 12 NA 13 NA 12 
India 0.120 72 0.156 91 0.159 89 NA 83 NA 84 
Indonesia 0.177 42 0.161 85 0.163 82 NA 94 NA 97 
Republic of 
Korea 
0.312 20 0.410 17 0.387 18 NA 15 NA 18 
Malaysia 0.205 38 0.302 32 0.292 32 NA 33 NA 36 
Philippines 0.110 76 0.193 69 0.212 57 NA 70 NA 75 
Singapore 0.402 13 0.500 2 0.465 4 NA 3 NA 2 
Thailand 0.182 40 0.225 53 0.215 54 NA 59 NA 61 
United 
States 
0.727 1 0.706 1 0.659 1 NA 1 NA 1 
Note: (a) The data shows three years moving average. 
(b) The indices are measured on a scale of 0 (minimum potential) to I (maximum potential) 
NA: 	Refers to not available. 
Source: Compiled from UNCTAD, World Investment Report (various issues). 
3.2.6 Global Competitiveness Index: 
Another method of assessing the investment potential of an economy for its ranking 
on global competitiveness is the Global Competitive Index (GCI). This 
comprehensive index was developed by the World Economic Forum (WEF) 2008 to 
measure national competitiveness and is published in the Global Competitive Report 
(GCR). It takes into account the micro and macro-economic foundation of national 
competitiveness, in which competitiveness is defined as the set of institutions, policies 
and factors that determine the level of productivity of a country and involves static 
and dynamic components. The overall GCI is the weighted average of three major 
components: (a) Basic Requirements (BR) namely, institution. infrastructure, 
macroeconomic stability. health and primary education, (b) Efficiency Enhancers 
(EE) i.e. higher education and training. goods market efficiency, labour market 
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efficiency. financial market sophistication, technological readiness and market size 
and (c) Innovations and Sophistication Factors (ISF); i.e. business sophistication, and 
innovation. 
Amongst the 131 countries for which GCi was computed, the US is ranked the 
highest with an overall index of 5.67, India was at 48 h` places and is still below that of 
China at 35. In terms of the components, India holds relatively low rank for BR i.e. 
74, but higher ranks for EE i.e. 31 and even higher for ISF i.e. 26 as compared to 
China (WEF, 2008). 
3.2.7 FDI and Gross Domestic Product Ratio: 
FDI inflows as a percentage to GDP is another indicator by which one can measure 
the cumulative FDI absorption relative to the size of an economy. It also signifies the 
relative openness of an economy vis-a-vis its other competing countries. 
A country with a FDIIGDP ratio, greater than unity is reckoned to have received more 
FDI than that implied by the size of its economy. It indicates that the country may 
have a comparative advantage in production or better growth prospects reflecting 
larger market size for foreign firms. However if the economy has the ratio value of 
less than one then it shows that the country may be protectionist and backward. 
Hence, FDI/GDP ratio is an index of the prevailing investment climate in the host 
country. 
The share of FDI inflows in GDP in India has been very small in absolute terms 
remaining less than one during 1991 to 2005 (Table 3.6). However, the ratio improved 
dramatically to 1.66 percent in 2006; thereafter it rose to 2.05 percent in 2007 and 
2.13 percent in 2008, which reflect the growth in the domestic economy, 
improvement in the investment climate as well as the buoyancy in FDI flows. As far 
as CAGR of FDI inflow, GDP, and FDUGDP ratio is concerned it was 27.33%. 
8.96% and 14.02% respectively during the entire period of 1991-2008. 
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Table 3.6: FDI Inflows and GDP in India (1991-2008). 
(In USS billion) 
Year FDI 
GDP (current 
market price) 
FDI/GDP 
( percent) 
1991-92 0.17 288.43 0.06 
1992-93 0.39 290.35 0.13 
1993-94 0.65 275.38 0.24 
1994-95 1.37 323.80 0.42 
1995-96 2.14 367.62 0.58 
1996-97 2.77 389.11 0.71 
1997-98 3.68 420.47 0.88 
1998-99 3.08 424.33 0.73 
1999-00 2.44 453.33 0.54 
2000-01 2.91 467.80 0.62 
2001-02 4.22 482.93 0.87 
2002-03 3.13 505.05 0.62 
2003-04 2.63 591.37 0.44 
2004-05 3.76 694.93 0.54 
2005-06# 5.55 840.47 0.66 
2006-07# 15.73 945.69 1.66 
2007-08# (P) 24.58 1198.03 2.05 
2008-09# (QE) 27.33 1284.44 2.13 
Note: (a) GDP used Base yearl999-2000. 
#: Base year 2004-05. 
P' refers to provisional, 
'QE' refer to quick estimates 
Data from 1993 onward are based on FEDAI (Foreign Exchange Dealers Association of India) 
indicatives rates. During 1991-93data are based on official exchange rate. 
(b)(iDP figures are given in rupees. These have been converted to USS figures by using the average 
cxchan_e rates for relevant financial years obtained from RBI. Ilandbook of statistics on Indian 
I-c nomvv 2010 (www.rhi.ort.in 
Source: Compiled from handbook of Statistics of the Indian Economy. RRI, 2007& 2010, Mumbai. 
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3.3 	Evolution of FDI Policy in India: 
For the purpose of analysis the study has been divided in two broad categories. 
1) FDI inflows in Pre-reform period. 
2) FDI inflows in post-reform period. 
3.3.1 FDI Inflows in Pre-reform Period: 
At the time of independence, the attitude towards foreign capital was one of fear and 
distrusts due to previous exploitative role played by the Britishers. The legal and 
constitutional framework governing FDI in India consisted of a complex jumble of 
legislative enactment and policy directions designed primarily for the regulation of 
domestic investment. The government exercised complete discretion and authority in 
interpreting and applying these legal and policy provisions to shape and control the 
FDI. The indoor government policy towards FDI before economic reform may be 
discussed under three different phases. Though these are not directly separable, it is 
convenient to look at these three phases. 
3.3.2 The Phase of Cautious and Selective Attitude towards FDI (1948-1967): 
After independence India adopted highly protective approach towards foreign capital 
though it was too ambitious towards the import of foreign capital. The industrial 
policy resolution of 1948 acknowledged the need for foreign capital to supplement the 
domestic saving in financing higher levels of investment. However it advocated an 
effective Indian control over the management of such foreign capital to ensure its 
regulation in the national interests (Gopiunath, 1997: 454). The suspicious hostility 
found expresses in the industrial policy of 1948, which although recognizes the role of 
foreign investment in the country emphasized that its regulation was necessary for 
national concerns. The aforesaid attitude resulted in obstruction of capital imports. In 
1949 Prime Minister JL Nehru emphasizes the necessity of foreign capital to 
parliament that it is necessary to supplement domestic capital but also to secure 
scientific, technical and industrial knowledge and capital equipment. Furthermore, 
Prime Minister JL Nehru has made a statement in 1949 giving three important 
assurances to foreign investors. 
65 
( /ulpter - 3 
' India would not make any discrimination between ti~reign and domestic 
Investors. 
Foreign exchange. permitting reasonable facilities would he given to foreign 
investors for remittance of profits and repatriation of capital. 
In case of nationalization of undertaking fair and equitable compensation 
would be paid to foreign investors. 
Though restrictions on FDI were relaxed but majority ownership and control was 
preferred in local hands except those industries using highly sophisticated technology 
and for export oriented sectors. A crisis in financial resource mobilization during 
1956-61 has further liberalized its attitude towards FDI. In a hid to attract foreign 
investment to finance foreign exchange component of projects a host of incentives 
and concessions were introduced. 
In 1961 foreign investment were welcomed in those industries which were earlier 
reserved for the public sector such as drugs, aluminum, heavy electrical equipment, 
fertilizers and synthetic rubber etc. The government also assured to treat equally 
foreign firms at par with domestic tines. By a declaration issued on June 2, 1950, the 
government assured the foreign capitalists that they could remit the profits on foreign 
investment made by them in the country (Mishra & Puri, 2002: 700). The policy 
statement of government issued on 1949 continued till 1956 industrial policy 
resolution, which had opened up immense field for foreign participation. The 
government failure to control TNCs especially the large oil companies who imported 
crude oil from the parent companies and shipped it their own tankers has led to the 
formation of the oil and natural gas commission (ONGC) and Indian Oil Corporation 
(IOC) in 1955 and 1959 respectively primarily with the objective of reducing the 
monopoly of the oil companies (Martinussen, 1988). This policy of state intervention 
also confronted to `commanding heights' of the objective of the 1950 industrial policy 
resolution. 
3.3.3 The Phase of Restrictive Attitude towards FDI (1968-1979): 
In the late 1960's the effects of foreign economic domination and foreign exchange 
drain have brought the tightening of the restrictions for FDI. regime. The liberalization 
of the policy towards foreign capital till mid 1960's have resulted in the outflows on 
account of remittance of dividends, profits. royalties and technical fees grew sharply 
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and become a significant proportion of the foreign exchange account of the country. 
This has resulted in foreign exchange crisis in the late 1960's and has led to the 
streamlining of procedures for foreign collaboration approvals and the adoption of a 
restrictive attitude. 
In 1968, on the recommendation of the Mudaliar Committee on foreign 
collaborations, Foreign Investment Board (FIB) was set up to deal with the case of 
foreign investments and collaborations with a maximum limit of 40 percent to the 
paid up equity capital of the company and upto Rs. 20 million share capital. The cases 
exceeding this limit was considered special and referred to the cabinet committee. A 
sub-committee of the FIB was empowered to approve cases involving foreign 
collaborations in which the proportion of foreign equity held did not exceed 25 
percent with an upper limit to Rs. 10 million. The administrative ministers were 
authorized to approve cases involving purely technical collaborations. Foreign 
investors unaccompanied by technology were not permitted (Kumar, 1994: 34). 
During this period, FDI was restricted on those coming without technical 
collaborations. Government also listed the industries where foreign participation was 
not desirable on the ground of local capabilities. Payment of royalties and fees was 
also capped to certain limits. Restrictions were also extended with respect to renewal 
of foreign collaborations and guidelines to use Indian consultancy services. 
In 1969 a more precise policy was evolved, Industries were divided into three groups, 
i.e. (i) foreign collaborations was not considered necessary (ii) FDI with technical 
collaboration, (iii) and only technical collaboration. Though, foreign collaborations 
were entertained in two out of the three industrial groups, viz., (i) FDI with technical 
collaboration, (ii) and only technical collaboration. 
The regulatory framework for FDI continued and was further consolidated with the 
enactment of Foreign Exchange Regulation Act (FERA), 1973. FERA required 
foreign companies to undergo compulsory registration under Indian corporate 
legislation upto a foreign equity holding of 40 percent. As a result of which flexibility 
of FERA was extended to foreign companies engaged in tea plantations, exports 
oriented business and high technology and high priority areas (Kumar 1998: 1322). 
'the exemptions given in FERA were for the following categories of non-resident 
companies. First companies were permitted to hold 74 percent of equity abroad if 
exports were of more than 60 percent of outputs. Second, permission for 51 percent of 
equity holding was allowed if 60 percent of the company's turnover was in core sector 
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with 10 percent of export commitment. Third. 100 percent export oriented companies 
were allowed 100 percent equity holding. Nevertheless, there was no discrimination 
between domestic and foreign companies apart from FERA companies. 
During, 1970. regulatory regime was tightened. as reflected in the industrial policy 
statement of 1977, which prohibited foreign collaborations in certain industries on the 
ground that indigenous technology in these industries had sufficiently developed. 
These industries included metallurgical, mechanical, engineering, rubber, chemical 
(other than fertilizers) and drugs and pharmaceutical industry. 
The regulatory framework under FERA was a partial success due to foreign exchange 
constraint, to some extent the objective of equity dilution was also fulfilled. As a 
result, the number of foreign branches came down considerably from 500 in 1974 to 
300 in 1980 (Martinussen, 1988). Several sectors of the industry were closed to 
foreign firms altogether. In many others, official entry conditions were so 
cumbersome and restrictive that new foreign capital inflows were effectively blocked. 
Thus, while achieving very little in the context of existing TNCs, FERA was effective 
in scaring away potential investors. The period from 1970-80 was the most restrictive 
from the point of view of FDI mainly because implementation of FERA was the 
principal item on the agenda of policy makers. 
However, to promote exports, during this period the Government established free 
trade zones (FTZs) at Kandla (Gujarat) and Santa-Cruz (Mumbai) in 1965 and 1972 
respectively. 
In 1973, more specific policy was evolved, detailing the number of industries where 
foreign companies could operate with or without FDI. Once again, the restrictions of 
FDI were made to sectors producing basic intermediate, capital and consumer goods. 
At the same time, the foreign equity limit was revised upward from 40 percent to 49 
percent in high technology and priority sectors and foreign participation was limited 
to only government joint ventures. 
3.3.4 The Phase of Semi-Liberalization (1980-1990): 
During this period, a partial liberal attitude towards foreign investment came into 
being with the announcement of industrial policy of 1980 and 1982 and Technology 
Policy of 1983. This phase was characterized by changes in the policy direction such 
as de-licensing some of the industrial rules and promotion of Indian manufacturing 
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exports, emphasizing on modernization of industries through liberalized imports of 
capital goods and technology. The restrictive features of Monopoly Restriction and 
Trade Policy (MRTP) Act were also liberalized. The policy changes, specilie to 
foreign investments included (i) setting up of four new Export Processing Zones 
(EPZs) for attracting foreign companies and (ii) relaxation of FERA for 100 percent 
Export Oriented Units (EOUs). Besides relaxation on 40 percent ceiling on foreign 
ownership was given and also on rules and procedures regarding payments of 
royalties and technical fees. This period marks the trade liberalization by tariff 
reduction and shifting of large number of items from import licensing to Open 
General Licensing (OGL). Further in March 1990 Government abolished industrial 
licensing for new units, for fixed investment upto Rs 250 million (Rs. 750 million for 
export oriented units) and units located in recognized backward areas (Kumar 1994: 
53). The foreign collaboration was freely allowed provided that the royalty payment 
did not exceed 5 percent on domestic sales and 8 percent on exports. 
All the measures adopted during this phase in fact enabled India to further move 
ahead with the process of liberalization, Privatization and globalization. 
3.3.5 Trends of FBI Inflows during Pre-reform Period: Before 1991: 
After independence the cautious FDI policy was resulted in a low level of FDI inflow 
in India. The amount of FDI increased from US$ 79 million in 1980 to reach a peak 
level US $ 252 million in 1989 thereafter it declined US $ 237 million in 1990 (Table 
3.7). The overall FDI inflow during 1980 to 1990 was fluctuating. FDI increased three 
times during the period of 1980-1990 and the CAGR (actual) wasl9.05% during the 
same period of time. 
Chapter - 3 
Table 3.7: FDI Inflow in India: Approval Vs Actual during 1980-90. 
(USS million) 
Year Approval Actual % growth (Actual) 
1980 11.2 79.0 - 
1981 12.5 92.0 16.5 
1982 66.2 72.0 -21.7 
1983 61.0 6.0 -91.7 
1984 99.4 19.0 216.7 
1985 102.9 106.0 457.9 
1986 84.9 118.0 11.3 
1987 83.1 212.0 79.7 
1988 172.3 91.0 -57.1 
1989 195.2 252.0 176.9 
1990 73.3 237.0 -6.0 
Source: Compiled from India's Investment Center. New Delhi and UNCTAD, World Investment 
Report (various issues). 
Figure 3.5 : 
FDI Inflow in India, Approval vs. Actual during 1980-90 
Years 
* Approval ♦- Actual -- percent growth (Actual) 
3.3.6 Country-wise break-up of FDI flows during Pre-reform Period: 
There was almost a fluctuating trend during the 1981 to 1990. The important feature 
is that except Germany (its share declined from US$6.2 million in 1980 to 5.5 million 
in 1990) almost all the countries have positive trend in FDI in inflows in India. In the 
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year 1981 the top five investing countries were Germany, USA, UK, Japan and 
Switzerland and together they accounted for 86 percent of total FDI inflows. In 1990, 
the top five investing countries are USA, Switzerland, Germany, UK and Italy and 
together, they accounted nearly 57 percent of FDI inflows (Table-3.8). 
Table: 3.8- FDI Inflows by Country of origin during 1981-1990. 
(In USS million) 
Year/ 
Country 
USA Germany Japan UK Italy Switzerland Others Total 
1981 2.6 6.2 0.7 0.8 0.1 0.5 1.6 12.5 
1982 5.3 3.7 26.5 1.7 4.2 1.2 23.6 66.2 
1983 13.7 4.8 15.9 9.7 1.1 1.1 14.7 61.0 
1984 7.9 2.5 5.4 1.6 0.7 0.4 80.9 99.4 
1985 32.3 9.6 12.7 3.0 5.6 0.7 38.1 102.0 
1986 23.3 16.0 4.6 6.1 1.9 2.6 30.4 84.9 
1987 22.8 7.6 5.3 6.5 2.3 6.8 31.8 83.1 
1988 69.8 22.3 12.5 10.0 22.0 1.2 34.5 172.3 
1989 38.3 74.2 5.4 20.6 4.3 4.8 47.6 195.2 
1990 19.7 5.4 2.9 5.2 3.9 7.7 28.5 73.3 
Note: Data are on approval basis and has been transferred from the exchange rate taken from the 
International Financial Statistics (Year Book) IMF, 2003. 
Source: Compiled from Indian Investment Center. 
Figure 3.6: 
t00 FDI Inflows by Country of Origin during 1981-1990 
Years 
-&USA ♦-Germany *-Japan -e-UK  
4-Italy Switzerland Others 
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3.3.7 Sector-wise break-up of FDI Inflow during Pre-reform Period: 
The top five sectors which have attracted the bulk of FDI were industrial machinery, 
chemicals, mechanical engineering, electrical and electronics and metallurgy and 
together they accounted for 54.87 percent in the year 1981. In 1990, the top five 
sectors were electrical and electronics, chemicals. industrial machinery, mechanical 
engineering and metallurgy and together they accounted 68.14 percent of the total 
FDI inflows (Table-3.9). 
As regards sector-wise distribution of foreign collaborations in terms of number, the 
largest number of 1678 out of a total 7486 during this period was in electrical and 
electronics sector with a share of 22.4 percent followed by industrial machinery with 
21.7 percent, chemical industry, mechanical engineering with 10.1 percent and 
transport sector with 6.7 percent (Gakhar, 2006: 64). 
Table: 3.9- Sector-wise distribution of FDI inflows during 1981-1990. 
(In US million) 
_ L 1I l  v. 	O 
C U 
Lr ^ rC O 
1981 1.2 1 2.7 1.2 0.1 5.1 11.3 54.87 
1982 35 1 2.1 0.6 0.3 20.4 59.4 65.66 
1983 0.8 7.7 2 2.3 0.5 20.4 33.7 39.47 
1984 62.4 5 4.7 4 2.2 0.7 79 99.11 
1985 7.1 24.4 2.7 6.8 12 10.7 63.7 83.20 
1986 23.8 23 0.8 6.4 10.9 1 65.9 98.48 
1987 31.3 14.2 6.2 1.3 1 5.8 59.8 90.30 
1988 25.1 28.3 3.1 9 9.5 30.3 105.3 71.23 
1989 57.5 24.4 2.5 3.9 12.4 25.8 126.5 79.60 
1990 8.6 9.8 4.5 3.6 1.3 13 40.8 68.14 
Note: Note: Data are on appro%al basis and has been transferred from the exchange rate taken from the 
International Financial Statistics (Year Book) I11:,  2003. 
Source: Compiled from Reserve Bank of India Bulletin (various issues). 
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Figure 3.7: 
Sector-wise Distrbition of FDl Inflows durng 1981-1990 
Years 
* Chemicals t Eiectrical& Industrial 	Mechanical ♦- Metallurgy Others 
Electronics Machinery Engineering 
3.4 	FDI inflows in Post-reform Period: Since 1991: 
After mid 1990 the political disturbances along with other economic problem gave 
rise to severe financial crisis in the Indian economy. The high rate of inflation, fiscal 
deficit and political instability downgraded the international credit of the country. 
This resulted in the erosion of the international community's confidence on our 
economy. The outflow of deposits especially by NRIs, a virtual stoppage of 
remittances from Indian workers in the Gulf countries and a sudden break out of Gulf 
war in January 1991 exacerbated the balance of payments crisis. The foreign 
exchange became so scanty that, it was insufficient to pay even for one week imports. 
As a result the economic liberalization process was introduced under Structural 
Adjustment Programme (SAP) with the support of IMF and the World Bank. This 
culminated into a series of economic reforms in 1991 along with a host of industrial 
policy reforms. NIP 1991 recognized the role of FDI in the process of industrial 
development in India in terms of bringing greater competitiveness and efficiency and 
also modernization, technological upgradation, creation a sound base for export 
promotion and above all integrating India with rest of the world. The major highlights 
of NIP 1991 changes are as under: 
Abolition of industrial licensing system except for 18 industries specified in the 
Annex-Il of the statement, which includes those industries which manufactured, 
hazardous chemicals and items of elitists consumption or of national concerns 
social well being and the environment concerns. 
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Ceiling of 40 percent foreign equity under FERA was done away with. 
Removal of registration under %1RTP Act. 
Foreign investment promotion board (IFIPB) was established and has been 
authorized to provide a single window clearance for all project proposals 
regarded by it. 
Introduction of the dual approval system for FDI proposals viz. (1) through an 
automatic approval channel for FDI in 35 priority sectors by RBI upto equity 
participation 51 percent and (ii) through formal government of India channel 
via FIPB/SIA. 
Existing companies were allowed to hike their foreign equity upto 51 percent in 
priority sector. 
%- Liberalization in the use of foreign brands name. 
Abolition of phased manufacturing programme (PMP) for high local content. 
r Dilution of dividend balancing conditions and its related exports obligation 
except in case of 22 consumer goods industries. 
Removal of restrictions of FDI in low technology sectors. 
> Automatic permission for technology agreement in high priority industries. 
Removal of condition for FDI with necessary technology agreements. 
Liberalization of technology imports. 
Permission for Non-Resident Indians (NRIs) and Overseas Corporate Bodies 
(OCBs) under automatic route with repatriation of capital income to invest up 
to 100 percent equity in high priority industries. 
India became a signatory to the convention of the Multilateral Investment 
Guarantee Agency (MIGA) for protection of foreign investments. It protects the 
foreign investors from non-commercial risks including risks of expropriation. 
The MRPT Act has been amended to remove the threshold limits of assets in 
respect of MRTP companies and dominant undertaking. This eliminates the 
requirement of prior approval undertaking. Also eliminates the requirement of 
prior approval of the government of India for establishment of new 
undertakings, expansion of undertakings, mergers. amalgamation and takeovers 
and appointment of directors under certain circumstances. 
Foreign investment in the power sector is actively encouraged and can take 
place either in the form a joint venture foreign equity. 
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r Provisions of FERA have been liberalized through an ordinance dated January 
9, 1993, as a result of which companies with more than 40 percent of foreign 
equity are also now treated on par with fully Indian owned companies. 
- Reduced tari ft' rates on a number of items and made the rupees partially 
convertible, under which 60 percent of export earning were converted at the 
market determined exchange rate under the provision of liberalized exchange 
rate management system (LERMS). Further, in 1993 rupees was made fully 
convertible. 
Tax rate on short term capital gain were reduced from 75 percent to 30 percent. 
An Electronic Hardware Technology Park (EHTP) scheme was set up to permit 
100 percent equity participation. 
All these measures adopted during 1991 marked a major departure of FDI policies 
adopted before 1991 and ushered a new era for FDI in India. These initial measures 
underwent revision and further liberalization measures were introduced subsequently 
after 1991 to project India as one of the top host countries for FDI. Following are the 
major reforms that came into being specifically in 1997, 2000 and post 2000. 
In December 1996, the government permitted automatic approval for FDI upto 74 
percent through RBI in 9 categories of industries. The catalog of items for automatic 
approvals of foreign equity by RBI was expanded by including 3 industries relating to 
mining business for foreign equity upto 50 percent and 13 additional industries for 
foreign equity upto 51 percent. The 48 industries related to mining business eligible 
for automatic approval upto 50 percent foreign equity and another set of industries 
suitable for 74 percent foreign equity was also considered. Besides, this also includes 
a number of other industries, which were crucial for rapid growth of the economy. 
Since 28 February 1996, NRIs were allowed to invest funds on non-repatriation basis 
in money markets mutual fund floated by public and private sector financial  
institutions and commercial banks. 
In January 1997 another 13 industries were brought under 51 percent foreign equity 
participation and 9 other high priority industries in metallurgical and infrastructure 
sectors were earmarked for equity participation which was raised upto 74 percent and 
100 percent for NRIs. A total of 1 1 l sectors were put under automatic approval with 
equity cap of upto 100 74 51i 49 and 24 percent. Further procedural simplification 
was brought in the automatic FD f approval channel. The earlier practice of obtaining 
prior approval was dispensed of and the companies were allowed to inform RBI after 
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shares were issued to non-resident companies. The FIPB relocated from prime 
minister's office to Secretariat for Industrial Approval. Ministry of Commerce and 
Industry. Government of India. 
Foreign Investment Promotion Council (FIPC) was set up by the government with a 
more target-oriented approach towards FDI Promotion. The basic function of the 
council was to identify specific sectors / projects within the country that requires FDI 
and target the specific regions and countries of the world for its mobilization. 
In 1998 NRIs were allowed to purchase shares in Indian companies in the secondary 
market subject to a limit of 5 percent of the company's total equity with 10 percent 
limit for aggregate NRIsiOCBs investment in the companies. State Bank of India 
launched a Resurgent India Bond Scheme denominated in the foreign currencies and 
was open to both NRIs,'OCBs and the bank acting in fiduciary capacity on behalf of 
them. The projects for electricity generation, transmission and distribution, roads and 
highways, ports, harbours and vehicular tunnels were permitted foreign equity 
participation upto 100 percent under the automatic route', provided foreign equity 
does not exceed Rs. 1500 crores. The government allowed 49 percent of the total 
equity in companies producing Global Personal Communications by Satellites 
(GPCS) Services etc. 
In August 1999 government of India set up Foreign Investment Implementation 
Authority (FIIA) within the ministry of industry to facilitate quick translation of FDI 
approvals into implementation by providing a pro-active one step after care service to 
foreign investor like helping them obtain necessary approvals and sorting their 
operational problems. FIIA is assisted by Fast Track Committee (FTC) which has 
been established in 30 Ministries / Departments of Government of India for 
monitoring and resolution of difficulties for sector specific projects (Chopra, 2004: 
123). 
In the year 2000 FDI policies have been further liberalized and all FDIs were 
permitted under the automatic approval route, except for a small negative list. The 
dividend balancing conditions for FDI in 22 consumer goods industries were dropped. 
The existing upper limit for Rs. I500 crores for FDI in projects involving electricity 
generation, transmission and distribution (other than automatic reactor plants) was 
4. 	Under automatic route does not require any prior approval either by govt. or Reserve Bank of 
India. The investors are only required to notify the concerned regional office to the Rf3f within 
30 days of receipt of inward remittances and file the required documents with that office 
within 30 days of issue of shares of foreign investors. 
76 
O ~`5 	CIuupu'r -3 
also dispensed with. The traditional EPZs were renamed as SEZs. It proposed the 100 
percent FDI investment by the automatic route in manufactured activities except for 
the followings (a) arm and ammunition, explosives and allied items of defence 
equipment. defence aircraft and warship, (b) narcotic and psychotropic substances and 
hazardous chemicals (c) atomic substances (d) distillation and brewing of alcoholic 
drink (e) cigarette! cigar and manufactured substances. In addition, the manufacturing 
units in SEZs were not subject to routine examination by customs. The inputs are 
allowed on self-certification basis, and the duty free materials are allowed for five 
years. Besides this a host of procedural simplification and operation were made like 
record keeping, inter unit transfer, sub-contracting, disposal of absolute materials etc 
(Economic Survey 2001-02: 119). Besides this a comprehensive package for 
development of SEZs including entitlement of these zones to procure duty free 
equipment, raw materials components etc. whether imports or purchased locally was 
introduced. Reduction in peak custom duty from 35 percent to 30 percent and it also 
provided an indication to further reductionirationalization in these duties into only 
two slabs of 10 percent for raw materials and components and 20 percent for final 
products (Economic Survey 2002-2003). From November 1'` 2000 the EPZs at 
Kandla Santa Cruz, Kochi and Surat have been converted into SEZs. Approval has 
also been given for setting up SEZs at Manguneri (Tamil Nadu), Posita (Gujarat), 
Kulpi (West Bengal) Paradeep (Orissa), Bhadohi and Kanpur (Uttar Pradesh) Kaki 
Nanda (Andhra Pradesh), Drongiri (Maharashtra) and Indore (Madhya Pradesh). 
In most of the manufacturing sectors such as textiles, paper, basic chemicals, non-
metallic mineral products, metal products, plastic, rubber, drugs and pharmaceuticals, 
ship or boat building, machinery and equipment and automobiles 100 percent FDI is 
permitted with automatic approval. In addition to above sectors such as hotels, 
tourism, courier services, airport, township, urban infrastructure facilities like roads, 
bridges, mass rapid transit system and manufacture of building materials in all metros 
including associated commercial development of real-estates also permitted 100 
percent FDI, but FDI limit to 24 percent continue for SSIs and 26 percent for defence 
equipment in the year 2001. 
The steering committee on FDI was set up by the planning commission in August 
2001 under Chairmanship of N.K. Singh which submitted its report in September 
2002 to the Prime Minister. It recommended that the ban on FDI in retail trade should 
not be lifted while for other sector such as oil marketing, petroleum exploration, 
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banking and financial services and real estates was raised to limit of 100 percent. 
According to committee the main reason for low level of FDI in several sectors was 
due to the absence of a credible regulatory framework. 
In 2004, the National Common Minimum Programme (NCMP) declares that PDl will 
continue to be encouraged and actively sought after especially in areas of 
infrastructure, high technology and exports. 
The peak rate of custom duty for non-agricultural products was reduced from 20 
percent to 15 percent in 2005. An additional 108 items, including 30 items in the 
category of textile products, i.e. hosiery were identified for de-reservation from the 
ambit of SSIs to help textiles and clothing exports in the post-quota regime. The 
emphasis on infrastructure development continued with the decision to set up a 
Special Purpose Vehicle (SPV) for large infrastructure projects. The SEZ bill was 
passed by Parliament in June 2005 and provides many attractive fiscal incentives and 
tax concessions for the developers as well as manufacturers. It provided confidence 
and stability to domestic and foreign investors and signal the government's 
commitment to SEZs policy. At present there are 15 functional SEZs and in principle 
approval has been given to 62 others (Economic Survey 2006-2007: 154). 
Due to financial constraint and declining production in agriculture, 100 percent FDI is 
permitted under the automatic route in floriculture, horticulture development of seeds, 
animal husbandry, pisiculture, aquaculture and cultivation of vegetables and 
mushrooms under controlled conditions and services related to agro and allied sectors 
(Annexure-1). 
Progressive and phased liberalization measures adopted for promoting FD[ during the 
post-reform period created a much-desired environment for business growth and FD[ 
inflows in India. The most important among all are abolition of industrial licensing 
requirement for business set up (except for few industries of strategic and 
environmental and locational concerns), gradual hiking up FDI ceiling in a phased 
manner (Box 3.2), increasing the number of sectors under automatic route and 
keeping few sectors such as industries requiring compulsory licensing, manufacturing 
items reserved for SSIs and investment locations attracting locational restrictions, 
liberalization of foreign exchange regulations by way of simplification of procedures 
for making inward and outward remittances, rationalization of both direct and indirect 
tax structure, rupee made fully convertible on trade account, removal of quantitative 
restriction on imports, financial sector reforms and decontrol of interest rates and the 
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Fiscal Responsibility and Budget Management Act (FRBMA) enacted in 2003. Apart 
from these, there were also several simplifications of procedures as part of investment 
facilitation, such as electronic tiling of applications, online chat facility with the 
applicants, online status on registration/ disposal of applications and dedicated e-mail 
facility for investment related queries to facilitate and hassle free FDI promotion in 
the country. 
Box 3.2: Liberalization of FDI Policies. 
Pre 1991 1991 1997 2000 Post 2000 
Allowed Upto 51 Upto Upto 100 More 	sectors 
selectively percent under 74/5 1/49 24 in percent under opened 	equity 
upto 40 "Automatic 111 sectors "Automatic cap 	raised, 
percent Route" for 35 under Route in all conditions, 
priority sectors "Automatic sectors except relaxed, 
Route", 100 a small foreign 
percent in negative list exchange 
some sectors management 
Source: Compiled from Economics Survey, Planning Commission. Government of India, (various 
issues) and Media reports. 
Apart from the above policy measures for attracting FDI, the Central Government and 
most of the State Governments offer various incentives to attract FDI in most desired 
sectors and also for directing investment to underdeveloped regions. Incentives like 
100 percent profit deduction are available for infrastructure, 100 percent tax deduction 
for exports and undertakings in SEZs and various capital subsidy and fiscal incentives 
are offered for encouraging FDI in underdeveloped northeastern states by the Central 
Government and several State Governments, incentives are also available for 
facilitating FDI projects such as single window approval system for setting up 
industrial units, making exemption of fees.'duty for electricity, registration and stamp, 
giving rebate on land cost, reserving plots for NRIs and EOUs, offering tax 
concessions etc. (Box 3.3). 
These policy changes intended for making India an investors, `friendly destination' 
for FDI has undergone more than a decade's experience. On the other hand, some FDI 
restrictions have been imposed by the government of India in order to protect the 
interest of the country. Sectors such as retail trading (except single brand product 
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retaining given in 26.c). atomic energy, lottery business and gambling and betting are 
prohibited. 
Box 3.3: Various Incentives Schemes for Attracting FDI. 
1)  100 percent protit deduction for developing, maintaining and 
operating infrastructure facilities. 
2)  Tax exemption of 100 percent on export profits for 10 years. 
3)  Deduction in respect of certain inter-corporate dividends to the 
~ 
C 
U 
extent of dividend declared. 
C 
4)  Various capital subsidy schemes and fiscal 	incentives for 
expansion in the north eastern region. 
5)  Tax deduction of 100 percent on profit for 5 years and 50 
percent for the next two years for undertaking in the SEZs. 
1)  Single window approval system for setting up industrial 
• units. 
E v 2)  Electricity duty, registration fees and stamp duty exceptions. 
o -- 3)  Reservation of plots for NRIs, EOUs and foreign investment 
projects. v > 4)  Rebate on land costs, tax concessions and octroi refunds. 
5)  Interest rate and fixed capital subsidy. 
Source: Compiled from Economic Survey, Planning Commission, Government of India, (various 
issues) and media report. 
3.4.1 Trends of FDI during Post-reform Period: 
The 1991, New economic policy measures reversed the past policies to rebuild 
foreign investors confidence in making investment outlets in India. During initial 
years of the reform periods, there used to be a large gap between FDI pledged during 
approval and actual FDI inflows realized in the country. The large difference between 
approval and actual FDI inflows during the early period from 1991 to 1998 may be 
due to liberalization process (Table 3.10). Further, during this period, many sectors 
were kept outside the FDI and those sectors that were available for FDI were tagged 
with upper limit, and other terms and conditions in the form of special case-by-case 
approval if the FDI proposal was outside the automatic channel. Besides, investors 
were cautious about continuity of the policy changes in future. These factors led to the 
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large difference in FDI actual inflows and approvals. which subsequently narrowed 
down during 1998 to 2000. 
Table 3.10: FDI in India: Approvals Vs Actual during 1991-2008. 
(VS S million) 
Year (April- 
Approval 
March) 
 
Actual 
Share of 
Inflows 
Approval 
(percent) 
percent growth
(Actual) 
199l-92 527 165 31.31 - 
1992-93 1976 393 19.89 138.18 
1993-94 2428 654 26.94 66.41 
1994-95 3178 1374 43.23 110.09 
1995-96 11439 2141 18.72 55.82 
1996-97 11484 2770 24.12 29.38 
1997-98 10984 3682 33.52 32.92 
1998-99 7532 3083 40.93 -16.27 
1999-2000 4266 2439 57.17 -20.89 
2000-2001 5754 2908 50.54 19.23 
2001-2002 3160 4222 133.60 45.18 
2002-2003 1654 3134 189.48 -25.77 
2003-2004 1353 2634 194.68 -15.95 
2004-2005 1913 3759 196.50 42.71 
2005-2006 1610 5546 344.47 47.54 
2006-2007* NA 15726 - 183.56 
2007-2008* NA 24581 - 56.30 
2008-2009* NA 27331 - 11.19 
Note: There is difference in aggregate FDI inflows data reported by RBI and SIA. Ministry of 
Commerce & Industry. Government of India. the difference may be due to errors and 
emissions. 
Autust- march 
Includes stock swap of shares USS 3.2 billion for year 2006-2007 and US$ 5 billion for the 
ear _'00--3005. 
Source: Economic Survey 2004-2005. Government of India, New Uelhi and SIA Newsletter (various 
FIN fact'hcets). 
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As far as amount of FDI is concerned it has been increased from US$ 165 million in 
1991 to US$ 4222 million in 2001, but thereafter it declined to US$ 3134 and US$ 
2634 in the year 2002 and 2003 respectively. However 2004 it has shown increasing 
trend. Similarly, growth rate too fluctuated during 1991 to 2009. In the year 1998, 
1999, 2002 and 2003 it was negative i.e. -16.3, -20.9, -25.8 and -15.9 percent 
respectively. Thereafter it increased to a high level of in 2006 i.e. 183.56%. The 
CAGR of actual FDI inflow is 24.28% during 1991-2008. 
3.4.2 Route-wise FDI Inflows during Post-reform Period: 
There are two main channels for the entry of FDI in India, the SIAIFIPB and the RBI 
Automatic Approval Route. From the inception economic reforms in India in 1991 
until the year 2000, most of the FDI came through the government route as there was 
strict monitoring of the approvals, therefore, FDI coming through the SIA/FIPB route 
was greater than the FDI coming through the RBI route (Table 3.11). However, there 
has been a dilution of this trend in the past several years. With the investment boom in 
India and different states competing for attracting FDI, the government has eased 
foreign investment regulations leading to a spurt in FDI coming through the RBI 
route, which is a positive sign. During 1991, 54.1 percent of total FDI was channeled 
through the SIA/FIPB route in contrast to 45.9 percent through the RBI route. The 
route wise FDI inflows fluctuated till 1998. During 1998, the FDI inflows through the 
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SIA/F[PB route accounted for 62.1 percent of total FDI inflows, while through RBI 
only 7.3 percent. Thereafter, there was an increase in share of inflows through the 
RBI's automatic route, a decrease in the share or inflows through the SIA/FIPB, 
whereas the share of inflows through acquisition existed between 30 to 20 percent. 
Table 3.11: Route-wise FDI Inflows in India (1991 -2008). 
(In US$ million) 
Year 
FIPB & 
SIA Route 
RBI 
Automatic 
Route 
Inflows 
through 
acquisition of 
existing 
share# 
RBI 
various 
NRI 
schemes* 
Total 
1991 (Aug.- 	
78 
Dec.) 
- - 66 144 
1992 	 188 18 - 59 265 
1993 340 79 - 189 608 
1994 511 116 - 365 992 
1995 1264 169 	 - 633 2066 
1996 1677 180 	 88 600 2545 
1997 2824 242 266 290 3622 
1998 2086 155 1028 91 3360 
1999 1474 181 467 83 2205 
2000 1474 395 479 81 2429 
2001 2142 720 658 51 3571 
2002 1450 813 1096 2 3361 
2003 934 509 637 - 2080 
2004 1055 1179 980 - 3214 
2005 1136 1558 1661 - 4355 
2006 1534 7121 2465 - 11120 
2007 2586 8889 4447 - 15922 
2008 3209 23651 6169 - 33029 
Total 25962 45975 20441 2510 94888 
Note: 1. Inflows through ADRs GDRs,FCCBs against FDI approvals have not been included. 
3. 4 Data poor to 1996 not provided by the RBI. 
3. * From 2003, RBI's various NRI aehemea inflows included under the heading RBI's Automatic 
Route 
Source: SIA Newsletter April 2009 http://siadipp nic in/ptiblicat'new,lTtr'atig2003/index.httn 
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Figure 3.9: 
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3.4.3 Country-wise break-up of FDI Inflows during Post-reform Period: 
Changing composition of FDI inflows by country of origin is another feature observed 
during post-reform period. The important feature is that almost all the leading investing 
countries have responded positively in response to liberalization policies. During the 
initial period of 1992-98 out of aggregate FDI inflows of US$ 9990 million (Table 3.12) 
79.8 percent of FDI inflows were from top ten countries such as Mauritius (30.7 percent) 
followed by the USA (18.1 percent), the UK (4,7 percent), Germany (6.4 percent) and so 
on. Mauritius is a major source of FDI inflows because of its 'tax haven' status. Double 
taxation avoidance agreement that India entered with Mauritius had become an additional 
benefits in the form of reducing tax liability for TNCs from the USA and the UK to route 
their investments through Mauritius. Although the share of USA has declined 
considerably, however these countries are still the largest source of FD1 inflows. During 
the period 1992 to 2008 percentage shares of FDI inflows from top ten countries 
underwent a compositional shift in favour of Mauritius, Singapore and the USA 
comprising 45.12 percent, 10.04 percent and 9.92 percent of the total inflows of FDI 
worth US$ 72718 million. With share of the UK 5.8 percent, Germany 3.3 percent, and 
Netherlands 4.3 percent and so on. Together they account for nearly 84.9 percent of total 
FDI inflows. 
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Table 3.12: FDI Inflows by Country of Origin during 1992.2008. 
(L.SS nilfion) 
S. 
No. 
Countries 
1992- 
93 
1993- 
94 
1994. 
95 
1995. 
96 
1996- 
97 
1997- 
98 
1998- 
99 
1999. 
2000 
2000. 
01 
2001. 
02 
2002- 
03 
2003. 
04 
2014. 
05 
1005. 
06 
2006. 
07 
2097- 
08 
2008- 
09(P) 
1 otal 
Share 
percent 
I. 1-fauritius NA NA 197 507 846 900 590 501 843 1863 534 381 830 1363 3780 9518 10165 32898 45.12 
2.  USA 12 99 203 195 241 687 453 355 310 364 268 297 469 346 106 950 123(i 212 	9,92 
3.  U.K. 7 98 144 71 54 NA NA NA 61 45 224 157 84 261 1809 508 690 4213 5.79 
4.  Germany 21 35 35 100 166 151 114 31 113 74 103 69 143 45 116 	486 611 .1413 3.32 
S. Netherlands 11 47 45 59 134 159 53 83 76 68 94 197 196 50 559 	601 682 3104 4.27 
6.  Japan 26 37 95 61 97 164 235 142 156 143 66 67 1?2 86 80 	457 266 3300 3.16 
7.  France 9 10 11 NA NA NA NA NA 	93 88 63 34 41 13 I00 136 437 1030 1.41 
8. Singapore 3 10 25 60 76 NA NA NA 32 54 39 IS 64 166 582 3827 3360 7303 16.04 
9. Switzerland 35 23 26 NA NA NA NA NA 8 6 35 5 64 68 57 19.2 135 654 0.90 
10. South 
Korea 
NA NA 12 24 6 333 85 8 14 3 IS 22 14 61 68 86 NA 761 1.05 
II. Others 136 45 76 351 446 562 470 462 194 280 327 218 300 762 1014 3180 2597 10910 15.03 
12. Total 280 404 612 1419 2057 2956 2000 1581 1910 2988 1658 1462 2320 3220 8871 18541 30179 72118 100.00 
Note: NA 	rulers to Not Available. 
P: 	Refer to Provisional 
Data in this table related to only equity capital under the RBI Automatic route and the Government route. Acquisition by shares of Indian companies by 
Non-Resident under section FEMA. 1999 and equity capital of unincorporated bodies are not included. 
Source: Compiled from Annual Report, Reserve Bank of India (various issues). 
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Figure 3.10: 
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3.4.4 Sector-wise break-up of FDI Inflows during Post-reform Period: 
Liberalization of FDI policy is also responsible for a changing sectoral distribution of 
FDI inflows in India. Manufacturing and other sectors which was dominating the 
aggregate FDI inflows during 1990 came down due to the emergence of services 
sector as an important recipient of FDI. During 1992-2000 engineering sector was the 
top most sector for receiving FDI with 20.4 percent followed by electronics & 
electrical equipment (12.5 percent), chemicals and allied product (11.7 percent), 
services (9.4 percent), Finance (7.6 percent), computers (5.8 percent), food and dairy 
products (5.8 percent) and pharmaceuticals (2.6 percent) of the total worth US$ 
13485. Their share together stood at 76.32 percent (Table 3.13A). On the other hand 
during 2000 to 2010 service sector has attracted the largest amount of FDI with a 
percent share of 20.35 followed by computer software with 8.5 percent, 
telecommunications 7.9 percent and soon. Together these top ten sectors accounted 
for 65.30 percent of total inflow during the same period (Table 3.13B). 
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'fable 3,I3;\: Sector-wise distribution of FDI Inflows during 1992.20110. 
(L'SS million) 
1 1999- Share 
Sector 	1992.93 1993-94 1994-95 1995-96 	1996.97 1997-98 1998-99 2000.01 Total 
2000 percent 
EnPeering 70 33 132 252 730 580 428 326 	273 2824 20.94 
Chemical and Allied 
47 72 141 117 304 257 376 120 	131 1581 11.72 
Product 
Finance 4 42 98 270 217 148 185 20 	40 1024 7.59 
Food and Dairy Product 28 44 61 85 238 112 19 121 75 783 5.81 
Services 2 20 93 100 15 321 368 116 226 1261 9.35 
Computers 8 8 10 52 59 139 106 99 306 787 5,84 
Drugs & 
3 50 10 55 48 34 28 54 62 344 2.55 
Phannaceuticals 
Electronics & Electrical 
33 57 56 130 154 645 228 172 213 1688 12.52 
Equipment 
Others 85 79 276 348 292 720 262 553 578 3193 23.68 
Total 280 405 877 1419 2057 2956 2000 1581 1910 13485 	l00.0O 
Note: Includes shares under section S of FEMA 1999 from 1995-96. 
Source: Compiled from, Annual Report, Reserve Bank of India (various Issues). 
Chapter - 3 
Figure 3.11 . 
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Table 3.13B: Sector-wise distribution of FDI Inflows during April 2000 to April 
2010. 
Sectors Amount of FDI Inflows Percentage 
of Inflows 
in terms of 
US$ 
In Rupees 
Crores 
In US$ million 
Service Sector 106992.07 23995.66 20.35 
Computer Software Hardware 44611.13 10044.41 8.52 
Telecommunication 42619.88 9360.76 7.94 
Housing & Real Estates (including 
Cineplex, 	Multiplex, 	Integrated 
Township & Commercial Complex 
etc. 
37614.76 8411.77 7.13 
Construction Activity 36065.91 8136.35 6.90 
Power 21466.46 4750.32 4.03 
Automobile Industry 20863.91 4607.06 3.90 
Metallurgical Industry 13844.71 3220.78 2.73 
Petroleum and Natural Gas 12026.07 2782.74 2.35 
Drugs & Pharmaceutical 7586.01 1707.52 1.45 
Others 182666.34 40925.49 34.70 
Total 526357.25 117942.86 100.00 
Note: (1) Sector-wise FDI inflows data re-classified as per segregation of data from April 2000 
onwards. 
(2) 
	
	Percentage of Inflows worked out in terms of USS and the above amount of inflows received 
through FIPB/SIA route, RBI's automatic route and acquisition of existing shares only. 
Source: Compiled from, SIA Newsletter, Fact Sheet on FDI from August 1991 to April 2010. 
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Figure 3.12 
Sector-wse FDI inflows 	 20% 
(2000-10) 
35% 
• Service Sector 
• Computer Software Hardware  
• TeIecon minicaion 
• Housing& Real Estates 
■ Construction Activity 
Power 
■ Automobile Industry 	 1% 	 8% 
• Metallurgical Industry 2%  
• Petroleum and Natural Ges 	 3% 7% • Drugs & Pharmaceutical 
4%  ■ Others 	 4% 	7% 
3.4.5 State-wise break-up of FDI Inflows during Post-reform Period: 
India is a Union of States with a strong central government. In practice, even in the 
absence of major constitutional reform, the balance of centre-state relations is 
beginning to shift from centralization to a greater acceptance of regional autonomy. 
Economic reforms assigned greater power to state governments and provoked greater 
competition among them. The 1995 decision to allow state governments to retain 
foreign exchange income was a landmark. State governments were free to identify the 
industries in which they wanted investment and to negotiate independently, although 
final clearance has still to be obtained from the FIAB (Foreign Investment Approval 
Board) or the RBI, depending on the size of investment. Greater financial autonomy 
has generally been welcomed by emerging regional elites. Business, with a high 
degree of regional concentration prefers to deal directly with MNCs rather than 
through many additional layers of central bureaucracy. Regional politicians appreciate 
that foreign investments in their states have created fresh employment and thus 
freeing resources for social welfare purposes. Orissa and Bihar are ranked as the worst 
states; to invest Bihar is graded the lowest due to lack of infrastructure facilities, low 
literacy rate and lowest purchasing power in the country however their position are 
improved now. The North and North Eastern States of Jammu & Kashmir, Assam, 
Arunachal Pradesh, Meghalaya, Mizoram, Manipur and Nagaland do not even figure 
on investors maps. Though they have a high investment potential in the field of 
tourism, huge hydropower potential scope for gains from border trades but the 
inadequate infrastructure, high security maintenance, spread of terrorist activities and 
89 
CltciptC,. — i 
natural calamities makes them unattractive of FDI_ The state wise trends in FDI shows 
that the RBI's regional offices at Maharashtra, New Delhi, Karnataka, Gujarat and 
Tamil Nadu and others have been the largest recipients of FDI in terms of cumulative 
FDI inflows with percentage share of 35.2 percent, 20.5 percent, 6.3 percent, 5.8 
percent and 4.9 percent respectively from April 2000 to April 2010 (Table 3.14). 
These states are known for their strong industrial base (like Gujarat) or as the software 
huh (like Karnataka and Delhi) and could be attributed to their better resources, 
infrastructure facilities, investors friendly, policies like single window clearance and 
investment promotion schemes like SEZs. Their share stood at 79.67 percent of total 
FDI inflow during the same period. 
Table 3.14: State-wise distribution of FDI Inflows during April 2000 to April 
2010. 
(In US$ million) 
RBI's Regional 
Office* 
State covered Amount of 
FDI inflows 
percent 
with FDI 
inflow 
Mumbai Maharashtra, Dadar and Nagar 
Haveli, Daman & Diu 39631 35.24 
New Delhi Delhi, Part of UP & Haryana 23055 20.50 
Bangalore Karnataka 7035 6.26 
Alunadabad Gujarat 6517 5.79 
Chennai Tamil Nadu, Pondicherry 5527 4.91 
Hyderabad Andhra Pradesh 4735 4.21 
Kolkata West Bengal, Sikkim, Andaman and 
Nicobar Islands 1393 1.24 
Chandigarh Chandigarh, Punjab, Haryana and 
Himachal Pradesh 749 0.67 
Panaji Goa 488 0.43 
Jaipur Rajasthan 469 0.42 
Others - 22869 20.33 
Total - 112468 100.00 
Note: 	Includes equity capital components only. 
* 	Refer to the region-wise FDI inflows are classified as per RBI's Regional Office received I=DL 
inflows. furnished by RBL Mumbai. 
Source: Compiled front, SIA Newsletter, Fact Sheet on FIN from August 1991 to April 2010. 
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Figure 3.13: 
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3.5 	FDI in India: Reasons for Slow Inflows: 
It has been observed that in absolute figures the FDI inflows in India is impressive but 
compared to the global flows the share of India is far from satisfactory. Since, India is 
a late comer in opening up her economy so it is unable to attract sufficient amount of 
FDI as compared to other developing countries. This is basically linked to its socio-
economic set up and policies taken after independence. The review presents broad 
generalization based on the perceptions of potential foreign investors and independent 
consultants who interact closely with them. It is argued that FDI is expected to play a 
supplementary and subsidiary role since it was used as a vehicle for technology 
transfer. The complete web of regulatory control and bureaucratic intervention 
accompanied by inadequate infrastructure is also regarded as major constraints. Here 
are some of the major policy impediments: 
3.5.1 Attitude of Foreign Investors towards India: 
All investments either foreign or domestic are made under the expectation of future 
profits. The economy benefits if economic policy contributes to the congenial 
investment climate of the economy. This brings up competition, creates a well 
functioning modem regulatory system and discourages artificial monopolies created 
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by the Government through entry barriers. The recognition and understanding of these 
facts can result in a more positive attitude towards FDI. 
There have been some real changes in the policy of the government of India towards 
foreign investment since 1990s, but foreign investors are still looked at with some 
suspicion. As per the traditional view some unhappy events in the past have a 
multiplier effect by adversely affecting the business environment in India. Besides the 
"Made in India" label is not conceived by the world as Synonymous with quality 
(Steering Committee, 2002: 21) when a foreign investor considers making any new 
investment decision, it goes through four stages in the decision making process and 
action cycle that is (a) Screening (b) Planning (c) Implementing (d) Operating and 
expanding. The biggest barrier for India is at the screening stage itself in the action 
cycle. "Often India looses out at the screening stage itself' (Boston Consultancy 
Group). This is primarily because we do not get across effectively to the decision-
making "board room" levels of corporate entities where a final decision is taken. Our 
promotional effort is quite often of a general nature and not corporate specific. India 
is, moreover, a multi-cultural society and a large number of MNC do not understand 
the diversity and the multi-plural nature of the society. Though in several cases, the 
foreign investor is discouraged even before he seriously considers a project, 220 of 
the Fortune 500 companies have some presence in India and several surveys (JBIC, 
Japan Exim bank, A T Kearney) show India as the most promising and profitable 
destination. On the other hand China is viewed as more business oriented because its 
decision making is faster and has more FDI thexidly policies. 
3.5.2 Policy Framework 
Most of the problems for investors arise because of domestic policy rules and 
procedures different from the FDI policy per se or its rules and procedures. The FDI 
policy, which has a lot of positive features, is summarized first, before highlighting 
the domestic policy related difficulties that are commonly the focus of adverse 
comment by investors and intermediaries. 
a) FDI Policy: India has one of the most transparent and liberal FDI regimes 
among the emerging and developing economies. By FDI regime we mean 
those restrictions that apply to foreign nationals and entities but not to Indian 
nationals and htdian owned entities. The differential treatment is limited to a 
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few entry rules spelling out the proportion of equity that the foreign entrant 
can hold in an Indian (registered) company or business. There are a few 
banned sectors and some sectors with limits on foreign equity proportion. The 
entry rules are clear and well defined and equity limits for foreign investment 
in selected sectors such as telecom quite explicit and well known. Most of the 
manufacturing sectors have been for many years on the 100 percent automatic 
route. Foreign equity is limited only in production of defence equipment (26 
percent). In the case of infrastructure services, there is a clear dichotomy. 
Highways and roads, ports, inland waterways and transport, and urban 
infrastructure and courier services are on the 100 per cent automatic route. 
India also has a clear policy of FDI in services, with 100 per cent automatic 
entry into many services such as construction, townships/resorts, hotels, 
tourism, films, IT/ISP/email/voice mail, business services & consultancy, 
renting and teasing, medical/heatth, education, advertising and wholesale 
trade. The financial intermediation section has sectoral caps like insurance (26 
percent) (Steering Committee: 32). 
b) Domestic Policy: The domestic policy framework affects all investment, 
whether the investor is Indian or foreign. To an extent, foreign companies or 
investors that have set up an Indian company or Joint Venture have become 
indigenized and thus can operate more or less competitively with other Indian 
company. They adjust themselves to the environment. 
Among the policy problems that have been identified by surveys as acting as 
additional hurdles for FDI are laws, regulatory systems and Government 
monopolies that do not have contemporary relevance. Labour laws discourage 
the entry of Greenfield FDI because of the fear that it would not be possible to 
downsize if and when there is a downturn in business. SSI reservations further 
limit the possibility of entering labour intensive sectors for export. More 
flexible labour laws that improve work culture and enhance productivity and 
SSI de-reservations will help attract employment generating FDI inflows of 
the kind seen in South East Asia in the seventies and eighties and in China 
since the nineties (Steering Committee, 2002:24-25). 
The Urban Land Ceiling Acts and Rent Control Acts in States are a serious 
constraint on the entire real estate sector. This is another sector that has 
attracted large amounts of FDI in many countries including China. 
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Weak credibility of regulatory system and multiple and conflicting roles of 
agencies and government has an adverse impact on new FDI investors which 
is greater than on domestic investors. All monopolistic have a strong self-
interest in preventing new entrants who can put competitive pressures. In the 
past government monopoly in infrastructure sectors has slowed down policy 
reform FDI was discouraged by the feet the pressure exerted by government 
monopolies through their parent departments would bias the regulatory system 
against new private competitions (Steering Committee, 200224-25). 
It is alleged that persistent fears of impending "fiscal crisis" is another 
constraint, and that a well articulated strategy for medium term fiscal 
consolidations would address these concerns. 
Through the foreign trade and tariff regime for SEZs approximates a genuine 
free trade zone the other elements of the policy framework and procedures 
remain virtually the same as in the domestic tariff area. The SEZs are therefore 
still not fully on par with the export zones of China with respect to labour 
intensive production (Steering committee: 24-25). 
3.5.3 Procedures: 
According to Boston Consulting Group, investors find it frustrating to navigate 
through the tangles of bureaucratic controls and procedures. Bureaucracy and red tape 
topped the list of investor concerns as they were cited by 39 per cent of respondents in 
the A T Kearney survey. Of the three stages of a project, namely general approval 
(e.g. FDI investment licence for items subject to licence), clearance (project specific 
approvals e.g. environmental clearance for specific location and product) and 
implementation, the second was the most oppressive. Three-fourth of the respondents 
in the survey indicated that (post-approval) clearances connected with investment 
were the most affected by India's red tape. According to CII (2002) study a typical 
power project requires 43 central government clearances and 57 state government 
level (including the local administration) clearances. Similarly the numbers of 
clearance for a typical mining project are 37 at the central government level and 47 at 
the state government level. though the number of approvals or clearances may not 
always he much lower in the OEDC countries like the USA and Japan the regulatory 
process is transparent with clear documentation requirements and decision rules based 
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largely on self certification and generally implemented through the legal profession. 
The government has set up an inter-ministerial committee to examine the existing 
procedures for investment approvals and implementations of projects and suggest 
measures to simplify and speed up the process for both public and private investment. 
The committee which was set up in September 2002 has submitted part I of its report 
(dealing with public sector projects) to the government. A sub-group of the committee 
is specifically looking into simplification of procedures relating to private investments 
(Qamar. 2003: 36). 
The FICCI (2001) study similarly cites centre-state duality as creating difficulties at 
both the approval and project implementation stage. These studies find that the 
bureaucracy in general is quite unhelpful in extending infrastructural facilities to any 
project that is being set up. This leads to time and costs overruns. At an operational 
level multiple returns have to be tiled every month. One effect of these bureaucratic 
delays is the low levels of realization of FDI inflows vis-a-vis the proposals cleared. 
3.5.4 Foreign Investment Promotion Board: 
The delays mentioned by foreign investors are not at the stage of FDI approval per se 
i.e. at the entry point whether through RBI automatic route or FIPB approval. The 
FIPB considers application on the basis of notified guidelines and disposes them 
within a 6-8 week time frame, as has been laid down by the cabinet. The entire 
process of FIPB application starting from their registration through the listing on 
FIPB agenda and their final disposal and dispatch on official communication is placed 
on website which adds to the transparency of decision making and enhances investor 
confidence. Similarly the underlying advisory support in the form of online chat 
facility and dedicated e-mail facility for existing and prospective investors has created 
an investor friendly image. A FICCI study on "Impediments to Investment" (2002) 
has acknowledged that the central level FIPB clearances have been successfully 
streamlined. The FIPB approval system has also rated as world class independent 
surveys conducted by CII (2000) and JICA (www.ticci.org.in). 
The FIIA framework has also been strengthened recently by adoption of a six-point 
strategy. This includes close interaction with companies at both operational and board 
room level followed up with administrative ministers, state governments and other 
concerned agencies and sector specific approach in resolving investment related 
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problems. The major implementation problems are encountered at the state level as 
projects that the regional meeting and for foreign investors under the FIIA cleared by 
industry secretary are now turning out to the problem solving platforms (Steering 
Committee, 2002:27). 
However according to Mayararn (2004) the establishment of FIIA to facilitate quick 
translation of FDI approvals into its implementation provides a proactive one stop 
after care service to foreign investors. The FIIA has created fast track committees in 
30 ministers.' department in the central government. The constitution of the FIIA is 
almost the same as the FIPB: whereas the secretariat for the FIPB is in the finance 
ministry that of the FIIA is in DIPP. However by creating two distinct bodies FIPB 
and FIIA the system has become more complex and confusing. 
3.5.5 Quality of Infrastructure: 
Poor infrastructure affects the productivity of the economy as a whole and hence it's 
GDP per capita GDP. It also reduces the comparative advantage of industries that 
are more intensive in the use of such infrastructure. Furthermore poor infrastructure 
has a greater effect on export production than on production for the domestic market. 
Inadequate and poor quality roads, railways and ports, raise export cost vis-a-vis, 
global competitors having better quality and lower cost infrastructure. As a foreign 
direct investor planning to set up an export base in developing or emerging countries 
has the option of choosing between India and other locations with better infrastructure 
and hence India fails in attracting export oriented FDI (Mohiuddin, 2003: 11). 
Problems in the power sector are reported to be a quite highly significant deterrent of 
FDI inflow in India. Besides lack of proper port facilities, warehouses are also known 
to be a significant deterrent of FDI in India. 
3.5.6 Pro-labour laws: 
Pro-labour laws or lack of exit policy in India is reported as the one of the major 
macro-economic harriers to FDI inflow in the country. Foreign investors wanted that 
there should be flexibility in the labour market conditions. There is excessive trade 
unionism in India. In most of the big organizations working in India there is a 
multiplicity of trade unions and if they get united on any issue then without conceding 
to their demand, the work is almost impossible. Even if they remain isolated from 
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each other than even satisfying some of the unions could not serve the purpose and 
work is obstructed by others. This is mainly because of the illiterate labour and also 
due to vested interest of their leaders. 
Similarly labour laws discourage the entry of Greenfield FDI because of the fear that 
it would not be possible to downsize it if and when there is a downturn in business. 
Labour laws, rules and procedures have led to deterioration in the work culture and 
the comparative advantage that is even beginning to be recognized by responsible 
trade unions. Pursuant to the announcement in the 2001-02 budget that labour laws 
would be reformed, a Group of Ministers was set up to work out the modalities. The 
Group of Ministers would suggest specific changes in the laws for the approval of the 
Cabinet (Steering committee, 2002:24). 
3.5.7 Corruption: 
Corruption in India is another major impediment to FDI inflow in the country. It is a 
consequence of the nexus between Bureaucracy, politics and criminals. India is now 
no longer considered a soft state. In 2011 India was ranked 95" out of 178 countries 
in "I ransparetcy International's Corruption Perceptions Index. 
Corruption has a negative impact on the level of investment and economic growth, on 
the quality of infrastructure and on the productivity of public investment (Tanzi and 
Davoodi, 1997), on health care and education services (Gupta ct al, 2000), and on 
income equality (Gupta, et a(,1998). All these factors are found to be important 
determinants of FDI location. Therefore, foreign investors tend to avoid investing in 
India with high levels of corruption. 
3.5.8 Obstacles and Delays: 
According AT Kearney survey (2001), almost all the respondents replied that they 
experienced bureaucratic problems in India; they reported bureaucratic delays as a 
very important deterrent of FDI inflow in India. Most of foreign firms reported that 
there was a large time gap in submitting proposal and getting the project cleared. Due 
to delay in the start of the project critical problems emerge such as cost of the project 
increased and they lost interest in the project. This brought uncertainty in business 
environment. In terms of the ease of doing business India ranks 133 s` in the world 
while Singapore rank 1'; Malaysia 23"~ and China 89. The number of days it takes in 
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India to enforce a contract is 1420 whereas 150 days in Singapore, 300 days in the US 
and 406 days in China. Similarly, for the time taken to close a business it takes 9 
months in Singapore, 20 months in China and 7 years in India (Economic Survey, 
2009-10: 28). 
According to Sengupta et al. (1997, Economic Times) bureaucratic red tapism is a 
significant impediment to FDI inflows and underlines that the reform of inefficient 
bureaucratic practices at the state level is even more pressing than at the centre. There 
is evidence that after having got the nod from the centre, foreign investor needs 
additional 30 or 40 approvals at the state level. 
Taxes levied on transportation of goods from state to state (such as control and entry 
tax) adversely impact the economic environment for export production. Such taxes 
lead to both cost and time delays on movement of inputs used in production of export 
products as well as in transport of the letter to the ports. Differential sale and excise 
taxes (centre and state) on small and large companies are found to be a deterrent to 
FDI in sector such as textiles (McKinsey 2001). Investment could raise the 
productivity and quality of textiles and thus make them competitive in global market 
remain unprofitable because they cannot overcome the tax advantages given to small 
producers in the domestic market (Steering Committee 2002: 30). 
The services sector received 20.4 percent of total FDI in India. As a state subject the 
states have to take the lead in simplifying and modernizing the policy and rules 
relating to this sector. At the local level issues pertaining to land acquisition, land use 
change, power connection, building plan approval are sources of project 
implementation delay. The state level issues were considered by the Govindrajan 
committee with a view to seeing how they can be alleviated. 
Thus, according to Gakhar (2006) foreign investment policy and procedures are the 
most important deterrent to FDI inflows in India which rank first with average score 
3.10. Growing fiscal deficit in the budgets of the central and states government is 
another impediment of ED] inflow in India. The time consuming clearance procedures 
with wide spread corruption, lack of proper infrastructure, pro labour laws, non-
transparcncy in policy guidelines and political interference and instability and so on 
are the major factors of low FDI inflows in India. According to Michael Gadbaw, 
Chairman of India Interest Group set up by US businesses interest in India" strict 
measures should be adopted to deal with such tendency". The FDI policy which has a 
lot of positive features is summarized first before highlighting the domestic policy 
98 
Chapter - 3 
related difficulties that are commonly the focus of adverse comment by investors and 
intermediaries. 
3.6 	Conclusion: 
FDI has played a significant role in the growth and development of the world 
economy, particularly in India. Our GDP has been grown four-fold since the year 
1991. According to World Development Report (2010) India ranked 3 h` in terms of 
PPP (purchasing power parity). It is also the 10 h` largest economy in terms of US 
dollar exchange rate. Furthermore, India is also the second fastest growing economy 
in the world with the highest economic growth rate. Though, China is the largest 
recipient of FDI but India is also increasingly becoming an important destination for 
FDI in Asia. Progressive liberalization of FDI policy has strengthened investor 
confidence with opening up of new sectors like integrated township, defence industry 
tea plantation etc. India's capacity as a host nation in attracting FDI has been 
enhanced during the post reforms period, but the quantum of FDI inflows relative to 
its size has been low as compared to other developing countries in general and some 
of the Asian countries like China in particular. Main reasons for these low FDI 
inflows has been related to the investment climate, poor infrastructure, foreign 
exchange rate fluctuation and business facilitation, which are comparatively at lower 
level. However, during pre liberalization period FDI increased at CAGR of 19.05% 
while during post liberalization period it has grown 24.28%. This indicates that 
liberalization has had a positive impact on FDI inflows in India. Since 1991 FDI 
inflows in India has increased approximately by more than 165 times as compared to 
pre liberalization period. 
Yet, it is important to note that the focus should not just be on the absolute amount of 
gross FDI inflows but also on the type. More specifically, while India has experienced 
an infusion of FDI inflows in recent times, a large portion of the new inflow have 
been in the form of Brownfield investment (M&As). Given that the latter does not 
necessarily imply new capital infusion into a country. the macroeconomic 
consequences of the two types of FDI can be quite different. The focus should not just 
be on the amount of Greenfield FDI inflows but also the positive externalities to be 
derived from them, including in terms of technological development. 
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With growing importance of FDI, host countries seek not just more such investment, 
but are also increasingly interested in its quality in terms of benefits for sustainable 
economic development. The impact of FDI depends on how closely they integrate in 
the local production process through sourcing raw-materials locally. The next chapter 
deals with the study on the growth and development of pharmaceutical industry. An 
attempt is made to famish a detailed of production, investment, R&D expenditure, 
new chemical entity etc. in the Indian pharmaceutical sector in this chapter. 
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Pharmaceutical Industry in India: An Overview 
	
4.1 	Introduction: 
Health is defined both as cause and effect of economic development, and the 
pharmaceutical industry is especially recognized in the `UN Millennium Development 
Goals' as an actor that can contribute to economic development. Pharmaceutical 
industry is classified as one of the most high-tech and capital-intensive industries. It is 
considered as the `life line' industry because its products play a crucial role in 
remedifying the suffering of diseased persons It is also significant contributor to the 
strength of any economy by creating jobs for millions and contributing to the export 
earnings. The distinctive feature of this industry is such that the goods produced by 
this sector can neither be substituted nor replaced. The pharmaceutical industry is one 
of the basic industries of the country and included in the priority list of the economic 
development programmes. 
Health for all is India's national objective. This objective can only be met by the 
increased production of the cheapest and safer drugs to the public. 
4.2 	Global Pharmaceuticals Industry: 
The origins of modem pharmaceutical industry can be traced back to the late 19'h 
century, when dye stuffs were found to have antiseptic properties. Roche, Ciba-Geigy 
and Sandoz all started as ancestry dyestuff companies which moved into synthetic 
pharmaceuticals and eventually become global players. In 1980s many 
pharmaceutical companies were doing well financially, and large investments were 
made in R&D. However, the global pharmaceutical industry is now facing declining 
R&D productivity, increasing generic substitution in the prescription area of drugs, 
and loss of income due to patent expiration. There has been a decline in profitability 
for a number of major global titms, due to expiry of some major patents and also from 
increased governmental interventions (ICRA, 2004). Thus, many companies have 
started to form alliances and merged with other firms in order to strengthen their 
presence. Outsourcing of production and research activity is increasing as firms are 
constantly looking for cheaper alternatives. Outsourcing is carried out in certain parts 
of the production chain and is expected to expand further in the future. 
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Fhe majority of `global pharmaceutical sales originate in the 'Triad' (US, European 
Union and Japan). and together they are accounting for over 80°0 of the world market. 
The global pharmaceutical sales have grown from USS 334 billion in 1999 to USS 
773 billion in 2008 and further to USS 776 billion in 2009 and is expected to grow to 
USS 880 billion in 201 l(IMS health 2009). 
At the regional level. US is the major pharmaceutical market accounting for around 
45°,'0 of global pharmaceutical sales, followed by Europe (24°0) and Japan (11%) 
(Priolker, 2009). Out of 15 major big pharma' companies eight of them are from 
USA, and the USA based company Pfizer sells 25 major pharmaceutical products 
most of which are block buster drugs. (Davidson and Greblov 2005:3). 
As per IMS health Inc. the highest regional global pharmaceutical sales was in North 
America with 40.3% share in the year 2008 followed by Europe (32%) Asia, Africa 
and Australia (1 1.8%) (Table-4.1). 
The leading global pharmaceutical companies are Pfizer with 5.7% market share 
followed by Glaxo Smith Kline (GSK) (5.6%), Sanofi Aventis (5%) and others. 
Together, the top ten companies accounted for 39.1% of total global pharma market 
sale (IMS health 2009). 
Table-4.1: Global Pharmaceutical Sales by Region (2006-081. 
Sales USS Billion Market Share (%) 
No. Region 
2006 2007 2008 2006 2007 2008 
1  North 289.9 304.5 3118 47.7 45.9 40.3 
America 
2. Europe 181.8 206.2 247.5 29.9 31.1 32.0 
3 Asia, Africa 52.0 62.2 90.8 8.6 9.4 11.8 
& Australia 
4. Japan 56.7 58.5 76.6 9.3 8.8 9.9 
5  Latin 27.5 32.0 46.5 4.5 4.8 6.0 
America 
Total 607.9 663.5 773.1 100.0 100.0 100.0 
Note: Ranked by 2008 Global sales 
Source: 1MS Health Inc. 
1. Rig pharma term referring to companies with very large sales, revenues generally in excess of USS 
billion. 
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Figure 4.1 : 
Global Pharmaceutical Sales by Region (2006-08) 
60 
so 
40 
30 
20 
10 	M  
2006 	 2007 2008 
Years 
• North America ■ Europe 	■ Asia, Africa & Australia 
• Japan 	■ Latin America 
4.2.1 Global Pharmaceutical Research and Development: 
Research and development is the back-bone of the pharmaceutical industry. Countries 
are increasingly looking at innovation and R&D as key drivers of competitive growth 
in this sector. 
USA is the biggest hub for pharmaceutical R&D. According to pharmaceutical 
research and manufacturing of America (PhRMA) in the year 2005 USA has spent 
more than US$ 50 billion in pharmaceutical R&D, followed by Europe ($25 billion) 
and Japan ($8 billion) (EXIM Bank, 2007: 28). At the company level Pfizer spent 
$7.9 billion in the year 2008, followed by Novartis ($7.2), Roche ($7.2) (Appendix-
II). 
4.2.2 Global Pharmaceutical Exports and Imports: 
The share of pharmaceutical products in world exports has grown over the years. It 
was 1.7% in 2000 which has increased to 2.6% in 2005 (Exim Bank 2007: 29). 
European Union as a bloc was the largest exporter accounting for 68.7% of total 
global pharmaceutical exports in 2008 followed by Switzerland (10.4%), USA 
(9.0%), China (1.9) and others. India occupies 6th position (1.4%). Together their 
shares stood at 96.8% of global pharmaceutical exports (Table-4.2). 
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Table-4.2: Major Eznorters of Pharmaceutical Products in the World (20091. 
Exporters Value (US$ Billions) % Share 
European Union (27)* 293.3 68.7 
Switzerland 44.2 10.4 
USA 38.3 9.0 
China 8.1 1.9 
Canada 6.2 1.4 
India 5.8 1.4 
Singapore 5.0 1.2 
Israel 4.8 1.1 
Jordan 3.7 0.9 
Australia 3.3 0.8 
Total 412.7 96.8 
Note: • refers to 27 number of member countries of EU. 
Source: compiled from International Trade Statistics, 2009. World Trade Organization 
Figure 4.2: 
Major Exporters of Pharmaceutical Products in the World (2008) 
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European Union as a bloc was also the largest importer of pharmaceutical products. In 
the year 2008 they imported 56.4% of world pharmaceutical imports followed by 
USA (14%), Switzerland (4.2%), Japan (2.7%) and others. Together their share stood 
at 87.4% of world pharmaceutical imports (Table- 4.3). 
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Table 43: Major Imnorters of Pharmaceutical Products in the World (20081. 
Imports Value (US$ Billions) % Share 
European Union (27)* 240.5 56.4 
USA 59.9 14.0 
Switzerland 17.8 4.2 
Japan 11.4 2.7 
Canada 11.0 2.6 
Russian Federation 9.2 2.2 
Australia 7.1 1.7 
China 5.5 1.3 
Brazil 5.0 1.2 
Turkey 4.7 1.1 
Total 372.1 87.4 
Note: • reters to 27 number of member countries of EU. 
Source: compiled from International Trade Statistics, 2009. World Trade Organization 
Figure 4.3: 
Major Imports of Pharmaceutical Products in the World (2008) 
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4.3 	Indian Pharmaceutical Industry: Historical background: 
Before, we study the pharmaceutical industry in India, a few points on the healthcare 
in the country would be necessary. India has about 16% of world's population 18% of 
world's mortality, 20% of world's morbidity but only 1 % of the world healthcare 
investment. As per Indian statistics the country has a total population of 1.15 billion 
(2008) of this 32.2%, 63.1% and 4.6%, of the population are in the age group of under 
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1 Sycars. 15-64 years and over 65 years respectively. Human Development Report 
(2011) ranked India as 134'f' on the Human Development Index. The Indian health 
care system is the most privatized in the world with 83% of healthcare expenses being 
borne privately. It also lacks specialized medical personnel. It had 6 physicians per 
10,000 people in the year 2007 while developed countries such as Russia Federation 
has 43. Switzerland has 41.and the USA and UK has 27 physicians per 10,000 people 
in the same year. Pharmaceutical expenditure as a percentage of total expenditure on 
health accounted for 50°c to 80%. The epidemiological data show that the tour major 
diseases from which the people of India suffer from are H1V-AIDS, TB, cancer and 
infectious diseases. As far as Indian pharmaceutical industry is concerned, it 
constitutes 2% of the world market. The annual per capita drug expenditure is USS3 
(Aggarwal et al 2006: 109). 
The history of modern Indian pharmaceutical industry (IPI) dates back to the early 
twentieth century when increased nationalism gave rise to greater interest in science, 
including pharmaceuticals. The foundation to two firms, which are still in existence 
today, marks the start of the modern pharmaceutical industry. One is Bengal Chemical 
and Pharmaceutical Work (BCPW) Ltd. set up in Kolkata by Acharya PC Ray in 
1901. The other is Alembic Chemical Works Co. Ltd. in Vadodara by TK Grajjar 
,Rajmitra and BD Amin in 1907 (Amin, 1939: 1-7). Both the companies began an 
important shift from traditional methods to a more scientific approach to the 
discovery, development and manufacture of pharmaceuticals. At the early stage of 
development, Indian pharmaceutical companies relied heavily on foreign companies 
for their bulk drug requirements. The development of the IPI can be divided into three 
phases, which are presented below. 
4.3.1 Indian Pharmaceutical Industry from 1900 to 1970: 
The pharmaceutical industry which had a scanty production scale of Rs. 100 million 
in 1947 (Pradhan and Alakshendra 2006: 3) was completely dominated by 
multinationals with more than 900o  of the domestic market share. These MNCs which 
were primarily trading and marketing subsidiaries of global firms were least interested 
in local production. Besides this India adopted the British patents and design act 1911, 
which granted product patent for a period of 14 years. This regime prohibited any 
kind of reverse engineering and processes developments by their domestic counter 
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parts. There were only few domestic firms in this sector even they were not capable of 
local production of bulk drugs due to lack of required technological capabilities. As a 
result of which drugs prices in India were amongst the highest in the world. 
Soon after independence India received technical and financial assistance from 
international organizations, such as the WHO and UNICEF, to set up the two giant 
plants. The public unit Hindustan Antibiotics Limited (HAL) was established in 1954 
and was provided with technical support, purchasing of equipment and machinery 
from the WHO and UNICEF. Indian drugs and Pharmaceuticals Limited (IDPL), 
another public sector enterprise, got access to import technology from overseas and 
developed more modern manufacturing facilities (Narayana, 1984). IDPL was 
provided financial assistance, technology and know-how by Soviet Union_ These 
public units produced critical drugs, such as penicillin and other anti-infective 
medicine. Currently both IDPL and HAL have been declared as sick units by the 
Board for Industrial and Financial Reconstruction (BIFR) and their contribution to 
production is negligible. But both these companies gave a tremendous boost to 
indigenous efforts to the private sector and contribute to its success. I'hcy created new 
confidence that India could also manufacture drugs in a big way (Anand, 1988).A 
large mass of technology was imported into India between 1950-1970.Many leading 
entrepreneurs got their training from these companies. The founder of Dr. Reddy's, 
one of the largest pharmaceutical companies in India today, worked at the IDPL, 
before he took off to start his own company. 
Multinationals are a part of India's pharmaceutical foundation in addition to public 
sector. India was attractive to foreign firms mainly due to its large market and 
increasing demand for drugs. At that time there was lack of competition in the 1PI, 
and the MNCs did well in India. They had good knowledge and technology to 
develop antibiotics and synthetic drugs and had advantage of their financial assets and 
management abilities. Consumer preference for foreign world-wide known drugs was 
also an added advantage for the MNCs in India. They were aggressive in marketing 
and managed to create a market for themselves in branded products. The foreign firms 
had more or less, a monopoly in the Indian pharmaceutical market at this time. 
4.3.2 Indian Pharmaceutical Industry from 1970 to 1990 
This period of 1970-1990 is very significant for the IPI since a few important changes 
that had implications on the growth of the IPI took place during this period. One of 
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the key changes was the implementation of the new Indian Patent Act (( 970) in 1972. 
Through this legislation the government abolished the product patent regime act of 
1911. The Patent Act of 1972 ensured that a tine could now patent only a single 
method or process for any particular drug. The patent tern was reduced to 5 years 
from the grant of the patent or 7 years from application filing. (Fink, 2000). The 
objective behind the new patent laws was to break the foreign companies monopoly 
and encourage domestic pharmaceutical companies to grow. Thereafter the IPI 
focused on reverse engineering. Between 1970 and 2005 India became a hot bed of 
firms like Cipla Ltd which focused their capabilities on developing cheap processes 
for globally patented drugs. They used Indian Patent Act to their advantage to 
compete against global pharmaceutical companies in domestic market and also in 
global markets. 
The growth of the market for generic pharmaceuticals in the US provided an 
opportunity for Indian manufacturers of generic drugs. According to DG Shah 
(Secretary General of the Indian Pharmaceutical Alliance),"It helped that the IPI had 
built its generic capabilities by then and could be the first mover in the US market." In 
1999 a total 193 manufacturing plants in India complied with USFDA (US Food and 
Drug Control, Administration) regulations. These plants represented 41% of all 
complying plants in Japan, Taiwan, Korea and India. All these development meant 
that by 2004 Indian firms enjoyed a 77% share in the domestic market compared to 
23% share of global pharmaceutical companies. The situation had been completely 
reversed from the early 1970s (Table-4.4). 
Table-4.4: Market shares of 1\INCs and Indian Companies in the Pharmaceutical 
Industry in India. 
Year MNCs (%) Indian Companies (%) 
1952 38 62 
1970 68 32 
1980 50 50 
1991 40 60 
1998 32 68 
2004 23 77 
2008 19 8l 
Source: S. Chaudhuri (2005): The 1WTO and India's Pharmaceuticals Industry: Patent Protection TRIPs 
and Developing Countries''. Oxford University Press, New Delhi and CMtli prowess database. 
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4.3.3 Indian Pharmaceutical Industry after 1995- Post TRIPs Period: 
Because of continuously declining shares of MNCs the developed countries were 
increasingly keen to reverse India's patent regime, even as Indian negotiators voiced 
concerns about the welfare effects of the higher domestic drug prices caused by 
stronger patents. But India eventually acquiesced to pressure from the developed 
countries by singing the WTO- TRIPs agreement in late 1994. It made a commitment 
to implement a globally consistent product patent regime by 2000. Changes to India's 
laws included 20 years patent term and the new law became effective from January 
l, 2005. 
The Product Patent Act (2005) was framed to maintain the competitiveness of Indian 
companies in the global generic pharmaceutical industry while ensuring consistency 
with the requirements of TRIPs. The post TRIPs period has seen considerable debate 
over where India's pharmaceutical industry is heading under the new patent system. 
As a result there were 413 product patent applications for cancer drugs at the Indian 
patent offices, 350 of them filed by MNCs. 
The evaluation of IPI can be shown in the following chart (chart-1). 
4.4 	Policy changes for Development of Pharmaceutical Industry in India: 
The government of India is strived hard to put pharmaceutical industry on the sound 
track of growth and development from late 1980s. Pharmaceutical industry in India is 
flourishing at an accelerated rate and it is assumed that soon India will be a global 
pharma super power in global pharmaceutical industry. 
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The Government of India has taken some strategic policy (including fiscal and EXIM) 
changes to move in that direction, which arc briefly described as follows: (NPP, 
2006). 
> The earlier policy of procuring industrial licensing for all kind of drugs has 
been abolished (it has recently been done for the last remaining bulk drugs 
produced by the use of recombinant DNA technology, bulk drugs requiring 
in-vivo use of nucleic acids and specific cell tissue targeted formulations). 
However, the need for obtaining manufacturing license under drugs and 
cosmetics Act, 1940 continues for all units, whether organized or small scale. 
The state drug controllers are authorized to issue such licenses in most cases. 
➢ Now, FD1 upto 100% is permitted, subject to stipulations laid down from time 
to time in the industrial policy through the automatic route in the case of all 
bulk drugs cleared by the drug controller general India (DCGI) and their 
intermediates and formulation. Recently bulk drugs produced by the use of 
recombinant DNA technology, bulk drugs requiring in-vivo use of nucleic 
acid as the active principles and special cell/tissues targeted formulation have 
also been allowed this facility. Besides 100% EOUs and units of EPZs enjoy 
a package of incentives and facilities, which include duty free imports of all 
type of capital goods, raw materials and consumables in addition to tax 
holidays against export. 
➢ Automatic approval for Foreign Technology Agreement (ETA) is already 
available in the cases of all the bulk drugs cleared by DCGI and their 
intermediates and formulation, except bulk drugs produced by the use of 
recombinant DNA technology, bulk drugs requiring in vivo use of nucleic 
acids as the active principles and specific cell/tissue targeted formulations. 
➢ Imports of drugs and pharmaceuticals are regulated through EXIM (Export 
and Import) policy and presently all items except those requiring clearance 
under the Narcotics and Psychotropic substances Act 1985 are allowed under 
OGL (Open General List). Further a centralized system of registration has 
been introduced under the Drugs and Cosmetic Act and rules made under 
these are administered by Ministry of Health and Family welfare (MOHF W). 
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Chart-l: Evaluation of Indian Pharmaceutical Industry. 
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➢ Exports are permitted in accordance with the EXI_VI policy and relevant 
procedures/rules formulated for the purpose by Director General of Foreign 
Trade (DGFT). Further, the exporters are allowed imports of inputs on duty free 
basis for export production. As a result, the industry has shown commendable 
export performance, the trade balance being positive. 
➢ In order to provide a boost to the pharmaceutical exports government constituted 
a separate pharmexil (Pharmaceutical export promotion council) on 12 May, 
2004. This council undertakes activities such as promoting exports, preparing 
country profiles, assessing export potential across the countries and to have 
gcater degree of interaction internationally. 
➢ As recommended by Mashelkar Committee in 1999, a Pharmaceutical Research 
and Development Support Fund (PRDSF) with a corpus of Rs.150 crores have 
been set up under the administrative control of the Department of Science and 
Technology. A Drug Development Promotion Board (DDPB) to administer the 
utilization of PRDSF has also been set up. 
➢ Product patent in pharmaceuticals has been introduced in the country, with effect 
from January I, 2005 by amending the patent Act 1970 in conformity with 
TRIPs agreement. 
➢ The revised schedule M2 of the drugs and cosmetic Act 1940 related to GM? 
(Good Manufacturing Practices) has cone into effect from Pt July 2005. This 
would in the long run strengthen the pharmaceutical industry as a producer of 
quality medicines. 
➢ VAT has been introduced in India with effect from 1s` April 2005 and on 
medicines it has been kept at 4% only. 
➢ Clinical trials are essential for drug development and therefore, schedule Y of 
the drugs and cosmetics Rule 1945 has been amended to allow for multicentric 
concurrent clinical trials in India Under these rules clinical trials have been 
defined and it has been made mandatory to take approval for conducting any 
type of clinical trials in India. Besides this GCP (Good Clinical Practices) 
guidelines have been published and made mandatory. 
2 Schedule NI implies Conditions with which premise., licensed for the manufacture of drugs. should 
continn. 
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> National Institutes of Pharmaceutical Education and Research (NIPER) under the 
aegis of ministry of chemicals and fertilizers is an institute of National 
importance established by an of the Act of Parliament and is engaged in training 
human resources in the field of pharmaceutical science. Government has decided 
to set up 6 new NIPERs indifferent regions of the country. 
D The creation of department of pharmaceutical on July I, 2008 also encourages 
the growth and diversity of this sector. As a new initiative the first 
pharmaceutical census of India (FPCI) was launched during 2007-08 to obtain 
the best and reliable data base for the sector. 
D In union budget 2008-09 finance minister P. Chidambaram brought down excise 
duty from 16% to 8% and zero excise duty on anti AIDS drugs. Resides 125% 
weighted deduction granted on expenditure for out sourced R&D, exemption of 
excise duty and 5% reduction in custom duty on certain specific life saving 
drugs and bulk drugs used in the manufacture of Anti-AIDS drugs. This augurs 
well for the industry. Besides this the rate of CST has been reduced from 3% to 
2% from 1" April 2008 and reduction in the general rate of CENVAT from 16% 
to 14% on medicines. The budget 2008-09 further reduced the excise duty across 
the board by 4%. This effectively meant reduction from 8% to 4% on 
formulation and 14% to 10% on bulk drugs. Whereas specific reduction in taxes 
for pharmaceutical goods will lead to a balanced industrial development in the 
pharmaceutical sector where there has been lopsided development especially in 
tax havens like Himachal Pradesh, Sikkim and Uttaranchal (express pharma 
2008). 
> A special scheme for setting up pharmaceutical parks for providing all facility 
under one roof in the country is provided and this scheme is based on Public 
Private Partnership. 
4.5 	Nature of Indian Pharmaceutical Industry: 
The Pharmaceutical Industry is different from other manufacturing industries in respects 
that the demand of Pharmaceutical products is of a different nature than other products. 
In this industry the choice- maker i.e. the physician and the buyer i.e. the patient are 
completely separated i.e. medicines are the only commodity in which the end-user (the 
paying patient) does not decide what to buy and at what cost. the doctor prescribes and 
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the patient pays. Besides the demand of these products is price inelastic. Pharmaceutical 
industry comes under orange category3 with due consideration from environmental and 
ecological perspective. The unique feature of IN is that it comprises mainly small and 
medium enterprises who contribute 42% of total pharmaceutical production and 62% of 
total employment. 
4.6 	Rationale for growth of Indian Pharmaceutical Industry: 
The pharmaceutical industry in India is very heterogeneous in nature but has shown a 
CAGR of 12-15% during post reform period. Higher growth rate is expected in future 
due to a number of socio-economic transformations occurring in the economy such as: 
➢ Life expectancy is on a rise- The average life expectancy in India is now (35 years 
(2010) as compared to 58 years in the 1990. India's improving healthcare 
delivery infrastructure has ensured the continued rise in life expectancy. The 
consequent increase in life expectancy drives the growing proportion of an aging 
population of the 60 age-group which will account for 11% of total population 
by 2021. This will give further boost to the growth of the pharrnaceutical 
industry. 
> Rising population- With a population approximating 12 billion, India is 
potentially a huge market fur the pharmaceutical industry. The growing middle-
class of around 300 million people has an increasing disposable income and 
higher healthcare expectations. Around 1/3's of the middle class can afford 
quality private healthcare services, and this number is constantly growing. This 
increased healthcare spending offer, greater opportunities for the pharmaceutical 
market. 
➢ Rising Income of Indian Households- The number of middle-income households 
(income S 2,275—$ 12,500) is expected to rise significantly. This will translate 
3. 'Green category encompasses all non-obnoxious and non-hazardous industries. These industries do not 
discharge effluent of polluting nature_'fhen comes Orange: an effluent generated by this category can he 
controlled using proven technology like conventional effluent treatment plants. Gaseous emissions by 
these companies can also be controlled using proven technology, whereas the Red  category encompasses 
all those industries having obnoxious and hazardous processes and effluents of highly polluting nature. 
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into greater spending power in healthcare, further boosting the pharmaceutical 
industry. 
Increased Consumer Expenditure on Healthcare- The years of 2000-2005 saw a 
shift in the Indian consumer's mindset, as evidenced by the increasing priority 
accorded to healthcare as a proportion of overall consumer expenditure. During 
this period, consumer expenditure on health goods and medical services showed a 
CAGR of 12.4%. 
7 increasing Penetration of Health insurance- In contrast to the developed 
countries, where insurers pay more than 80% of the individual's healthcare cost, 
Indian insurers contribute a very small proportion. At present only 3% of the 
healthcare cost of an Indian patient is paid by insurers; 80o of costs are borne by 
the individual. However, the insurance sector shows significant improvement, as 
evidenced by the 37.3% increase in the number of policies sold in 2003 2004 
compared to 2001-2002. 
➢ Changing Disease Profile- The Indian population is experiencing a shift in 
disease profiles. Traditionally, the acute disease segment held a significant share 
of the Indian pharmaceutical market. But with increase in affluence, rise in life 
expectancy and the start of lifestyle related conditions, the disease profile is 
gradually shifting towards a growth in the chronic diseases segment. India has the 
largest pool of diabetic patients in the world., with more than 41 million people 
suffering from the disease; this is projected to reach 73.5million in 2025. 
4.7 	Trends in Production of Indian Pharmaceutical Industry: 
The Indian pharmaceutical sector is a mixture of both organized and unorganized firms. 
They range from large firms that are either subsidiaries of MNCs or wholly Indian 
companies to medium and small sized companies. As per directory of pharmaceutical 
manufacturing units in India (2007), there are 10563 pharmaceutical manufacturers 
across the country, as against the commonly quoted figure of 23,000 manufacturing 
units. Out of these 10563 units, 8174 (77.4%) manufacturing formulation and remaining 
2389 (22.6%) are engaged in manufacturing of bulk drugs. Pharmaceutical industry in 
Indian is highly fragmented, having about 300 units in the organized sector including 45 
MNCs and 5 public sector enterprises. These firms account for 70% of India's total 
production of pharmaceuticals. 
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Similarly the IPI arc very unevenly distributed according to their manufacturing units. As 
per Mashelkar Committee (200 3) more than 75% drug manufacturing licenses are in 7 
states namely, Maharashtra, Gujarat, Tamil Nadu, Andhra Pradesh, Karnataka, West 
Bengal and Goa, whereas 10 states namely Bihar, Delhi, Haryana, Kerala, Madhya 
Pradesh, Orissa, Punjah, Rajasthan, Andaman & Nicohar, Island and Uttar Pradesh 
account for 20% of drug manufacturing units. The remaining I states and union 
territories have only 5% of manufacturing plants. The chief reason for this regional 
pharmaceutical imbalance is that almost all of the total 22 pharmaceutical & biotech 
SEZs are located in the states of Andhra Pradesh, Maharashtra, Gujarat and Karnataka 
(Express pharma, 2007). 
The process of drug manufacturing has two interlinked components (a) bulk drugs (b) 
formulation. The domestic formulation market can be further classified into: (i) retail and 
(ii) institutional drug market. In India institutional drug market is quite limited 
accounting only 15% of total formulations sales (IBEF, 2008:4). The bulk drug industry 
closely resembles a perfectly competitive market; there is large number of players in 
almost all the bulk drugs markets with none enjoying market dominance. But the 
formulation market in India as elsewhere in the world is dominated by the large 
companies. Additionally the IPI manufacture close to 500 bulk drugs belonging to 
several therapeutic segments such as anti-infective, pain management, cardiovascular 
(CVS), Central Nervous System (CNS) and anti-diabetics and formulation is made for 
around 60,000 packs in 60 therapeutic categories are made (Jha, 2007:3959). Although 
formulations account for a large share of the overall pharmaceutical production in value 
terms the proportionate share of bulk drugs has been increasing. Since the mid 1990s 
India's strong base in the chemical industry facilitated the development of bulk drug 
manufacture reverse engineering and competitiveness contribute. During 1990-91 to 
1995-96 both bulk drugs and formulations production were going at 6% and 5% CAGR 
respectively. Thereafter the growth rate of bulk drugs production was higher than the 
formulation. But it is important to note that during 2005-06 to 2008-09 the growth rate 
of bulk drugs production was nearly half (14%) as compared to the growth rate of 
formulation production i.e. 24% (Table-4.6). 
Bulk drugs began to be produced in the country on a large scale from 1970 onwards. The 
most rapid growth of both hulk drugs and formulation has taken place from the 1990s 
onwards. As a result production of bulk drugs sharply increased from I US$417.1 million 
in 1990-91 to US$3503.2 million in 200S-09. Currently, India is the third largest bulk 
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drugs producer after China and Italy and will expect to be the second largest after China 
in future (Express Pharma. 2010a). Similarly formulation production increased from 
USS2194.3 million to USS 15390.8 million over the same years (Table 4.5). Growth rate 
of the production of bulk drugs revealed the same increasing trends since 1998. Whereas 
formulation shown fluctuating trends which was highest in 2007 (32%). 
Table-4.5: Production of Bulk Drugs and Formulation at Current Prices in India 
(1990-2008). 
(USS million & % 
Year 
Bulk Drug 
Production 
Growth 
Rate 
Formulation 
Production 
Growth 
Rate 
Total 
Production 
"" 
Growth 
Rate 
1990-91 417.1 - 2194.3 - NA - 
1991-92 396.5 -4.9 2114.5 -3.6 2510.6 - 
1992-93 444.0 12.0 2316.6 9.6 2760.6 10.0 
1993-94 420.4 -5.3 2197.5 -5.1 2617.8 -5.2 
1994-95 483.4 15.0 2527.1 15.0 3010.5 15.0 
1995-96 562.3 16.3 2816.4 11.4 3810.7 26.6 
1996-97 617.5 9.8 2964.4 5.3 4286.8 12.5 
1997-98 722.6 17.0 3324.5 12.1 4677.4 9.1 
1998-99 762.2 5.5 3360.3 1.1 4560.0 -2.5 
1999-00 876.3 15.0 3703.0 10.2 5086.4 11.5 
2000-01 1009.6 15.2 4087.8 10.4 5655.2 11.2 
2001-02 1152.3 14.1 4471.2 9.4 5761.7 1.9 
2002-03 1343.4 16.6 4976.3 11.3 6317.2 9.6 
2003-04 1658.6 23.5 5942.5 19.4 7665.3 21.3 
2004-05 1994.3 20.2 7052.1 18.7 9295.5 21.3 
2005-06 NA - NA - 10390.2 11.8 
2006-07 2676.6 - 10072 - 11922.3 14.7 
2007-08 3346.7 25.0 13256.9 31.6 15734.6 32.0 
2008-09 3503.2 4.7 15390.8 16.1 17567.6 11.6 
Note: During 1990 to 1994 figures do not includes production from unorganized sector which is estimated 
at an additional 35% of the production. 
NA: refers to not available, 
#: Estimated value. 
;; : Total production included bulk drug production, ti~rmulation production and over-the-counter 
production 
Source: Compiled from Bulk Dnig manufacturer association Hyderabad and Indian drug manufacturer 
association %lumbai, data bank. RBI I handbook of statistics on Indian economy. 2009 Economic Survey 
_2008-09. Govt. of India, and ('MIL "Industry market size and shares (various years). 
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Table-4.6: Compound Annual Growth Rate of Production in the Pharmaceutical 
Industry in India. 
Year Bulk Drugs Formulations 
1990-91 to 1995-96 6.0 5.1 
1996-97 to 2004-05 15.4 10.9 
1991-92 to 2004-05 13.1 9.2 
2006-07 to 2008-09 14.4 23.6 
Source: Same as Table-4.6 
Interestingly, in 1980-81, exports constituted only five per cent of the total bulk drug 
production. This figure grew rapidly to touch 19 per cent by 1986-87 and by 1994; 
around 50 per cent was exported. Today almost 80-90 percent of the total bulk drug 
production is exported. 
4.8 	Pharmaceuticals Export and Import in India: 
IPI has emerged as a global player, satisfying a significant portion of world generic 
drugs4 needs. It is not only because of low cost manufacturing, operations and research 
base but also a combination of additional factors like process improvements in bulk 
drugs, faster recruitment for conducting clinical trials, availability of skilled manpower 
and developed regulatory skills. India exports pharmaceuticals to more than 200 
countries around the world including highly regulated markets of USA, Western Europe, 
Japan and Australia, and as ranked 17th largest pharma exporter in the world. Since 1987-
88 India's exports have exceeded import. It had grown from US$ 96.3 million in 1980-
81 (Chaudhuri,2005:45) to US$ 448.5 million in 1990-91, further US$ 3.3 billion in 
4. A generic drug is usually introduced in the market after the patent expiry date of the original molecule. 
It is identified after its chemical name rather than the branded advertised name. Generic drugs are carried 
out though reverse engineering of molecules to arrive at the same chemical structure as the original drug. 
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2005 and US $ 6.3 billion in 2008 (Table 4.7). In the late 90s India's exports more than 
doubled and accounted nearly 40% of total industrial production and approximately 30% 
of its revenues. 
Additionally IPI is one of the foreign exchange earning sectors in India. An increase in 
foreign exchange reserves reduces the costs of liquidity risk. It also leads to a decline in 
consumption, although investment and economic growth may improve when the tradable 
sector is capital intensive i.e. pharma sector. Enhanced foreign exchange reserves help 
the Indian economy for preventing sudden reversals in capital flows. Foreign exchange 
earnings by pharma sector increased tremendously from LESS 285.9 million in 1991 to 
US$6890.1 million in 2008. But the percentage share of foreign exchange earnings by 
pharma sector to the total foreign exchange is 2.7% (2008) and shown fluctuating trends 
during entire period. 
India has enjoyed trade surplus since 1987-88, and it has increased to US$14.3 mil lion in 
the year 1988 to USS215.6 million in 1990 and further USS4.3 billion in 2008-09. It was 
expected that India's exports will show strong growth in future because US$60 billion 
patented drugs lost their patent protection in the US and Western Europe (Appendix-Ill). 
ASSOCHAM predicts that Indian companies will capture at least 30% of the 
replacement market of generic drugs. One of the basic reasons for this dramatic exports 
expansion seems to be the efforts of Indian pharmaceutical companies to develop their 
own marketing and trade supporting centers in the developed countries and emergence of 
generic segments as cheaper alternatives to branded products. Most of the Indian firms 
have built their own brand-names and formulations in developed countries market and 
are known for their internationally certified manufacturing facilities for quality and 
safety. Apart from these advantages. Indian firms are also leveraging benefits from 
forging strategic and marketing alliance with local liras in the destination markets. As 
far as CAGR of pharmaceutical exports are concerned, it is 16% during 1991 to 2008. 
Similarly the CAOR of imports and balance of trade are 11.6 % and 20.1% respectively 
over the same period of time (Table-4.8). Other important factors for enhancing Indian 
pharmaceutical exports are: 
➢ Declining profit margin in domestic market, 
➢ Extreme price competitive nature of domestic market, 
Opening up of semi regulatory markets of Eastern Europe, Japan and many other 
Africa counties. 
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Table-0 7; Value of Export and Import of Drugs and F1(ormaceotieals in India (1990.21$08). 
1$i million & %) 
Toll 
Eaport 
Grmv(h 
Rals(6) 
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hnpods 
Growh 
Kte;to) 
Trade 
Balance 
tCoI.2 
CoI.4) 
Year 
 aa1h 
Rate( %) 
Phamacearial 
as a %of India's 
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manufactured 
eap0its 
Intansharein 
*nrIC Phan 	enical 
Eapnn 
PhamtaFEN Growth Rater%)  
",6 Shm'e of
pha:maFEE 
(0ulFE 
1990-91 44R5 22.9 - 21S6 43 NA N.A N4 
1991.92 564.4 25,8 244.3 4.9 320.1 48.5 4.8 NA 265.a 3.1 
1992.93 • 54.5 49 242A ',8 302,1 .5,6 3.8 0.9 312.9 9.4 1'- 
I993-94 5677 4.2 2392 -I.? 3281 3.6 3.8 09 361.7 7. 19 
199495 04.9 22.7 3135 31,1 382.3 169 3.9 1.0 941 47.. 2.1 
995-96 525 -4.5 7864 23.] 138.6 -63.7 43 10 771.1 427 3.6 
96-9i 70 34.4 579,1 499 116.7 -8.6 5.0 09 8129 )a 3,1 
19a7A6 8:4' 16.8 6218 'Al 21$^_3 59,E i5 09 9])9 144 
1998•99 C.) -02 595.2 -43 221.1 Ll 5.8 1,0 971,9 3,0 
I!~'quad! 010.1 K.7 ti27.6 54 281.9 14.5 5.2 10 11052 ?9 
201001 .069.4 115 6637 59 4052 43S 4,3 0 115 13.6 30 
2P2602 1198 Il 889 313 11; 2.8 41 1.1 15720 252 29 
2002-[3 15197 26° 589.1 -33.4 9302 1971 5.0 1.0 19821 26.1 2.6 
210;-04 2105 285 636.3 7!9 14687 57,9 52 1,0 2612.3 21.B 23 
2104-0 211§ 707 692.9 6.9 2059 40.1 £,9 12 3007.3 15.1 2.I 
2K S-Cfi 1l.9 tLS t0Z33 4^.8 127b.1 8' 4.8 ID 36412 11.1 2.1 
22010' 3tisi19 Ill 1395.: 26.5 2396,8 7.1 4.7 2 4911.9 349 2.5 
2007-8' 55043 49,1 1630.3 259 3814.,4 617 7 I' 62262 26,F 2.0, 
2008-09 6157 13,7 :970,5 2a9 41S6.5 t6 42 14 6390, 03 2.7 
Yde: 41`ipures arc pruvisinrml 
Source: Compilul Gna Drug S9snufaD:una Aswieialinn (Indial, IadianDrug ManLIae1arer Assc ialioa lumual Publica(ioa (various iasued, J.molm' G.reral m`Cummere:al 
Inlellipcc aril Sraris'.ics Kolkala, Epetls and icrpans Cgmea are in rupees. These h vc been convened :c CSS figures by using the aver ge exdrange rate for 
rlevanl financial years iniained from RBI, Handbook of alalis1ies ou Indian Economy 2010 (wunr.rbi.atg,fa ),Department of Pherm&ceulital GUI New Delhi @ 
United Nations"InremauorvaI Trade Statistics year heria (vanous gears) 
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Agura4.6: 
Fort and Import of PhanlMccuticals India (1990-2008). 
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Table-4.8: Compound Annual Growth Rate of Pharmaceutical Export, Import and 
Trade Balance. 
Year Pharmaceutical Export 
Pharmaceutical 
Imports 
Pharmaceutical Trade 
Balance 
1990-1995 4.2 9.8 -4.5 
1990-2000 7.8 13.8 -0.2 
2001-2008 26.7 17.0 37.9 
1991-2008 16.0 11.6 20.1 
Source: Same as table 4.7 
y Exports have growth to constitute a major source of revenue for India's major 
pharmaceutical companies including Cipla Dr. Reddy's and Ranbaxy5 whose 
collective exports accounting for more than 50% of their total annual turnover. In 
2005-06 Ranbaxy derived nearly 80% of sales revenue from exports and 
international acquisition. whereas Dr. Reddy's and Cipla drive 66% and 50% 
respectively. 
Most Indian pharmaceutical companies have significant competitive advantages 
in R&D to build a generic product pipeline; which includes high technical skill 
levels in the development of non-infringing processes, bio-equivalent 
formulations and development of regulatory submissions at lower cost. 
➢ Labour costs in India are about 1/7th the level in developed countries and offer an 
apparent cost advantages. 
Many blockbusters drugs in the US market are seeing the expiry of their patents 
over the coming years. 
5. Since 2008 Ranbaxy is subsidiary of Japanese pharmaceutical Daichii Sankyo. 
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> Over the years Abbreviated New Drug Application (ANDA) & Drug Master File 
(DMF) tiling of key Indian pharmaceutical players has grown, to become 
comparable to that of key global players. 
> Apart from availability of cheaper labour India also has many local 
manufacturing equipment manufacturers. These equipments arc of high quality 
and low cost, therefore reducing the cost of capital. 
Y Competition in the India's domestic formulation market has made it inevitable for 
API suppliers to continuously develop alternative production methods to improve 
yield or reduce costs. This ensures that India has a significant cost advantage due 
to process engineering. 
Therefore, exports constitute a substantial part of the total production with15% CACR, 
while the domestic market grows at 5% only. The formulations constitute nearly 55% of 
the total exports and the rest 45% comes fl-um bulk drugs. Currently there are around 
3000 registered exporters of which 1500 are active exporters in India. Maharashtra leads 
in pharmaceutical exports with a share of 38% followed by Andlua Pradesh, Haryana, 
Gujarat, Karnataka, Tamil Nadu, Delhi, and Chandigarh with the shares of 23%, 8%, 
8% , 6%, 4%, 3% and 2% respectively (Pharmaxil. 2009). 
Pharmaceutical export as a percent of India's total manufactured exports has shown 
fluctuating trend during 1991 to 2008, this currently stands in 4.7%. Shares of Indian 
pharmaceutical export in world pharmaceutical export has also shown increasing trend 
(Table-4.7). 
4.9 	Direction of Indian Pharmaceutical Export and Import: 
India's pharmaceuticals export is to more than 200 countries. On a country wise basis the 
top five destinations of India's pharmaceutical products during 2007-08 are the USA 
(19%), Germany (4.7%), Russia (4%), U.K. (3.7%) and China (2.8%) (Tahle-4.9). All 
the major Indian pharmaceutical companies are looking at the global market to accelerate 
their growth performance. These include such potential regulated markets as the US. 
Japan and Europe. the semi regulated markets of BRICS (Brazil, Russia, India China and 
South Africa) countries and least regulated markets of Afi9ca, middle east and South East 
Asia. India has become a very important source of generic drugs for the developing 
countries and one of the leading suppliers of cheapest AIDS drugs to the world. India 
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exported US$1.35 billion worth of pharmaceuticals to Asia and $497.7 million to 
ASEAN countries. (DO?, 2009). 
India's largest single export market continues to be the US, which is also the world's 
largest generic drug market. Pharmaceutical exports to US grew from US$53.9 million in 
1991-92 to $1546.9 million in 2008. But, as a percentage of total exports to the US, it 
declined slightly from 171% in the year 2002 to 14.3% in 2005 (Table-4.9). This decline 
can he attributed to, such factors as introduction of authorized generic drugs by domestic 
US pharmaceutical giants, lagging profits, declining generic drug prices and growing 
competition from other low cost countries, particularly Israel, China, Korea and those 
from East Europe. 
India's top tell export destinations arc USA, Gennany, Russia, UK, China, Brazil, 
Canada, Italy. Singapore and Japan which together accounting for about 60% of total 
Indian pharmaceutical exports in 1991 and 37% in 2008. But now the Indian 
pharmaceutical exports destination have turned more towards African, South East Asian 
and Other developing countries (Table-4.9). 
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"table-4.9: Top Ten Destinations of Indian Pharmaceutical Exports (1991-2008). 
(USS million and %) 
G 
1991- 53.9 64.7 127.0 16.8 0.3 NA 4.5 8.4 13.3 11.8 500.0 
92# (10.8) (12.9) (25.4) (3.4) (0.1) (0.9) (1.7) (2.7) (2.4) 
1992- 52.8 65.2 36.9 15.1 0.8 NA 5.1 12.2 9.7 9.5 420.0 
93# (12.6) (15.5) (8.8) (3.6) (0.2) (1.2) (2.9) (2.3) (2.3) 
1993- 56.7 56.2 66.2 16.3 2.0 NA 4.5 7.6 10.0 8.0 471.7 
94# (12.0) (11.9) (14.0) (3.5) (0.4) (1.0) (1.6) (2.1) (1.7) 
1994- 85.8 91.2 89.8 23.6 6.3 2.9 10.6 17.9 22.7 20.4 800.4 
95 (10.7) (11.4) (11.2) (2.9) (0.8) (0.4) (1.3) (2.2) (2.8) (2.5) 
1995- 126.9 102.4 90.9 34.2 10.8 5.1 10.5 21.6 26.0 14.4 1020.6 
96 (12.4) (10.0) (8.9) (3.4) (1.1) (0.5) (1.0) (2.1) (2.5) (1.4) 
1996- 141.0 103.8 109.0 42.1 26.0 9.4 13.1 31.7 48.0 21.9 1224.1 
97 (11.5) (8.5) (8.9) (3.4) (2.1) (0.8) (1.1) (2.6) (3.9) (1.8) 
1997- 159.3 112.0 106.1 60.0 37.1 15.6 17.2 43.3 40.0 23.8 1459.9 
98 (10.9) (7.7) (7.3) (4.1) (2.5) (1.1) (1.2) (3.0) (2.7) (1.6) 
1998- 172.2 89.3 47.6 47.1 42.7 25.0 23.6 37.0 39.3 27.7 1486.7 
99 (11.6) (6.0) (3.2) (3.2) (2.9) (1.7) (1.6) (2.5) (2.6) (1.9) 
1999- 166.1 80.3 122.9 49.3 46.0 42.8 25.7 38.4 55.3 28.4 1670.6 
00 (9.9) (4.8) (7.4) (3.0) (2.8) (2.6) (1.5) (2.3) (3.3) (1.7) 
2000- 215.5 94.0 108.9 53.9 57.1 80.2 36.7 31.7 47.0 30.6 1914 
01 (11.3) (4.9) (5.7) (2.8) (3.0) (4.2) (1.9) (1.7) (2.5) (1.6) 
2001- 345.1 105.8 101.2 59.3 80.3 73.7 31.4 25.2 42.3 31.8 2068.2 
02 (16.7) (5.1) (4.9) (2.9) (3.9) (3.6) (1.5) (1.2) (2.0) (1.5) 
2002- 455.7 161.7 107.2 89.0 92.9 76.1 52.9 36.5 43.9 50.1 2655.5 
03 (17.1) (6.1) (4.0) (3.4) (3.5) (2.9) (2.0) (1.4) (1.7) (1.9) 
2003- 492.2 211.2 140.0 109.1 102.3 87.1 90.1 63.3 48.3 55.1 3312.7 
04 (14.9) (6.4) (4.2) (3.3) (3.1) (2.6) (2.7) (1.9) (1.5) (1.7) 
2004- 604.0 206.5 172.2 130.4 121.2 109.0 110.2 67.7 53.1 64.1 3973 
05 (15.2) (5.2) (4.3) (3.3) (3.1) (2.7) (2.8) (1.7) (1.3) (1.6) 
2005- 715.5 253.0 242.8 187.7 177.0 140.4 118.6 95.4 86.6 70.6 4994.6 
06 (14.3) (5.1) (4.9) (3.8) (3.5) (2.8) (2.4) (1.9) (1.7) (1.4) 
2006- 989.2 296.7 291.8 199.1 151.6 171.6 124.2 111.4 91.2 72.2 5939.1 
07 (16.6) (5.0) (4.9) (3.4) (2.6) (2.9) (2.1) (1.9) (1.5) (1.2) 
2007- 1451.1 359.8 309.1 284.9 218.5 191.7 196.1 117.1 99.7 90.8 7644.0 
08 (19.0) (4.7) (4.0) (3.7) (2.9) (2.5) (2.6) (1.5) (1.3) (1.2) 
2008- 1546.9 314.0 330.8 268.5 122.3 221.9 237.5 110.6 NA NA 8610.1 
09 (18.0) (3.6) (3.8) (3.1) (1.4) (2.6) (2.8) (1.3) 
Note: # 	During 1991-92 to 1993-94 figures were in rupees, these have been converted to USS 
figures by using the average exchange rates for the relevant financial years obtained 
from RBI. Handbook of statistics of Indian economy 2008 (www.rbi.org.in), 
Figures in the parenthesis are percentage shares. 
Source: 	Compiled from CMIE '.Foreign Trade and 130Ps". (various issues) Centre for 
Monitoring Indian Economy Pvt. Ltd.. Mumbai 
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Rgnre 4.7. 
Top Ten Destinations of Indian Pharr ceutkal Fats (1991.2008) 
1800 
1600 
1400 
1200 
1000 
600 
400 
0 
}USA 
• Cemnny 
} Russia 
'UK 
*Canada 
+h*, 
f Singapore 
+Japan 
gftggftftft 
Yeas 
With the growth of the pharmaceutical industry and increase in production, this sector 
has also seen an increasing trend in imports. Major pharmaceutical suppliers include 
China (41%), Switzerland (13%), USA (11%), Germany (5%), Denmark (4%), Italy 
(3%) and others. Together these top ten importing countries i.e. China, Switzerland, 
USA, Germany, Denmark, Italy, France, UK. Japan and Netherland accounted for nearly 
72% in the 1991 and 84% of total pharmaceutical imports in the year 2008 (Table 4.10). 
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"Table-4.10: Top Ten Destinations of Indian Pharmaceutical Imports (1991-2008). 
(US$ million and °o ) 
i -  .h 
1991- 11.9 21.9 17.2 14.6 0.4 18.2 11.2 13.0 6.5 14.0 180.1 
92# (6.6) (12.2) (9.6) (8.1) (0.2) (10.1) (6.2) (7.2) (3.6) (7.8) 
1992- 16.4 19.1 26.8 16.6 4.6 25.5 10.2 12.8 4.8 17.7 222.8 
93t (7.4) (8.6) (12.0) (7.4) (2.1) (11.4) (4.6) (5.7) (2.2) (7.9) 
1993- 12.1 19.9 24.2 9.5 11.7 14.5 9.5 12.2 7.1 15.0 189.8 
94» (6.4) (10.5) (12.8) (5.0) (6.2) (7.6) (5.0) (6.4) (3.7) (7.9) 
1994- 16.5 28.8 41.5 9.8 37.2 19.7 14.8 20.1 9.2 19.5 298.6 
95 (5.5) (9.6) (13.9) (3.3) (12.5) (6.6) (5.0) (6.7) (3.1) (6.5) 
1995- 19.9 45.3 50.5 13.4 74.3 27.2 16.0 21.3 9.7 23.5 406.6 
96 (4.9) (11.2) (12.4) (3.3) (18.3) (6.7) (3.9) (5.2) (2.4) (5.8) 
1996- 12.0 25.8 40.6 8.3 58.7 23.9 9.8 22.2 8.5 16.7 307.1 
97 (3.9) (8.4) (13.2) (2.7) (19.1) (7.8) (3.2) (7.2) (2.8) (5.4) 
1997- 19.0 40.5 30.0 13.1 65.6 20.7 33.3 32.6 12.1 21.4 389.8 
98 (4.9) (10.4) (7.7) (3.4) (16.8) (5.3) (8.5) (8.4) (3.1) (5.5) 
1998- 31.4 37.2 28.9 10.9 71.3 17.1 21.9 26.0 12.9 18.8 383.8 
99 (8.2) (9.7) (7.5) (2.8) (18.6) (4.5) (5.7) (6.8) (3.4) (4.9) 
1999- 33.0 29.2 28.1 13.9 73.0 30.0 18.4 26.4 11.5 18.4 373.4 
00 (8.8) (7.8) (7.5) (3.7) (19.6) (8.0) (4.9) (7.1) (3.1) (4.9) 
2000- 29.0 26.7 35.0 14.8 70.0 12.4 21.2 23.8 12.2 18.4 373.0 
01 (7.8) (7.2) (9.4) (4.0) (18.8) (3.3) (5.7) (6.4) (3.3) (4.9) 
2001- 32.8 33.6 37.4 NA 105.2 18.8 18.3 19.9 8.9 20.8 426.2 
02 (7.7) (7.9) (8.8) (24.7) (4.4) (4.3) (4.7) (2.1) (4.9) 
2002- 86.7 50.6 42.2 22.5 150.2 34.0 32.3 19.7 12.5 18.8 593.2 
03 (14.6) (8.5) (7.1) (3.8) (25.3) (5.7) (5.4) (3.3) (2.1 (3.2) 
2003- 72.4 57.4 28.5 28.2 184.9 43.4 25.2 30.7 11.7 21.3 644.2 
04 (11.2) (8.9) (4.4) (4.4) (28.7) (6.7) (3.9) (4.8) (1.8) (3.3) 
2004- 83.5 66.3 42.0 23.9 202.1 29.2 24.2 29.1 13.1 27.1 705.1 
05 (11.8) (9.4) (6.0) (3.4) (28.7) (4.1) (3.4) (4.1) (1.9) (3.6) 
2005- 123.7 96.1 63.0 39.2 356.5 38.6 36.0 30.2 14.1 21.3 1027.6 
06 (12.0) (9.4) (6.1) (3.8) (34.7) (3.8) (3.5) (2.9) (1.4) (2.1)  
2006- 243.6 107.3 91.3 39.7 469.2 55.7 37.1 34.5 16.8 16.3 1292.3 
07 (18.9) (8.3) (7.1) (3.1) (36.3) (4.3) (2.9) (2.7) (1.3) (1.3) 
2007- 227.1 163.9 98.4 71.4 686.6 51.9 49.0 40.0 20.7 17.0 1668.2 
08 (13.6) (9.8) (5.9) (4.3) (41.2) (3.1) (2.9) (2.4) (1.2) (1.0) 
2048- 273.0 204.6 104.6 76.1 698.7 70.0 55.4 48.1 22.5 17.9 1876.6 
09 (14.5) (10.9) (5.6) (4.1) (37.2) (3.7) (3.0) (2.6) (1.2) (1.0) 
Note: -during 1991-92 to 1993-94 figures was in rupees. These have been converted to US$ figures by 
using average exchange tables for the relevant financial years obtained from RBI. Handbook of 
statistics of India's Lconomy 2008. 
Source: Same as table 4. IO 
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Figure 4.8: 
Top Ten Destinations of Indian Fbammcutica1 lkonts (1991.2008) 
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4.10 Research and Development in Indian Pharmaceutical Industry: 
In today's world, ability to develop low cost technologies and become owner of 
intellectual property is one of the most important requirements for becoming leaders in 
knowledge based pharmaceutical industry. It is a paradox that not even a single Indian 
company is undertaking original technological development and R&D. If we can 
combine our low cost advantage with indigenous technology, our industry could become 
a leading global player. 
Pharmaceutical industry being one of the most technology intensive industries, R&D 
investment plays a crucial role in its growth. This industry is a typical case where R&D 
and profitability are closely interrelated. R&D in the sector includes directional research 
for solutions along with the existing medical requirements. Pharmaceutical R&D may 
also be aimed at improving the existing solutions to improve the efficiency and safety of 
medicines. It can be broadly classified into three categories (1) Development of New 
Chemical Entries (NCEs) (2) Modifications of Existing NCEs (New chemical 
derivatives, new formulations, new combinations, new and modified dosages forms or 
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Novel Drug Delivery System (NDDS)6 (3) Development of new process for 
manufacturing drugs (whether old or new) or generic products. Till recently, R&D in 
Indian pharmaceutical companies has been primarily of the third type i.e. generic 
products. 
An important reason why Indian companies undertake R&D for generic drugs is because 
new drug development is a costly, time consuming and risky business. The activities can 
be broadly classified into pre-clinical and clinical stages. The objective of the pro-clinical 
stage is to develop a promising molecule which is safe in animal testing. At the clinical 
stage, the molecule is tested on humans and is developed for manufacturing and 
marketing. The fully capitalized cost of a new drug has been estimated to be USS847 
million abroad (DiMasi of al, 2003:151-185). 
However, the Indian private sector started investing in R&D for developing new drugs 
only since the mid 1990s when TRIPs came into effect. It was initiated by Dr. Reddy's 
and Ranbaxy. Thereafter., a few other companies have also joined in. At present, there are 
about 15 Indian pharmaceutical companies which have been set up or are in the process 
of setting up new research centers with NDDR as a major objective. Ranbaxy has spent 
the largest amount of USS108.5 million in the year 2008 followed by Dr. Reddy's 
laboratories US$81.3 million, Sun pharnra US$66 million and others (Table 4.11). It is 
indicated that in 2008-09 top ten leading companies together spent US$484.1 million on 
R&D including that on new drug development. However as can been seen this amount of 
(USS484.I million) is much less than what is spent (US$847 million) by developed 
countries on a single new drugs. 
6 NDDS- Traditionally the must common term of drug adminis [ration was or a I administration. However, 
it has been found to be not very effective way of dclivenng drugs to the body. Besides focusing on mode 
of administrate on NDDS a focuses on finding new dssage forms so Ilse effectivencso of the drugs 
enhanced. 
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fable-4.l I: R&D Expenditure of the Leading Indian Pharmaceutical Companies (1998-2008), 
(l'SS million) 
p 	•' n r~ n n n n n _ r~ 
.. .' 
w 
' .' U 
w a x 
a ro a J a C N 
1998 	10.4 
i 
2.7 2.4 6.2 - 4.6 - 0.8 - 1.0 - 5.6 - 2.2 • NA - 
1999 	12.S 212.6  72.5 8.4 3S.S 4.9 6.3 1.2 60.7 23 128.2 7.0 25.0 3.3 50.0 NA 
2000 12.7 -0.5 5.1 66.0 	4.5 6.7 7.1 -15.1 5.6 12.7 2.3 88.3 4.5 92.0 5.1 -26.4 1.8 47 NA 
2001 16.3 28.5 10.8 110.9 5.3 18.9 6.4 -10.8 8.9 AS 2.5 11.9 4.7 4.6 4.7 -9.0 1.3 -28.7 NA 
2002 39.5 142.2 15.2 40.9 7.0 32.1 7.0 10.1 7.8 •12.1 6.4 150.9 6.4 36.8 10.7 129.6 2.9 126.6 	7.8 
2003 59.2 49.9 	30.3 98.7 20.8 197.5 12.9 84.0 18.9 141.5 7.9 24.5 8.6 34.6 12.2 	14,3 	4.7 63.9 	10.1 29.5 
2004 73,1 23,4 	43.9 45.2 28.0 34.7 15.3 18.8 22.7 20.4 10.8 35.4 14.9 73.1 21.7 	77.6 	10.8 129.1 	18.5 	82.2 
2005 110.2 	50.8 57.6 31.1 32.4 15.7 18.4 20.2 27.0 18.7 10.6 -1.5 19.8 33.4 35.1 61.8 	12.2 13.2 24.5 32.7 
2006 85.2 	2.2.7 47.5 •17.6 44.6 	37.5 	30.5 65.7 27.4 1.4 	9.9 -6.2 16.3 -17.6 	38.9 ' 	10.5 	117.0 Hs 31.4 	28.1 
2007 111.4 	311." 59.6 25.5 67.6 	51.5 	36.8 20.8 32.4 18.5 	10.4 	4.8 22.0 34.9 	56.2 	44.6 	23.5 	38.2 49.3 	57.3 
2008 108.1 2.6 S 1.3 36.6 66.1 	-2.1 	38.0 33 30.6 •5.5 11.8 12.9 26.0 18? 56.2 0.1 4.1 -82.3 61.5 	24.6 
Note: 	(R. rcicrs to (ironlh Rate. 
N;1 rcters to Not Available. 
Source: Compiled from Annual Report (Various years) and websites of the respected companies. 
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Figure 4.9: 
R&D E enditure ofthe Indian Leading Phartnaceutical Companies (1998-2008) 
Another reason that forced Indian companies to enhance their R&D efforts and 
investment is changes in patent law under TRIPs obligation preventing the reverse 
engineering of patent molecules. Consequently moving in the value chain of R&D during 
pre TRIPs period from process development accounted for 65%, NDDS 39% and NCEs 
5%. In post TRIPs era this changed and accounted for 35%, 35% and 30% respectively. 
According to Chaturvedi and Chataway (2006) earlier only about 2% of total sales was 
spent on R&D but now, the average R&D expenditure has gone up to around 5-6% in 
2003-04. Among these companies Ranbaxy, Dr. Reddy's, Cipla, Wockhardt, Torrent etc 
are prominent investors. 
Though, spending on R&D in relation to the GDP has increased over the years in India, 
but the difference between their spending and that of the developed countries still 
remains considerably high. India spends approximately 0.88% of its GDP on R&D 
which is quite low compared to countries like China ( 1.4% of GDP) and other 
developed countries spending more than 2% of their GDP (Patnaik et al., 2009). The 
growing trends of R&D expenditure may be a good sign but not a sufficient condition to 
ensure rising competitiveness for Indian Pharmaceutical sector. As Ernst and Young 
estimated R&D expenditure as a percentage of sales in India was 1.4% in 2001 which 
has increased 9.9% in the year 2008. During 1991-2008 the CAGR is 21.71%. It is 
important to note that during the period of 1995 to 2008, R&D expenditure of the 
domestic pharma companies (29.8%) was much higher compared to foreign firms 
(21.4%) (Table-4.12). Foreign companies started spending more only after 
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implementation of "I'RIPs period. It is further indicated that R&D intensity in India has 
improved over the period of time particularly during post TRIPS era. While, India has 
consistently increased its R&D expenditure and enjoyed a favourable trade balance in 
pharmaceutical products, its export share in the world market is still less than one and 
half per cent. At this juncture, it is important for the government to encourage the small 
and medium firms by providing low cost finance for research with subsidy facilities for 
indigenous research activities. 
Table-4.12: Trends of R&D Expenditure in India Pharmaceutical Industry (1991-
2008. 
(US8 million) 
Year 
Domestic 
R&D Exp. 
Foreign 
R&D Exp. 
Total R&D 
Exp. 
Growth rate 
(%) 
R&D 
Intensity 
1990-91 - - 34.6 - NA 
1991-92 - - 35.5 2.6 0.01 
1992-93 - - 36.8 3.7 0.01 
1993-94 - - 39.8 8.2 0.01 
1994-95 - - 44.7 12.3 0.01 
1995-96 24.9 19.8 44.7 0.0 0.01 
1996-97 40.3 23.6 63.9 43.0 0.02 
1997-98 40.8 24.6 65.4 2.3 0.01 
1998-99 
1999-00 
37.3 
50.7 
21.9 
18.5 
59.2 
69.2 
-9.5 
16.9 
0.01 
0.01 
2000-01 57.2 20.1 77.3 11.7 0.01 
2001-02 92.2 23.3 115.5 49.4 0.02 
2002-03 123 22.6 145.6 26.1 0.02 
2003-04 147.4 49.9 197.3 35.5 0.02 
2004-05 239.4 76.5 315.9 60.1 0.03 
2005-06 346.3 115.8 462.1 46.3 0.04 
2006-07 408.6 180.1 588.7 27.4 0.04 
2007-08 574.3 168.4 742.7 26.2 0.04 
2008-09 638.9 161.3 800.2 7.7 0.05 
Note: During 1990-1994 do not find separate data for domestic & foreign expenditure. 
Source: Compiled from Indiastat database & Bulk Drub_ Manufacturers Association India 
Note: R&l) Intensity defined as the ratio of expenditures by a firm on R&D to the firm's sales (Net Sales). 
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Figure 4.10 : 
R&D Fipenditure in India Pham*ceutical Industry (1995-2008) 
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During 1991-2008 with CAGR of 27.33% India's investment level is indicated a healthy 
growth rate (Table-4.13). Availability of skilled researchers, protection of IPRs, 
availability of patient, level of local skills, legal environment, physical, infrastructure, 
low cost research and access to scientific cluster etc are the main determinants of 
pharmaceutical R&D in India. 
Table-4.13: Investment trends in Indian Pharmaceuticals industry (1991-2008). 
(USS million & %) 
Year Investment Growth Rate (%) 
1991 38.4 - 
1992 46.5 21.1 
1993 126.9 172.9 
1994 238.1 87.6 
1995 233.7 -1.8 
1996 265.1 13.4 
1997 345.9 30.5 
1998 385.9 11.6 
1999 572 48.2 
2000 581.4 1.6 
2001 511 -12.1 
2002 550.5 7.7 
2003 957.7 74.0 
2004 1324.1 38.3 
2005 1628.8 23.0 
2006 2446.1 50.2 
2007 4123.5 68.6 
2008 4117.1 -0.2 
Source: Compiled from CMIE "Industry Financial Aggregates and Ratio (Various years). Investment 
figures in rupees. These have been converted to USS by using the average exchange ratio for the relevant 
financial years obtained by RBI handbook of statistic on Indian economy, 2009. 
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Figure 4.11 : 
Investment in Indian Pfiam~aceuticals industry (1991-2008). 
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A major criticism often levied against the IPI is that it focuses mainly on reverse 
engineering and spends less on R&D investment. Hence in order to strengthen the 
pharmaceutical industry's R&D capabilities and to identify the support required by them 
to undertake domestic R&D, a committee was setup in 1999 by the name of 
Pharmaceutical Research and Development Committee (PRDC). To promote R&D in 
pharmaceutical government also established department of pharmaceutical which is 
working as a separate body under ministry of chemicals and fertilizers from July 1, 2008, 
Additionally Government of India has taken a number of initiatives to promote R&D 
activities in this sector such as: 
1. Weighted tax reduction of 125% to the sponsor of sponsored research 
programmes in universities approved technological institution and national 
laboratories. 
2. Weighted tax reduction of 150% of R&D expenditure incurred in the in house 
R&D centers (approved by Department of Scientific and Industrial Research, 
Government of India) of companies engaged in biotechnology, production of 
drugs. 
3. Income tax holidays of ten consecutive assessment years for commercial R&D 
companies. 
4. Reduction in custom duty from 7.5% to 5% on 15 specified machinery for 
pharmaceutical and biotechnology sector. 
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5. 	Pass through status to be granted to venture capital funds in respect of 
investments in venture capital under takings in biotechnology (Budget 2007-08). 
4.10.1 New Chemical Entities (NCEs): 
New chemical entities is an expensive time consuming and risky business, as 10,000 
molecules enter the drug discovery stage but only one drug is approved for marketing. 
There are many NCEs which are at different stages of development. The largest spenders 
are Dr. Reddy's and Nicholas Piramal, Ranbaxy. Some of these have successfiuly 
completed pre-clinical trial and are at different stages of clinical trials. 
According to H. Kajaria (Executive director of Pharma KPMG) Indian Pharmaceutical 
companies have spend $ 500 million in the year 2010 on NCE research and expected to 
spend $ 1.2 billion by 2015. 
Dr. Reddy's has 4 molecules in its NCE pipeline in 2008. Similarly Sun pharma, 
Nicholas Piramal, Wockhardt, Ranbaxy Zydus Cadila and Lupin have four, thirteen, five, 
seven, four and four respectively (Appendix-IV). Recently Ranbaxy launched India's 
first new drug, SynriamTM, for the treatment of uncomplicated Plasmodium falciparum 
malaria, in adults. 
It is important to note that none of these companies is engaged in the entire process of 
dmg development because they do not have all the skills and the finds required. 
4,10.2 Abbreviated New Drug .Applications (ANDAs): 
For marketing a formulation to USA, Indian companies are required to file an ANDA. 
When a company files an ANDA it is required to mention the suppliers of the bulk drugs 
and DMF numbers. This is an expensive and time consuming process and the approval 
may take up to five years. Of the total ANDAs approved in the USA, 30% is of Indian 
making, the second place next to USA. Various other agencies like Medicines control 
healthcare products regulatory agency (MHRA) U.K, Therapeutic Goods Administration 
(TGA) Australia and Health Promotion Board (HPB) Canada are also being filed from 
India. There are 13? (29%) ANDAs approved during 2007-08 followed by Israel 40 
(9%) Germany 25 (5%), Canada 24 (5%) and others (Table 4.14A). (DOP, 2009-10). As 
far as domestic companies are concerned in the year 2008 Ranbaxy submitted 6 ANDAs 
in the USA and has the largest basket of products in the US market with 142 approved 
drugs and another 98 application were pending for approved (DOP, 2008). It is followed 
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by Dr. Reddy's (70), Sun Pharma (53), Wockhardt (23), Cadila (34), Glanmark (40) and 
Aurobindo (67), (Table 4.14(B)). 
fable- 4.14(A): Country-wise ANDAs Approvals (2007-08). 
Country In Number Share % 
USA 169 38 
India 132 29 
Israel 40 9 
Germany 25 5 
Canada 24 5 
Switzerland 19 4 
Iceland 14 3 
Jordan 11 2 
China NA NA 
Others 25 5 
Source: 	Compiled from DeDartment of Pharmaceutical. Annual Reuort 2009-10. Government of 
India, New Delhi. 
Figure 4.12: 
Country Wise ANDAs Approvals (2007-08) 
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Table- 4.14 (B): Company-wise ANDAs filing from India as up to 2008. 
(In numbers) 
Company ANDAs filing as on 31 March 2008 
ANDA Approvals as on 
31 March 2008 
Ranbaxy 241 142 
Dr. Reddy's 122 70 
Sun Pharma Indus 142 53 
Wockhardt 57 23 
Cadila Healthcare 81 34 
Glenmark 51 40 
Torrent 11 4 
Aurobindo 128 67 
Lupin 90 34 
Cipla j 	NA NA 
Source: Compiled from Annual Report of Respected Companies. 
Figure 4.13: 
Company Wise ANDAs filing from India as up to 2008 (%) 
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4.10.3 Drug Master Files (DMFs): 
For exporting bulk drugs to USA, Indian manufacturers are required to file a DMF. The 
company filing a DMF is required to submit confidential detailed information on kind of 
equipment, location of the plant. description of production facility process chemistry, 
raw materials specification, stability data etc. The cost of filing a DMF can be estimated 
to be US$200,000 depending on the product (the steps involved in the processes and the 
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number of test to be done etc) (Chaudhuri, 2005: 188). One-third of all DMFs with 
USFDA come out of Indian facilities. Now India has the highest number of FDA 
approved Plants (119) in addition to 84, MI-IRA approved plant in UK. Recently, 1735 
(3 1 %) DMFs were filed by India which is higher than Spain Italy, China and Israel put 
together, followed by USA (20%), Italy (13%), and Others (Table 4.15(A)). Company 
wise Dr. Reddy's has the largest DMFs (55) in the year 2008 (Table 4.15(B)). 
Table-4.15 (A): Country-wise DMFs Filed with USFDA (2008). 
Country In Number Share % 
India 1735 31 
USA 1054 20 
Italy 679 13 
China 563 10 
Japan 311 6 
Germany 286 5 
Spain 248 5 
France 200 4 
Switzerland 163 3 
Israel 162 3 
Source: Compiled from, Annual Report 2009-10, Department of Pharmaceutical, Government of India. 
Figure 4.14: 
Country Wise DMF Filed with USFDA (2008) 
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A DMF is submitted to gain the confidence for out-sourcing. The growing number of 
DMF also signifies the increase in the number of contracts that Indian players have 
garnered. 
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Table- 4.15 (B): Company-wise DMFs Filed from India as upto 2008. 
(In numbers) 
Company DMF Filing with USFDA as on 31 March 2008 
Global DMF filings as on 
31 March 2008 
Ranbaxy NA 271 
Dr. Reddy's 127 281 
Sun Pharmaceutical NA 101 
Wockhardt 8 NA 
Cadila Healthcare 59 NA 
Glenmark 30 37 
Torrent 6 23 
Aurobindo 122 1017 
Lupin NA NA 
Cipla 87 NA 
Source: Compiled from, Annual Report of Respected Companies 
# On December 2007 
Figure 4.15: 
Company µise DMF Filed as upto 2008 
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4.10.4 Patent Protection: 
The principal economic rationale for granting patent is that it will stimulate investment 
for research and innovation. Patent protection is considered to be important in the 
pharmaceutical sector because, the costs of developing a new drug are high and the costs 
of developing process for manufacturing a new drug are low (Grabowski 2002). Till the 
early 1970s India essentially has a product patent regime in pharmaceutical. It was 
abolished in 1972 (Patent Act 1970). Many economists argued that Indian patent Act 
1970 was crucial in the growth of the Indian pharmaceutical sector because it gave space 
to Indian companies to develop alternate process which they did so successfully. 
After establishment of WTO, TRIPS came in to effect with introduction of full product 
patent protection in all fields including pharmaceutical. After TRIPs, India had to 
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introduce product patent by January I, 2005. The term of patents is now for 20 years. 
All the product patent applications held in the mail box7 are also required to be taken up 
for examination from January 1, 2005. Currently a total of 35218 patent applications 
were in field out of which, 6040 (17%) are from domestic companies and 29178 from 
foreign applicants (Economic times, 2009) Dr. Reddy filed the largest number of patent 
applications (147) followed by Ranbaxy (101), Avesthagen Ltd., (66) and others (Table 
4.16). 
Table-4.16: Top Ten Indian Applicants for Patents from Pharmaceutical Sector 
(2008). 
Company Application Filed in Number 
Dr. Reddy's 147 
Ranbaxy 101 
Avesthagen Ltd. 66 
Cadila Healthcare Ltd 57 
Matrix Laboratories Ltd 54 
Orchid Chemical & Pharmaceutical Ltd 22 
Aurobindo Pharma 22 
Jubilant Organosys Ltd 21 
Ind Swift Laboratories Ltd 19 
Panacea Biotech Ltd. 15 
Source: Compiled from, Annual Report (2008-09), Office of Controller General of Patents, Designs, 
Trademarks and Geographical Indication. Government of India, New Delhi. 
Figure 4.16 
Top Ten Indian Applicants for Patents from Pharmaceutical Industry (2008). 
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7. The mail box is a facility introduced through the first amendment to the patent Act in 1999. It allows 
filing of applications for product patents for drugs, agrochemicals and food products discovered drug the 
period January 1995 December 2004 The patent office will begin examination these application from 
January and any patent based on the mail box filings if granted will be effective for 20 years from the date 
of mail box application. 
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4.11 Contract Research and Manufacturing Services (CRAMS): 
Recently contract manufacturing' has emerged as a new growth strategy for many Indian 
pharmaceutical companies, by offering contract services like marketing, research, 
clinical trials, data management and laboratory services to global pharmaceutical 
companies (India infolinc, 2000). The process of out-sourcing brings substantial 
economic gains to global firms as they give contract for the production of their products 
to those who can work cost effectively and qualitatively thus relieving them to focus on 
their core competencies and high value-added operations like research and marketing. 
For Indian firms out-sourcing not only provides additional sources of revenue, but also 
access to new technologies, marketing networks and best business practices abroad. 
Important reason for CRAMS lbr sweeping across the sectors is severe cost pressure of 
global market. India is the fastest growing custom manufacturing out-sourcing 
destination with a growth rate of 43%, which is thrice of the global market rate. The 
developed pharmaceutical industry is increasingly facing cost pressures due to rising 
manpower cost, higher regulatory risk and also the R&D productivity of these players 
has gone down significantly in recent years. In addition, the process of getting approval 
for new products in regulated markets requires strict compliance of quality norms, which 
is stringent and is also subject to high legal risk. It is causing MNCs to out-source part of 
their R&D and manufacturing activities to low cost destinations like India. About a third 
of total R&D investment by the global pharmaceutical industry, estimated at $40 - $50 
billion, could be made in India over the next 10 years. 
Hence India is emerging as the global hub Ior CRAMS due to its low cost advantage and 
world class quality standards as per the GMP norms. The diverse disease profile and 
abundance of patient in the country provides better ground for clinical trials. India has 
leveraged this advantage to attract clinical trials process out sourced by the companies 
involved in innovation. Majority of the contract manufacturing deals relate to production 
of APIs and intermediates, in which India possesses competence. Ranhaxy was the first 
Indian companies to adopt the strategy of contract manufacturing, licensing and 
collaborative research to strengthen it competitive strength in Indian and overseas 
market. Nicholas Piramal, Sharun Chemicals. Devis Lab. Dishman Pharma, Cadila 
Healthcare, Lupin and Aurobindo Pharma are some of the companies which have 
S. Contact manufacturing is manufacturing ofa product by a job shop on behalf ofan external customer. 
Normally, the customer supplies the drawings and specifications as well as the quality control criteria. 
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witnessed impressive growth in revenues from their CRAMs business. Consequently. 
India's share of the global out sourcing market is too grown from 2.2% in 2008 to 3.5% 
in 2010 (Express Pharma. 2010a). Besides Indian contract manufacturing segment was 
worth around S350 million in 2007, S605 million in 2008 and is expected to grow up to 
['SS 1 billion in 2010. It is growing at a rate of 25% per annum. 
This phenomenon now covers a wider range of inter firm cooperation like strategic 
marketing alliances, collaborative research and out-licensing. On 1" March 1997 and 
June 1998 Dr. Reddy Licensed out its two molecules namely Balagtilazone and 
Ragaglitazar to Novo Nordisk of Denmark for further development (India Infoline, 
2004). 
Further, India is among the fastest growing clinical trial`' destinations, with a growth rate 
of two and half times the overall market growth rate. The country also participate in 7%.,0 
of global phase III and 3.2% of phase II trials with industry sponsored trials 
demonstrating a CAGR of 39% between 2004-08 (Ernst &Yong, 2010: 45-46) 
4.12 Employment in Indian Pharmaceutical Industry: 
In the last decade the pharmaceutical industry has grown by CAGR 12-15%. The rapid 
expansion of pharmaceutical sector has opened up several job opportunities. As per 
KMPG (2006) pharmaceutical industry employs 29 million people (5 million direct and 
24 million indirect). It indicates that pharmaceutical employment has increased nearly 
twice since 1995 and is growing with 4% CAGR (Table-4.17). In major Indian states like 
Maharashtra, Gujarat and Andhra Pradesh this sector employs the largest number of 
people. The ministry of pharmaceutical has estimated that this sector has created around 
2.2 million employment opportunities. Besides this the industry offers great employment 
opportunities for researchers and other skilled workers due to the factors like increasing 
out-sourcing and expansion of the sector. The concept of pharma retail chain that has 
gained momentum in the recent years has also created numerous employment 
opportunities. 
9. A clinical trial is a research -study to answer specific questions about vaccines or new therapies or new 
ways of using known treatments. It also called medical research and research studies are used to determine 
whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the 
fastest and safest way to tittd treatmei is that %vork. 
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Table-4.17: Emulovment level in Indian nharmaceutical industry (1995-2008). 
Years No. of Employees in Pharma sector Growth Rate (%) 
1995 181497 
1996 204609 12.7 
1997 211614 3.4 
1998 189295 -10.5 
1999 213999 13.1 
2000 243410 13.7 
2001 233704 -4.0 
2002 226416 -3.1 
2003 223556 -1.3 
2004 240791 7.7 
2005 265396 10.2 
2006 290021 9.3 
2007 336211 15.9 
2008 353692 5.2 
Source: Bulk Drug Manufacturers association in India, Hyderabad. 
Flgure-4.17: 
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4.13 Chinese Threat and India Pharmaceutical Industry: 
India and China account for 7% of world pharmaceutical industry in value terms with 
revenues of US$28 billion (www.industrychannel.com). Chinese Pharmaceutical 
industry is 4.5 times larger in size than the Indian industry. It is growing at 17% annually 
in comparison to 12-15%'% growth rate of Indian Pharmaceutical. Besides this China has 
also established a large number of profit oriented R&D institutions, which are 
independent of government funding in contrast to institutions in India which are mostly 
dependent on government funding. FDI in Chinese pharmaceutical sector is 20 times 
more than in India. 
Currently, China is being touted as the biggest threat to the IPI, as Chinese producers 
have gained market share in various developed and developing countries by dumping 
products at low cost. Almost 60% to 70% of our pharmaceutical requirement of 
intermediates is sourced from China. Recently, China cracked down on its chemical 
industry in order to enforce environmental legislation leading to short supply of chemical 
intermediates, increasing their prices uneconomically for Indian drug manufacturers. On 
one hand, this severely affected bottom lines of Indian companies while on the other 
hand their supply schedules were also disturbed. Indian drug companies largely depend 
on imports from China for bulk drugs. It was 2.9% in 2004-05 and increased to 5.1% in 
2008-09 (Express Pharma, 2010a). India must reduce its dependency for these 
intermediates on China. However; Indian pharmaceutical companies have shown 
remarkable resilience. Their pharmaceutical products are far superior in quality and 
safety to Chinese companies, which rely on ancillaries that roll out products of in 
consistent quality. 
4.14 Strength, Weakness, Opportunities and Threats (SWOT) Analysis of Indian 
Pharmaceutical Industry: 
Indian pharmaceutical was of at critical crossroad where key decision by firms and 
government set the direction and chart the course for the sector from 2005 onwards. 
Hence it is fruitful to do SWOT analysis at this stage and identify strength, weakness. 
opportunity's and threats so that something can be done to claim as well grab larger 
share of the domestic as well as global phanna market. SWOT analysis focuses on the 
internal and external environment examining strength and weakness in the internal 
environment and opportunity and threat in the external environment. 
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Strength: Huge population of over a billion, and large middle class population, large 
volume of production, high demand for modern medicines especially in rural areas, 
lowest cost of production with a skilled labour force, sound chemical industry and 
excellent chemistry with process reengineeting skills, strong and well developed 
manufacturing base, high standard of purity as India has the largest number of USFDA 
approved plant, increasing liberalized government policies and existence of a world class 
cold chain infrastructure are the major strength of Indian pharmaceutical sector. 
Weakness: Price regulation, lack of product patent low barriers to entry leads to intense 
competition adversely affecting growth in value terms, non-availability of major 
intermediates for bulk drugs, dependence on imports from China, lack of experience to 
exploit efficiently new patent regime, low level of strategic planning for future, low 
share in world pharmaceutical production, low level of R&D expenditure, absence of 
association between institute and industry and production of counterfeit drugs are the 
main weakness of Indian pharmaceutical sector. 
Opportunities: Existence of product patent and a large number of drugs going off patent 
in the US and Europe during 2005-2011, lowest cost producer, largest number of 
USFDA approved plant outside the USA, incredible exports potentials, increasing 
income of the middle class, globalization i.e. easier international trading with opening of 
new markets, and increasing aging population in India and abroad are the main 
opportunities for 121. Additionally, India has emerged as the centre of "healthcare 
tourism" in the entire world. It has the potential to attract one million medical tourists per 
year. Apollo clinics have spread across 37 locations in India and abroad. It is the largest 
private healthcare service provider in Asia and 3 1`  largest in the world. It provides 
healthcare at a fraction of cost compared to developed world. 
Threats: Implementation of VAT, dumping of bulk drugs and formulations by 
neighbouring countries particularly China, non tariff barriers imposed by developed 
countries and competition from MNCs, high cost of discovery for new products and 
fewer discoveries, low growth of domestic formulation market as compared to export. 
Cheap import of bulk drugs from China are the major threats for IPI. However, on the 
quality front India is better placed relative to China. 
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4.15 Indian Pharmaceutical Industry in Global Market: 
The global market for pharmaceutical industry has shown tremendous growth over the 
past decade. But the geographic spread of this growth has been very uneven. Large 
markets in the world are USA (45%), Europe (24%) and Japan (11%). China contributed 
2% and India's contribution was a meager I ,8% (Pi iolkar, 2009), 
The Indian industry is highly fragmented with no firm controlling more than 7% of the 
market (ICRA, 2004:82). The top ten companies in India hold approximately 37% of the 
market, which is lower than the global structure of 44%. IPI has been consistently 
growing at a 12-15% (CAGR) as against global average of 4-7% during 2008-13 (Times 
of India, 2009). One of the unique features of Indian pharmaceutical market is that it has 
dominated branded generic (80%) and rest (14%) generic-generic drugs market (Yes 
Bank Report, 2009). India accounts for 22% of global generic market. Top global 
generic players in 2007 were Teva ($9.I billion), Sandoz ($5.8 billion), Mylan ($4.6 
billion) and Watson ($2.7 billion). Together they accounted for 47% of the US market in 
2009. As compared to these foreign companies Ranbaxy share was $1.7 billion, Dr. 
Reddy's SI.7 billion and Wockhardt 0.4 billion (DOP, 2009-10). 
India has 793 WHO cGMP (Current Good Manufacturing Practices) approved 
Pharmaceutical Plants (DOP, 2009-10). Further India has the highest number of USFDA 
approved plant (119 plants) outside the US. India accounts for over 1/3" of Drug master 
files and 30% of all approved ANDAs in the USA placing it at the second position next 
only to USA. Even in patent challenges India ranks next to USA with a share of 21% of 
patent challenges. The country also stands at 3rd position in terms of volume of 
production (10% of global share) and 14°i in terms of value (1.5%). Besides this India 
has about 2% of the world pharmaceutical market (DOP, 2009). 
However, there is a vast gap in the amount of pharmaceutical R&D expenses undertaken 
by foreign companies (15-20%) and the Indian companies (5-8%). 
It is heartening to observe that India has increased its pharmaceutical exports at a rapid 
pace since the 1990s. Our trade balance increased to $200 million in 1990 to $4.3 billion 
in 2003. India is top 17"' net exporter in the world. However, irrespective of its 
impressive export growth rates. India's share in the global pharmaceutical exports has 
not shown much improvement. It is hovering around 1%. Further, as per WHO study 
India accounts nearly 113 s` of world's spurious drugs market (Sagan et.al, 2006). 
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Similarly if we compare our per capita drug expenditure to other developed countries it 
is quite low i.e. S3 while in USA it is $222. (Aggaiwal of al 2006: 109). 
4.16 Issues arising out of \%TO Regime: 
The WTO was established on January I. 1995 and is responsible for making and 
enforcing rules for trade between nations. Apart from goods the two other broad areas 
that WTO covers are services and intellectual property, which previously belonged to the 
domestic domain. Accordingly. WTO administers not only the Multilateral Trade 
Agreement (MTA) in goods but also the General Agreement on Trade in Services 
(GATS) and the Agreement on Trade Related Aspects of Intellectual Property Rights 
(TRIPS) which came into existence with WTO. Therefore, the TRIPs agreement was 
born to protect the interests of the industry trade and services. India was a signatory 
member to the TRIPs agreement. 
Certain issues and developments arising out of WTO regime, pose a major challenge to 
our manufacturers. Due to TRIPs with GMP compliances schedule M1° compliance was 
made mandatory. As GMP is considered as the bench mark of product quality, it is 
important not only for maintaining market share in domestic market but also for 
accessing extremely competitive export markets. The financial constraints hindered the 
small firms from adopting GMP criteria and as a result 9% of SSIs were unable to 
comply with it and S% were closed. (Iyear, 2008: II). It adversely affects the production 
of bulk drugs and level of employment. 
II has been argued that the IPR regime can significantly constrain access to technology 
by developing countries and increase their dependence on imports. The domestic firms 
would under such circumstances be left with no option but to collaborate with the foreign 
firms. Besides a strong patent system can also dissuade innovative activity by domestic 
firms whose R&D function is dependent on the spillover effects of other firms, and 
therefore they would be adversely affected by the restricted access to these spillovers 
(Kumar, 2003: 209-224). 
A number of studies have examined the effect on prices of medicines during the post 
TRIPs period. They have argued that it has stimulated welfare losses for the consumers 
in developing countries like India. On account of it a work shop was held at NIPER on 
22 April 2006, which tbund that prices of drugs in India have been by and large stable 
10. Schedule M-Conditions with which premises, licensed for the manufacture of drugs, should confirm 
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and no sudden changes in prices have occurred. many reasons have been cited for this 
important amongst than are (a) majority of drugs marketed in India are generic (b) a 
very large volume of production by pharmaceutical industry (c) acquiring patent do not 
automatically translate into product and (d) TRIPs is just one of the many factors 
affecting prices. 
4.17 Conclusion: 
Pharmaceutical industry contributes to the welfare of humanity and provides significant 
socio-economic benefits to the society through creation of jobs, supply chains and 
community development. The industry also plays an important role in technological 
innovation, which may reduce costs of economic activity elsewhere in the economy. 
Unlike other consumer goods, prices of medicines arc inelastic in the sense that a rise or 
fall in the price of medicine is not going to significantly change the demand for the drug. 
IPI is one of the world's largest and most developed, ranking fourth in terms of volume 
and thirteenth in terms of value. The country accounts for an estimated 10% of global 
production and around 2% of world markets in pharmaceuticals. It has over the years 
made significant progress in infrastructure development, technical capability and hence 
produced a wide range of phanuaceutical products. The industry now produces bulk 
drugs under all major therapeutic groups. It has a sizable technically skilled manpower 
with prowess in process development and downstream processing. It has the capital 
investment of about US$4.lbillion. It produced bulk drugs of value of US$3.5 billion 
and formulations worth US$15.4billion in 2008. Bulk drugs have grown at a rate of 
approximately 14%, and formulation by 24% in the nineties. There is an increasing 
interest and investment in R&D. It provides employments to 29 million people. The 
contribution of pharmaceutical sector in India's GDP is 2% and 12% of manufacturing 
sector GDP. 
The industry has achieved a global status through firm level strategies industry initiatives 
and also with appropriate policy support. Presently, 70% of local requirement for bulk 
drugs and almost all the demands for formulations are met by the domestic industry. In 
addition to catering to the needs of the domestic demand it is also the leading supplier of 
hulk drugs and cheap formulations to the world and engaged in contract manufacturing, 
contract research, clinical trials and contracts R&D. Huge population with a large 
growing middle class, low cost of production but high quality standard and existence of 
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good infrastructure are the main strengths of Indian pharmaceutical. China is being 
touted as the biggest threat to the WI, but large opportunities exist for Indian companics 
internationally as many Indian drug manufacturing facilities conform to international 
quality certilicates like USFDA, UK MCA. This provides an advantage to Indian 
manufacturers, over Chinese. 
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A Statistical Approach to FDI in hrdian pharmaceutical Sector: Test of 
Hypotheses. 
5.1 	Introduction: 
As has been mentioned in the earlier chapters the importance of FDI inflows for a 
developing economy like India can never be ignored as the FDt inflow not only integrates 
the host economy with the world economy, but also acts as a developmental resource in 
the form of capital, technology, managerial and marketing know-how and market access 
required for sustained economic growth and development. Moreover, FDI inflows can 
make the relationship between domestic and foreign enterprises more dynamic in terns 
of technology and environment. It is needless to mention that pharmaceutical sector is a 
knowledge-based sector; FD[ plays an important role for the development of this sector. 
The pharmaceutical industry is perhaps amongst a few sectors in India whose foundation 
is built on the process of internalization. Therefore, it has been selected as one of the sun-
rise sector where concerted efforts are being made to attract FDI. 
The P31 in the IPI is mainly market- seeking. The advantage for MNCs in the 
pharmaceutical industry is that India has a large domestic market with 1.2 billion 
populations and a wide disease pattern. Other factors that attract foreign investors are 
relatively cheap and skilled labour force and english is widely spoken. which makes 
communication easy for foreign investors. The production of pharmaceuticals is also 
relatively cheap in India and there is a strong production base in the country. It is easy to 
get good quality bulk drugs. Because of India's focus on reverse engineering and 
development of production processes, it has high technical competence in production in 
the pharmaceutical industry. All this makes this industry attractive for foreign investors. 
The industry is also highly competitive among suppliers, which gives the MNCs a good 
bargaining position. India has many advantages for foreign investors and consequently, 
the country has future potential to become an attractive destination for outsourcing in 
drug discovery and clinical research. 
The present chapter aims at exploring the nature of interrelation between the FDI in India 
and the pharmaceutical industry. The analysis of the chapter concentrates on the absolute 
figure first and then provides a statistical analysis of the same. As has been mentioned in 
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the introductory chapters, some hypotheses need to he tested with regard to the role of 
FDI in the Indian pharmaceutical sector. 
Section-A 
5.2 	Policies regarding FIB in the Pharmaceutical Sector: 
The foreign pharmaceutical firms in India have met a restrictive environment. There used 
to be perfonuanee requirements for the foreign firms investing in the IPI, in order to 
create linkages between foreign and domestic firms. 
According to section 29 of FERA, 1973 the foreign companies producing in India were to 
dilute their foreign equity holdings to not more than 74%. But the Hathi Committee 
(1975) in its report did not find any justification of this exemption and recommenced the 
dilution of foreign equity in the pharmaceutical companies to 40% and progressively to 
26%. 
Drugs policy 1978, was the first comprehensive drugs policy to be announced by the 
Indian government in the light of the recommendations of Hathi Committee. It was very 
critical for the role of VINCs in a sense that they did not lake much initiative in 
developing the industry from the basic stages. It emphasized self-sufficiency in the 
production of drugs. The drug policy 1978 imposed restrictions on the FERA companies 
which were not applicable to other sectors. The Pharmaceutical MNCs which were 
manufacturing formulations only or bulk drugs not involving high technology were 
required to reduce foreign equity to 40% or below. Production of bulk drugs and 
formulations from basic raw materials involving high technology, were determined 
foreign equity by a high I evel. 
A number of drugs were reserved for the public sector and the Indian companies 
(companies with foreign equity of 40% or below). The government gave production 
license to FERA companies only if they were involved in high technology bulk drugs and 
related formulations, provided half of the bulk drug manufacture should be sold to other 
formulators. Besides, they were required to produce bulk drugs and formulations in the 
ratio 1:5 which were further made more restrictive in the drug policy of 1986 by 
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changing the ratio requirement to 1:4. The FERA companies were also denied access to 
the scheme of de-licensing introduced for 94 bulk drugs (Chaudhari, 2005: 133-134). 
Thus foreign investment increased in a period of stringent regulations along with an 
increase in productive capacity though no new MNCs entered in the pharmaceutical 
sector, but many big companies such as Ciba-Geigy, Pfizer, Glaxo and Jonson & Jenson 
continued and increased their manufacturing activities. 
The pharmaceutical industry is one of the key industries that were much largely affected 
by the economic reforms. Iu t990s various significant changes occurred in the 
pharmaceutical sector. All those drugs which were reserved for the production by the 
public sector enterprises were delicensed in two stages. One immediate impact of this 
delicensing of the drugs was that its production increased tremendously with increasing 
the competition among the domestic companies and foreign companies. The increased 
production has positive impact on exports and Balance of Trade (BOT). The government 
also increased the automatic approval limit for FDI in the pharmaceutical sector from 
40% to 51%in 1994. further it was increased to 74% in March 2000 and 100% in 
December 200LWith the modification of drug policy in September 1994, there has been 
significant changes in this sector. Industrial licensing for the manufacture of all drugs & 
pharmaceutical has been abolished with some exception. Technology imports have been 
uncontrolled with automatic approval for foreign technology agreements in the case of 
almost all drugs. Later on price control has been substantially diluted i.e. 70% to 50%, 
35% and 25% respectively during pre-reforrn period, 1995, 1997 and 2002. Besides this 
removal of restrictions on the royalty or technical fee payments, removal of restrictions 
on inclusion of restrictive clauses in the agreement and no scrutiny for repetitive imports 
etc also imposed. In 1995 government signed the TRIPs agreement. All these measures 
resulted in an uneven growth of the domestic pharmaceutical sector. 
R&D requirements have been a condition for foreign firms  in India. For instance, it was 
compulsory for foreign pharmaceutical companies to set up R&D facilities and spend at 
least 4 percent on R&D of their turnover annually, if their turnover was more than Rs. 50 
million (Dhar and Rao, 2002). To enter into long-term consultancy agreements with 
relevant R&D institution in the country, within 2 years of FDI approval, was also an 
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option. Furthermore, technology transfer is one of the main objectives for host countries 
attracting FDI. 
5.3 	Effects of EDT in Indian Pharmaceutical Industry: 
FDI is often seen as a catalyst of India's economic growth and development. Importance 
of FDI is not only that the foreign investor finances the investment in new plants and 
equipment, but it can be a measure of transfer of technology, knowledge and capital for 
the host country's industries. Additionally FDT comes with financial and managerial 
resources, access to large markets, technical assistance and strategic assets, such as brand 
name, which give the host firms domestic and international comparative advantages. 
According to Dunning (1970) the foreign company's management and technological 
skills from the parent company can be seen as a 'brain-drain in reverse' to the local 
economy, as they gain particularly scarce and needed entrepreneurial skills. 
The inflow of FDZs into India has increased since the liberalization started. This 
influenced the pharmaceutical sector in several ways. The public units that had a 
production monopoly in certain drugs were opened up for competition and privatization 
(Aggarwal, 2004). Besides, the requirement for certain ratio in bulk drug production 
was removed. Equity share and approvals of FDI in the pharmaceutical industry were 
relaxed and number of drugs under price control was reduced. 
This change in the attitude of Indian government towards FDI stems from the realization 
that FDI not only provide financial resources but, also arc a source of technical, 
managerial and organizational knowledge which are largely not available in the country. 
Therefore, FDI is widely considered as advantageous for the host economy since it can 
result in spillover effects by various channels such as increased competition, transfer of 
technology and imitation effects (Bergman, 2006: 4-6). 
5.3.1 Competitive Effects: 
This is the most important indirect benefit that FDI companies may generate in the host 
economy. Foreign firms have been a part of the IPI since its initial stage. When the first 
time MNCs entered the Indian market, they basically had a monopoly in the industry, and 
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thus there were no spillover effects in terms of increased competition. Currently, the 
domestic industry is welt developed, which means that MNCs and the domestic firms 
compete at the same level. In 1992, thirteen companies of the top twenty had foreign 
origins, but today the number of MNCs at the top has decreased because of lower profit 
margins and increased competition from domestic firms (Felker et al, 1997). The 
presence of MNCs in India has a large impact on the competitive environment in the IPI 
and encourages the domestic firms to upgrade their technology and investments in 
marketing. This increased competition forces local firms to improve their productivity by 
using more efficiently existing resources shifting to sophisticated and advanced 
technology providing training to workers and undertaking R&D expenditure to develop 
local technologies. 
Important factors for a firm to succeed and be able to compete effectively in the 
pharmaceutical industry are costs, research orientation, product portfolio, production 
capability and marketing & distribution network. The MNCs in India are characterized by 
advantage in many of these factors, while their domestic competitors have an advantage 
in production capacities and costs. Since the foreign firms do not have cost advantage in 
production, they invest large sums in marketing and fieldwork to promote drugs. 
Currently, the domestic companies seem to have adopted the MNCs' marketing skill and 
strategies to be able to compete. The domestic firms are more or less forced to try to keep 
up with the MNCs' marketing abilities and the local firm's increased market share 
indicates they have been doing well (Bergman, 2006: 17-18). 
The spillover effects from competition can be expected to increase in the future. The 
Indian economy is getting increasingly liberalized and the government of India wants to 
raise FDI further in the pharmaceutical industry in order to stimulate competition. 
With the introduction of the product patent regime in 2005, more research- based 
pharmaceutical companies are expected to establish their presence in India. The enhanced 
competitive environment in the new patent regime may be difficult for the small-scale 
producers. Many of the small-scale producers are lacking production product quality and 
many are also inefficient. It will be tough for the small firms to handle the competition 
and transition to the new patent regime. It is likely that many small-scale firms have to 
lower their production or shut down. Yet, spillover effects from competition lead to the 
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reduction of inefficient firms, and in the short term unproductive firms are likely to be 
swept off the market. On the other hand, in the long term, the industry is likely to develop 
because of better allocation of resources (Bergman, 2006: 17-18). 
5.3.2 Imitation and demonstration Effects: 
The presence of FD[ in the host economy may also lead to diffusion of information on 
new technology, production process, quality control techniques, marketing and 
management strategy to the domestic firms so as to improve their productivity level. 
MNCs have advantages due to their possession of proprietary technology management 
and marketing skills. Though FDI these expertise arc brought into host country. 
According to Blomstom et al (1999) it represents `learning by watching effects'. 
The IPI is basically built upon imitation and demonstration effects through reverse 
engineering of foreign developed molecules and technology. The MNCs that entered the 
IPI after independence introduced new drugs and technology into the country. The public 
policies that were implemented in the 1970s allowed copying and diffusion of 
technological knowledge and expertise from foreign firms (Felker et al.1997). Foreign 
firms in India have "unwillingly" contributed to the industry's development through 
domestic firms imitating their products. Imitation of already existing products has led to 
know-how adoption and technological development for the local companies. 
Consequently, the spillover effects from imitation of foreign firms technology and 
knowledge seem to have been large in the IPI (Bergmann, 2006: 18-19). 
Currently, mostly all Indian companies are generic firms. Many of the larger domestic 
firms possess advanced technology and it can be argued that the spillovcrs from imitation 
are not as strong as in the past. However, there is still scope for spillover effects through 
imitation if the MNCs introduce new technology in the Indian industry. With a strong 
patent regime for protection of 1PKs, spillover effects through imitation are less likely to 
be generated in the future. The adoption of the new patent regime is likely to limit the 
imitative R&D carried out in India, which might affect the development in the industry in 
the short run. In the long run however, it is argued that an effective protection of 1PR is 
necessary for the industry to grow further. India has innovative capabilities and 
increasing numbers of domestic firms are investing in R&D for developing new 
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molecules. Spillover effects through imitation are probably going to decrease but with the 
establishment of more foreign firms, new technology is entering the country and, through 
collaboration, demonstration effects can still occur (Bergnnam, 2006: 18-19). 
5.3.3 Transfer of Technology Effects: 
In terms of technology transfer, spillover effects, can be created if the MNCs use more 
advanced technology in their production processes than domestic companies. 
Consequently, technology and productivity gaps between the foreign and local firma may 
stimulate spillover effects. Technology in the pharmaceutical industry is often very 
complex and the need for up-grading the technology is large due to the rapid pace of new 
drug discovery and strict requirements of safety and efficiency (Narayana, 1984). Foreign 
pharmaceutical affiliates in India receive up to date technology from their parent firm, 
both in managerial practices and in manufacturing facilities, which could encourage 
spillover effects. 
Spillover effects in terms of technology transfer from MNCs in the WI seem to have 
taken place at an early stage. The Indian government wanted to build a strong 
pharmaceutical industry and welcomed the entry of MNCs in order to strengthen the 
domestic industry through their sophisticated technical know-how. The foreign 
companies had modern managerial expertise and sophisticated technical knowledge. In 
the early stage, foreign pharmaceutical companies invested more in India than the public 
and large Indian firms. The MNCs contributed to technology advancement in the 
industry, mainly through imitation, and the enhancement in technology from foreign 
fines enabled domestic firms to increase productivity and build competitiveness in new 
areas (Bergman, 2006: 20). 
Currently, the largest Indian domestic firms have advanced technology and science-
based facilities, so the technology gap between the foreign and the large domestic players 
is narrow. The MNCs in India made technology available to the domestic industry at an 
early stage, but today technology transfer is rather limited. Since the MNCs do not 
conduct much R&D in India, the domestic firms' (the larger ones) technology is equally 
developed as the MNCs (Table-4.12). Yet, there might be more technology transfer in the 
future when the IPRs are protected. 
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5.3.4 Research and Development Effects: 
R&D intensity in the IPI is rather low and the spillover effects from MNCs in terns of 
innovative R&D seem to be negligible. The weak patent regime is one of the main causes 
for limited R&D activities in India. The MNCs' share in R&D in IPI is very low and the 
average intensity was 0.3% of the annual turnover in 1990 and in 2001 it increased to 
0.7% (Pradhan, 2003). Though R&D by MNCs has increased in India, but it is still low. 
On the other hand, Indian firms have increased their R&D a great deal in the last years. 
With the advent of new patent regime, the business models have begun to change and the 
larger Indian firms have started to shift towards innovative research and invest heavily in 
R&D. Consequently, R&D expenses have increased at a higher rate of 5.07 during the 
post-TRIPs period against 3.88 in pre-TRIPs period (Kiran and Mishra, 2009: 148-160). 
Currently, there is a vast gap between the R&D expenditure of domestic firms (5-8%) 
and global companies (20-25%). An Indian company has never introduced a new product, 
based on newly discovered molecules, in the market. To do so, the need of financial 
means is immense and the risk is large. Cooperation with a MNC can therefore help 
domestic firms in the research process. Thus, there seem to be some potential spillover 
effects in R&D through collaboration between foreign and domestic firms. Furthermore, 
collaboration projects are expected to be beneficial for the domestic firm since the MNCs 
bring in financial means and at the same time help Indian companies to gain international 
credibility and move up the learning curve (Bergman, 2006: 22-23). 
R&D centers in the IPI have begun to emerge, which increases employment opportunities 
and also reverses the brain drain from India (AstraZeneca in Bangalore, Nicholas Piramal 
in Mumbai, Wockhardt in Aurangabad, Ranbaxy's center in Gurgaon, Lupin in Pune, and 
Sun Pharma in Baroda) (OPPI,2005). The R&D centers attract Indian scientists who 
earlier migrated to developed countries to find suitable work opportunities. With the new 
patent regime and enhanced work pool of skilled labour, it is very likely that MNCs will 
begin innovative research in India in the future. R&D activity is very competitive, Which 
can benefit the domestic industry in terms of increased focus on innovation and 
improvement. If the foreign companies start to develop R&D units in India, the 
competition is likely to increase among the players in the industry. Further spillover 
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effects in terms of competition in R&D activities will possibly he generated in the future. 
As more domestic companies engage in various parts of the R&D, the knowledge gap 
between the firms will decrease and the absorption capability of spillover effects increase 
(Bergman, 2006: 22-23). 
5.3.5 Human Capital Effects: 
An educated, well trained and skilled workforce generally characterizes FDI firms. When 
these well trained workers migrate to the domestic fins or start their own enterprises, it 
results in local productivity growth (Blomstrom and Persson, 1983; World Investment 
report, 1999). 
Well trained employees can be a source of a firm's productivity gain when the resources 
are used more efficiently. Training and development of employees across all levels is a 
key investment area for many of the MNCs. The aim of investment in training is to make 
each employee highly productive. According to Bergman (2006), the MNCs provide 
more and better training than the average domestic firms. 'thus, there seem to be spillover 
effects generated in terms of human capital in the IPI. 
Many of the MNCs provide a great deal of in-house training and offer programs for 
everyone from top employees to floor staff in the firms. For instance; AstraZeneca has 
"focus on creating a strong performance driven culture and improving the capability of its 
employees" (AstraZeneca India Ltd. Directors report, 2004). A part of AstraZeneca's 
human resource development plan is to train employees abroad. Each year some of the 
employees are transferred to other AstraZeneca affiliates to work. The international 
transfer can be a future asset for the employees and the firm, since new ideas are 
exchanged in different affiliations. It is favourable for the employees, in terms of 
internationalization, to receive knowledge and system and corporate culture in foreign 
countries. Many of the MNCs in India seem to send their employees to other foreign 
affiliates, for training in various departments of the cooperation (Bergman. 2006: 23-24). 
GSK invests lots in human resources to strengthen the competence of their workforce in 
India. They have trained many people in management positions and factory workers have 
received on the job training in GMP, safety and productivity. Manufacturing operational 
excellence training and development activities are held at the factories, focusing on 
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building awareness, knowledge management and training of staff in manufacturing 
practices to increase productivity of the plants (GSK Directors report, 2004). According 
to GSK, the multinationals have helped to develop the IPI in terms of educating people, 
especially in marketing and scientific communication skills, but also in finance, 
machinery operations and maintenance. Through the MNCs' presence in the industry the 
domestic timts get access to new ideas and the local workers gain more knowledge about 
international practices. The multinational affiliates in India follow the parent companies' 
training schemes, which are often well developed, and it can be argued that this 
advantage has benefited the Indian industry as a whole in terms of increased know- how 
(Bergman, 2006: 24). 
The explanation of the higher employee costs is the higher wages paid by the 
multinationals. Additionally, the MNCs invest a lot in training of employees in 
promotional activities. The fact that the IvINCs focus a lot on the productivity of their 
employees creates a strong competitive environment in the industry. The multinationals 
in India spend more money on employee costs than their domestic counterparts. It was 
7.2% of the income for domestic firms, whereas 11.4% of income for MNCs in 1997 
which was increased 7.5% of income for domestic firms and 12% for MNCs in 2004. In 
order to keep up with the multinationals, the domestic firms must invest in their work 
force too. The employee cost for domestic firms has increased in the last decade. One 
reason for the increased costs could be that more qualified employees are hired due to 
larger investments in R&D; consequently, higher wages are paid (Bergman, 2006: 24). 
A high level of education makes the absorption capacities of spillover effects larger. The 
Indian work-force is very well educated and thus the comprehensive educational level in 
India increases the possibility for spillover effects from MNCs since it is easy for the 
employees to benefit from more advanced foreign management skills and technology. 
5.3.6 Industrial Management Effects: 
The domestic industry can benefit from FDI through the superior industrial management 
skills that the MNCs possess (Dunning, 1970). Because of the threat of market loss, 
foreign companies can raise managerial incentives in host- country enterprises. A well 
functioning industrial management is very important for a firm's growth and efficient 
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management can increase the productivity of the firm significantly. Aggarwal (2004) 
finds that insufficient marketing infrastructure and lack of information affect Indian 
domestic pharmaceutical firms negatively in terns of export performance. The lack of 
marketing skills forces Indian firms to produce for the domestic market instead of 
expanding into the global market. It can therefore be argued that spillover effects in terms 
of marketing infrastructure are especially important for funs that want to expand 
internationally. 
The spillover effects in the industrial management area seem to be immense in India's 
pharmaceutical industry. The pharmaceutical industry is highly dependent on marketing 
and distribution network. The industry's sales promotion is essentially intended for the 
physicians, who prescribe the products to the patients and not for the consumer directly. 
Medical Sales Representatives (MSRs) consequently have a large influence on 
physicians, who often rely on the MSRs regarding new drugs in the market. This calls for 
a detailed system of medical knowledge and the marketing representatives need to be 
well trained, technically qualified and specialized in the products and their effects on the 
patients (Narayana, 1984). Marketing and promotional performance strongly affects the 
outcome of the pharmaceutical firms. The MNCs in India have very well developed 
marketing techniques and have been able to capture large shares of the market due to 
their aggressive marketing performances. 
According to GSK, the foreign pharmaceutical firms have contributed a great deal to the 
domestic industry in terms of management, organizational and marketing practices. "The 
MNCs have brought the latest manufacturing techniques and marketing practices into the 
pharmaceutical industry in India". For instance GSK itself was the first firm that 
introduced medical promotion activities such as the MSR system in India (Sanglikar, 
2005). By introducing new marketing ideas and management techniques that were 
unknown in India, spillover effects to local firms were created (Bergman, 2006: 27-28). 
The marketing and selling costs have always been higher for MNCs than for domestic 
firms in India, It was 6.5% of revenue for Indian firms whereas 10.1% for MNCs in the 
year 1997 which was increased 9.6% for Indian firms and 11.2% for MNCs during 2003. 
Basic reason for the MNCs higher costs is their concentration in formulations, which 
traditionally require more promotional activities than bulk manufacturing. However the 
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marketing costs have also increased for the domestic players in India. "I'his trend could be 
explained by their increased focus on formulation and improved sales infrastructure. The 
enhanced importance of brand building, due to the new patent regime and increased 
export of products, could also explain the increased costs (Bergman, 2006: 27-28). 
Another aspect of benefits from the MNCs, in terms of industrial management, is their 
consciousness of quality standards. The foreign companies have always been aware of 
quality and safety aspects of manufacturing pharmaceuticals. According to Narayana 
(1984) all foreign companies in India, and domestic units collaborating with foreign 
firms, are said to be safe from a quality perspective. If a domestic pharmaceutical turn 
wants to expand beyond the domestic market it must learn international standards in 
regard to the products and production processes. To be able to export to the regulated 
markets (in developed countries) the firm must have reached a certain standard in quality 
control. Authorities in regulated markets, which are in control of quality of products and 
manufacturing facilities, are very strict. It is difficult and expensive to navigate through 
the tough regulatory regimes in the developed countries. Extensive company reports for 
documentation of production processes and products are required to start exporting and 
thus expand into regulated markets. Today, the largest Indian companies have 
comprehended the importance of documentation and are able to comply with health and 
safety requirements in different countries, thus continuing to expand into the regulated 
markets. The presence of foreign fines in India has contributed to increase the awareness 
of quality standards in the domestic industry. Since the foreign firms demand high quality 
bulk and good manufacturing practices, they indirectly (or directly in some cases) put 
pressure on the domestic suppliers to increasing their standards and supply of good 
quality bulk. Spillover effects in terms of quality standards are therefore generated in the 
industry (Bergman, 2006: 28). 
5.3.7 Linkage Effects: 
Efficiency spillovers can further operate through subcontracting relationship between 
foreign and domestic fines. These vertical inter-firm linkages are beneficial lbr both the 
FDI and non-FDI firms. For FDI firms, subcontracting certain production activities to 
specialized local firms and concentrating on their core lines of production is a means of 
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achieving cost reduction and efficiency improvement. Subcontracting is also beneficial 
for local subcontractors as it provides these firms new markets along with exposure to 
new forms of production and management organization and further access to technical 
assistance and training support to upgrade their technological capabilities (World Bank, 
1997). 
Although FDI is associated with these positive spillover effects, this does not rule out 
negative effect from it. This aspect of spillovers is often discussed in the context of 
crowding out from FDI, which can occur through these two channels: 
Product market- FDI firms with ownership (51-100%) enjoy specific advantages such as 
superior technological capabilities, skill, new management techniques, marketing 
networks, etc. not only overcome entry barriers but also have an edge over domestic 
enterprises. Further, due to their large entry size and trans-border operation they enjoy 
scale and scope economies. All these factors contribute to the increased market power of 
FDI firms and consequent market concentration. On the contrary, domestic fines 
characterized by low technological capabilities, high cost, and inefficiency face negative 
scale effect as a result of their declining market share. Negative scale, in turn, raises cost 
of production of domestic firms and as a result of which these firm face further decline in 
their market share. This cumulative impact of the entry of FDI firms on the market 
position of domestic firms may lead to crowding out of many small sized domestic firms. 
Thus, entry of FDI firms may adversely affect learning and growth of local firms in 
competing activities (Markusen and Vemables, 1997; World Investment report, 1999). 
Financial market- FDI firms, given their size and other advantages of being a part of a 
global system of production, usually have a preferential access to local capital through 
financial institutions in the host country. This may lead to credit rationing for small sized 
local firms by reducing their access to capital or raising costs of borrowing (World 
Investment report. 1999), 
5.4 	Trends and Patterns of FDI Inflow in Indian Pharmaceutical Industry: 
The inflow of FDIs into India has increased since the economic reform i.e. 1991, Annual 
FDI inflows in India's pharmaceutical sector have grown steadily from USS 0.3 million 
in 1991 to UDS 292 million in 2004, declining to i1S$172 million in 2005 and 
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rebounding to US$214.8 million and US$334.1 million in 2006 and 2007 respectively. 
Thereafter it again declined and reached to USS 18 .5 million in the year 2008 (Table- 
5.3A). It is indicated that the pharmaceutical FDI increased sharply in 2004 (462.6% of 
growth rate), decreased in 2005 and then rebounded in 2006. 1'he decline in 2005 may be 
attributable to substantial uncertainty as to how India will implement and interpret its 
new patent regime. The increase in FDI inflows in IPl has helped in expansion, growth 
and development of the industry. This in turn has led to the improvement in the quality of 
products. 
It is noticeable from the table (Table-5.3A) that the total amount of FDI inflow in India 
was only US$165 million in 1991 and over the period it observed an increasing trend to 
take a figure of US$27331million in the year 2008, which is almost 166 times that of the 
figure of 1991. During the period under consideration it has observed wide fluctuations. 
The growth rate indicates considerable fluctuations both positive and negative rates, and 
is highest in 2006 (183.6%). 
As far as Pharmaceutical FDI inflow is concerned it is indicated that it was only mere 
US$0.3 million in 1991 and over the period it also observed an increasing trend and reach 
highest US$ 334.1 million in 2007 and thereafter it decline IS$t81.5million in 2008, 
which is 605 times that of the of 1991. The growth rate indicates considerable 
fluctuations both in positive and negative rates, and highest in 1992 (3600%). The CAGR 
of total FDI in India during 1991-2008 was 24.3% whereas FDI in pharmaceutical is 27% 
(Table-5.3A). 
It is indicated that the percentage share of Pharmaceutical FDI in total FDI increased 
considerably after 1991 and reached the highest level in 2004 (7.8%) but thereafter it 
declined frequently mainly due to uncertainty about patent regime impact and global 
recession. 
The largest source of FDI in India's pharmaceutical industry is Mauritius (56.4%). 
Singapore is the second largest source (1 1.2%) followed by the USA (5.8). UAE (4.7%), 
and Canada (4%). Together they accounted for more than 80% of FDI in this sector 
during 2008-09 (DOP, 2009). 
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As far as types of FDI are concerned, FDI in India comes in various forms including 
Greenfield projects (both the establishment of new facilities and the expansion of existing 
one), strategic alliances between foreign and domestic fines and M&As. 
During 2002-06 foreign firms undertook about 80 Greenfield investment projects in the 
pharmaceutical and health biotechnology sectors. Most of the projects were for new 
facilities (83%) rather than expansions of existing facilities (17%). Further R&D was 
reported as the focus of most of the projects (59%) followed by manufacturing (26%) and 
sales & services (9%) (Bloodgood, 2007: 8-1-16). 
The majority of Greenfield project were undertaken by North American firms (51%), 
followed by European firths including those outside of the European Union (36%). Both 
North American and European Union firms concentrated their investment activities in 
R&D, with share of 66% and 62% respectively. The next most frequent investment 
activity for North American firms was in sales & services (20%) followed by 
manufacturing (15%). Similarly for European Union firms most remaining investment 
activity was focused on manufacturing (34%) while only 3% was focused on sales & 
services activities (Table-5.1). 
Table-5.1: Greenfield FD! in the pharmaceutical and Health Biotechnology Sectors 
by Source Region and Activity (2002-06). 
(In numbers) 
Activity! 
North America 	Europe Asia Pacific Middle Fast 
Region 
No. of %of No. of %of No. of %of Na of %of 
projects Projects projects I Projects projects Projects projects Projects 
R&D 27 66 18 62 0 0 2 67 
Manufact 
1 	6 15 10 34 4 57 1 33 
wring 
Sales & 
8 20 1 3 3 43 0 0 
Services 
Total 41 29 7 3 
Note' Because of rounding figures may not total IUU%. 
Sources: QUO Consulting Ltd. Loco Monitor FDI database. US international trade commission, 2007: 8-11 
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Furthermore, as far as the issue of quality of FDI is concerned, recently R&D activity has 
accounted for the highest number of projects with a total of 34, representing 43% of 
investment projects. Among the top business activities, this activity also recorded the 
highest average growth rate at 440'0 per annum (Tahle-5.2). 
Table-5.2: Industry analysis- Number of Projects by Activity (2003-08). 
(In numbers) 
Business Activities/Year o 0 0 0 
N 
0 
x 
0 
Average annual 
° ° ° 0 ° ° growth 
R&D 2 4 10 5 8 5 34 44 
Manufacturing 3 8 6 3 3 5 28 NA 
Sales, marketing & Support 2 2 3 1 1 9 NA 
Design, Development & - 1 1 - 2 1 5 NA 
testing 
Business Services - - 1 - - - I NA 
Head quarters - - - 1 - - 1 NA 
Logistics, Distribution & - - - - I - I NA 
Transportation 
Retail - 1 - - - - 1 NA 
Total 5 16 20 12 15 12 80 42 
Source: FDI Market Intelligence. Available at: http: www.fdimarkets.com 
It shows that a large number of R&D investment projects are focused on the development 
of facilities for clinical research, clinical trials and other such modules that only integrate 
the Indian talent and facilities into the global objectives of foreign pharmaceutical firms. 
As such these R&D projects have little to do with the needs of local population (Abrol et 
al, 2011). 
Strategic alliances between multinational and domestic tines are an important part of FDI 
in the R&D and manufacturing sectors. In the R&D area, contract research organizations 
(CROs) otter pharmaceutical firms a range of services including product development, 
clinical trial management. laboratory services, and data management. The top three 
reasons. MNCs cite tbbr performing clinical trials in India are the number of potential 
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clinical trial subjects, cost savings, and the country's disease profile (Bloodgood„ 2007: 
R-1.16). 
Another major focus of FDI by MNCs in India is outsourced contract manufacturing. 
This contract manufacturing includes the production of interutediates, active 
pharmaceutical ingredients (APIs), hulk drugs, formulations, and generic drugs. U.S.-
based Pfizer, for example, maintains a single drug manufacturing facility in India, but 
also outsources manufacturing to about 20 Indian companies. U.S.-based Merck has 
recently decided to outsource 35 percent of its manufacturing processes to developing 
countries, and particularly India, in order to substantially reduce costs. According to 
Merck, the critical factor" driving the decision to increase Indian investment was the 
patent law change. The Indian government has noted that "top MNCs like Pfizer, Merck, 
GSK. Sanofi Aventis, Novartis, Teva, etc. are largely depending on Indian companies for 
many of their APIs and intermediates". 
One important reason for India's strength in the area of contract manufacturing compared 
to other emerging markets is the large number of manufacturing facilities that the U.S. 
Food and Drug Administration (FDA) have certified. FDA certification allows 
pharmaceutical products to be imported into the United States. Outside of the United 
States, India has the largest number of FDA approved manufacturing facilities, 
numbering 112 in 2008. Another reason for the strength of contract manufacturing is the 
large number of scientists and engineers with unique skills in the areas of process 
chemistry and biochemistry. 
When we come to the patterns of investment by global pharmaceutical firms in the IPI. it 
is noted that a large part of the newer investments of foreign firms in manufacturing 
activity have largely been for the expansion of formulation activity. Newer investments 
in the bulk drug were few and far between. Further after the post TRIPs era situation to 
create certainly far more permissive environment for imports. MNCs can be expected to 
increase operating freedom to shill to import based production for a number of product 
segments. Second their preference for the establishment of new operations through the 
incorporation of wholly owned subsidiaries is also confinned. Further quite a large part 
of the new FD1 in pharmaceuticals had been devoted for the benefit of M&As and 
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takeovers to facilitate the patent firms to increase their control over the operations located 
in India. 
Royalty figures have been extremely small for the domestic firms. Although the number 
of companies paying royalty has declined slightly in 2007 as compared to 2003, there are 
still many firms which are acquiring and absorbing new technologies to compete in the 
global market. This decline possibly is due to the increasing amount of money spent on 
in-house research facilities. Pradhan (2003) reported on the basis of a R&D survey that in 
terms of R&D intensity foreign firms are still far behind Indian firms. The observed R&D 
intensity of domestic firms, 2.6% compared to foreign firms which is low at 0.74%. 
Section-B 
The present section is concerned about the statistical approach to FDI in Pharmaceutical 
industry. The variables under consideration include FDI, production, investment, 
profitability, export and employment. Efforts have also been made to present a profile of 
comparison between the total FDI in India and the FDI inflows in the IPI. 
It is noticeable that in the year 1991 the actual amount of FDI inflow in India was only 
US$165 million in the year 1991 and over the period it observed an increasing trend to 
take a figure of USS2733 1 million in 2008, which is almost 166 times that of the figure of 
1991 (Table-5.3A). During the period under consideration it has observed wide 
fluctuations in the form that the minimum US$165 million and the maximum US$ 27331 
million. The growth rate also indicates considerable fluctuation both in positive and 
negative rates, which is highest in 2006 (184%). It demonstrates that the inflow is 
dictated by the external sources rather than an internal factor. The statistical description 
of total FDI and FDI in pharmaceutical sector in terms of mean, SD, CV, t-ratio 
minimum, maximum and CAGR. 
The average FDI takes a value of USS5919 million with a SD of USS8042.5 million. The 
t-ratio suggests that the estimate is statistically significant at 10% level. The CV as high 
as 1.36 suggest the fluctuating nature of the variable. The CAGR is 24.3% during 1991-
2008. 
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Tahle-5.3A: FDI Inflows in Indian Pharmaceutical Sector (1991-2008). 
(USS million) 
Years 
Amount of 
total FDI in 
India 
Growth 
Rate (%) 
FDI Inflow 
in PI 
Growth 
Rate (%) 
Percentage of phanna 
FDI in total FDI 
1991* 165 - 0.3" - 0.18 
1992 393 138.2 11.1# 3600.0 2.82 
1993 654 66.4 9.8 -11.7 1.50 
1994 1374 110.1 51.9 429.6 3.78 
1995 2141 55.8 59.5 14.6 2.78 
1996 2770 29.4 34.4 -42.2 1.24 
1997 3682 32.9 60.0 74.4 1.63 
1998 3083 -16.3 23.1 -61.5 0.75 
1999 2439 -20.9 18.6 -19.5 0.76 
2000 2908 19.2 70.9 281.2 2.44 
2001 4222 45.2 82.8 16.8 1.96 
2002 3134 -25.8 28.0 -66.2 0.89 
2003 2634 -16.0 51.9 85.4 1.97 
2004 3759 42.7 292.0 462,6 7.77 
2005 5546 47.5 172.0 -41.1 3.10 
2006 15726 183.6 2149 1.37 
2007** 24581 56.3 334.1 55,5 1.36 
2008** 27331 11.2 181.5 -45.7 0.66 
Note: * refer Data for August to March 
** refer Figures are Provisional 
4 refers Data for January to December 
Source: Various issues of SIA Newsletter (FDI Data Cell) DIPP, Minixtry of Commerce & Industry, 
Government of India, New Delhi. 
Economic Survey (Various issues), Ministry of Finance, Government of India. Ncw Delhi. 
Handbook of Statistics on Indian Economy, RBC 2009. 
Department of Pharmaceutical, Annual Report 2009-10, Ministry of chemical & Fertilizes, Government of 
India, New Delhi 
Rajya Sabha question number 615 cabled in Rajya Sabha on 25-11-2009 by Mr. Joytiraditya Scindia MOS- 
MOCC, New Delhi. 
FDI figures are in rupees, they have been converted to LESS by using average exchange rates for relevant 
financial years obtained from RBI Handbook of Statistics on Indian Lconomy, 2009. 
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Fire: 5.1 
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Similarly FDI inflow in Indian pharmaceutical was only USS0.3 million and over the 
period it also observed an increasing trend and reach highest US$334.1 million in 2007 
and thereafter it decline US$181.5 million in 2008, which is 605 times that of the figure 
of 1991. The growth rates indicate considerable fluctuations both in positive and negative 
rates and highest in 1992 (3600%). The share of pharmaceutical industry FDI in total FDI 
was 2.05% on an average. The inflow in pharmaceutical takes a mean of US$94.3 million 
and a SD of US$ 100.9 million. The fluctuation is demonstrated by the CV of 1.07. The 
CAGR is 27% during period under consideration. One of the reasons behind such high 
growth rate is the big difference between the minimum and maximum figures of FDI 
inflows in pharmaceutical industry. The minimum is US$0.3 million in 1991 and 
maximum US$334.1 million in 2007. However, the Durbin-Watson test shows the 
positive correlation between these two variables i.e. total FDI inflow and FDIPI (Table-
5.3B). 
As far as nature of FDI in the IPI is concerned, it has been bifurcated in terms of 
technical and financial nature. In total there are 659 FDI projects in the pharmaceutical 
sector that got approval during 1991-2008. The total amount involved is US$ 106.5 
billion out of which Pharmaceutical sector share US$1696.7 million. Out of the total 659 
projects 386 were of financial nature and 273 of technical nature. The proportion of 
financial project is 58.6% and that of technical nature is 41.4%. It seems that FDI in 
pharmaceutical industry helps us to overcome both the constraints of poor capital 
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'fable-5.3B: Statistical description of total FDI and FDI in Pharmaceutical industry 
(1991-2008). 
(In t: SS million) 
Total FDI FDI in Pharmaceutical industry 
Mean 5919 94.26 
SD 8042.5 100.91 
CV 1.36 1.07 
Minimum 165 0.3 
Maximum 27331 334.1 
CAGR 24.28 27.03 
t-ratio 4.19*** 
d (Durbin-Watson test) 1.4 
***: significant at 10%-a level 
Source: l able 5.3A 
tormation and technological backwardness. However it is indicated that there is 
significant decrease in number of financial cases approved since 2004. A similar drop has 
been observed in technical cases also since 1998 (Table-5.4). 
Table-5.4: FDI in Indian Pharmaceutical Sector during 1991-2008 (Technical & 
Financial). 
Year 
(Jan-Dec) 
No. of FDI cases approved 
(Financial) 
No. of FDI cases approved 
(Technical) 
1991 2 2 
1992 9 15 
1993 17 17 
1994 21 26 
1995 19 31 
1996 26 19 
1997 25 31 
1998 16 30 
1999 19 24 
2000 39 23 
2001 41 13 
2002 43 18 
2003 46 16 
2004 45 4 
2005 12 1 
2006 2 1 
2007 1 2 
2008 
Total 
3 
386 
0 
273 
Source: Compiled from I)IPI'. SI:\ Newsletter, 2008, New f)elhi. 
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5.5 	Investment in Pharmaceutical Industry and the FBl Inflows: 
It has been observed that the pharmaceutical investment was US$ 38.4 million in 1991 
and gradually increased to USS4117.Imillion in 2008, which is almost 107 times that of 
1991 figures. The inflow of ED! in Pharmaceutical sector which was only US$030 
million in 1991 increased to US$ I81 .5 million in 2008. Hence the share of FDI in total 
investment of phamtaceutical industry was 11.8% on an average. The mean of 
pharmaceutical industry investment is US$ 1027.4 million with a SD of USS 1282.5 
million. The mean of the FDI inflows in the pharmaceutical industry is USS 94.3 million 
with a SD of US$ 100.9 million. The t-ratio is statistically significant at 10% level. The 
CV is 1.24 in case of the investment in pharmaceutical industry and 1.07 in case of FDI 
inflows. This demonstrates the unstable nature of FDI inflows in the industry. (Table-
5.5A). 
The growth rate of phamia investment shows fluctuating trend both in positive and 
negative rates and was highest in the year 1992 (173%). As far as CAGR of FDI in FDIPI 
in investment in pharmaceutical are concerned it was 27% and 27.3% respectively. 
An attempt has been made to explore the relation between the investment in 
pharmaceutical industry and FDI inflow in pharmaceutical industry. It is hypothesized 
that the changes in the investment in pharmaceutical industry is not functionally 
depended on the FDI inflow in pharmaceutical industry. In view of the fact that the 
investment of pharmaceutical industry depends on a number of variables in addition to 
the FDI inflows, there are other variables that have been taken under consideration like 
total production, profit and export. The estimates of the empirical multivariate regression 
are represented in table (5.5-B). The dependent variable is the investment in 
pharmaceutical industry and independent variables arc the FD1 inflow in the 
pharmaceutical industry (FDIPI), total production, export and profit. It has been observed 
that the regression function takes an F-value of 117.8 which is statistically significant at 
5% level. It seems that functional relation assumed by the empirical regression line is true 
i.e. the investment in pharmaceutical industry is explainable by the FDI inflows in the 
industry. The coefficient of determinants shows that 97% of the variation of the 
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dependent variable can be explained by the regression equation. However the coefficients 
of slopes are not statistically significant in general. 
Table-5.5A: Statement of Investment in Pharmaceutical industry and the Inflows of 
FDI (1991-2008). 
(In USS million & %) 
Years 
FDI Inflow in 
Phannaceutical 
industry 
Growth 
Rate 
Pharmaceutical 
Investment 
Growth 
Rate 
% of FDI in 
total 
investment 
1991 0.3* - 38.4 - 0.8 
1992 11.1* 3600.0 46.5 21.1 23.9 
1993 9.8* -11.7 126.9 172.9 7.7 
1994 51.9 429.6 238.1 87.6 21.8 
1995 59.5 14.6 233.7 -1.8 25.5 
1996 34.4 -42.2 265.1 13.4 13.0 
1997 60.0 74.4 345.9 30.5 17.3 
1998 23.1 -61.5 385.9 11.6 6.0 
1999 18.6 -19.5 572.0 48.2 3.3 
2000 70.9 281.2 581.4 1.6 12.2 
2001 82.8 16.8 511.0 -12.1 16.2 
2002 28.0 -66.2 550.5 7.7 5.1 
2003 51.9 85.4 957.7 74.0 5.4 
2004 292.0 462.6 1324.1 38.3 22.1 
2005 172.0 -41.1 1628.8 23.0 10.6 
2006 214.8 24.9 2446.1 50.2 8.8 
2007** 334.1 55.5 4123.5 68.6 8.1 
2008** 181.5 -45.7 4117.1 -0.2 4.4 
Mean 94.26 1027.37 
SD 100.90 1282.48 
CV 1.07 1.25 
Minimum 0.30 38.4 
Maximum 334.1 4123.5 
CAGR 27.0 27.3 
t-ratio 5.69*** 
Note: * refers Data for January to December 
** refer Figures are Provisional 
s'  *significant at 10% level 
Source: Compiled from Various issues of SIA Newsletter (FDI Data Cell) DIPP. Ministry of Commerce & 
lndustr Government of India. New Delhi. 
Handbook of Statistics on Indian Economy. RUt. 2009 
Department of Pharmaceutical. Annual Report 2009-10. Ministry of chemical & Fertilizes. Government of' 
India, New Delhi 
Rajya Sabha question number 615 tabled in Rajva Sabha on 25-1 1-2009 by Mr. Joytiraditya Scindia M1OS- 
M-tUCL. New Delhi. 
CMIE "Industry Financial Aggregates and Ratio (Various years). 
FDIPI & investment figures in rupees. they have been converted to USS by using average exchange rates 
for relevant financial years obtained from 8131 Handbook of'Statistics on Indian Economy. 2009. 
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Most of the coefficients of independent variables are not statistically significant. It is only 
export statistically significant at 5% level. The FDI inflow in the pharmaceutical industry 
fails to explain the variation in the investment of the industry. However the value of `d' 
(Durbin-Watson test) is significant as 0.957 and indicates the positive serial correlation 
amongst the variables. It is indicated that export and profit has important positively 
significant variables for enhancing the level of investment in pharmaceutical sector while 
FDIPI has not. 
Modell: Investment =a+ [, FDIPI+02 total production+ 03 profit +04 export +µr--(1). 
Investment=-326.06+(-0.086)FDIPI+0.007total production+0.I28profit+0.667export+ gt 
Table-Sill: Regression estimates of Pharmaceutical Investment against the FD! 
Inflows: 
Constant FDIPI Total Production Profit Export 
Coefficient -326.06 -0.086 0.007 0.128 0.667 
t-ratio -1.37 -0.071 0.066 0.393 2.67' • 
R- squared 0.973 
F oos 	4,13) 117.8 
d(Durbin-Watson test) 0.957 
'•: significant at 5% level. 
179 
Chapter - 5 
5.6 	Production of Pharmaceutical Industry and the FDI Inflows: 
The production figures indicate that in 1991 the figure was US$2510.6 million, where as 
that increased to US$17567.6 million in 2008 which is seven times higher than that of the 
1991. The mean of the variable is US$6868.4 million and the SD's US$ 4463.5 million. 
The t-ratio is 6.01 suggesting that the mean is statistically significant at 10% level. The 
variable is considerably stable as is demonstrated by a comparatively low coefficient of 
variance of 0.65 (Table-5.6A). 
The growth rate indicates considerable fluctuations both in positive and negative rates 
and highest in the year 2007 (32%). The CAGR of total pharmaceutical production and 
FDI inflow in pharmaceutical industry is 1.7% and 27% respectively. 
It is tempting to find out whether the production in pharmaceutical industry is a function 
of FDI concentrated in that sector. The null hypothesis is that the production of 
pharmaceutical industry is not a function of FDI inflows in the sector. The dependent 
variable of the regression is the pharmaceutical total production. The independent 
variables are the FDIPI, profit, investment and export of the industry. The regression 
parameters are represented in table (5.6B). It can be noticed that the regression gives a 
good fit. The F-statistic suggests that the null hypothesis of untrue relation should be 
rejected at 5% level. The coefficient of determinant is as high as 0.98 to indicate 98% of 
the variation in the production of pharmaceutical industry could have been explained by 
the regression equation. Durbin-Watson test indicates the positive serial correlation 
amongst the variables. 
Among the independent variables only the export is statistically significant at 10% level. 
The FDI inflow however is not statistically significant to indicate that the production in 
the pharmaceutical industry could not be explained by the FDI inflow in the industry. It is 
indicated that the export, FDIPI and profit are positively significant for the improvement 
of pharmaceutical total production. 
Model-2: Production —a+B1 FDTPI+B,profit+93investment-B4export+p,— (2). 
Production=2195.74+0.777FD1PI f 0.646protit 10.05investment+2.24export+p1  
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"Table-5.6A: Statement of Total Production of Pharmaceutical Industry and Inflow 
of FDI (1991-2008). 
(In US$ million & %) 
Years 
FDI Inflow in 
Pharmaceutical industry 
Growth 
Rate 
Pharmaceutical 
"I otal Production Growth Rate 
1991 0.3* - 2510.6 - 
1992 1 1.1 * 3600.0 2760.6 10.0 
1993 9.8* -11.7 2617.8 -5.2 
1994 51.9 429.6 3010.5 15.0 
1995 59.5 14.6 3810.7 26.6 
1996 34.4 -42.2 4286.8 12.5 
1997 60.0 74.4 4677.4 9.1 
1998 23.1 -61.5 4560.0 -2.5 
1999 18.6 -19.5 5086.4 11.5 
2000 70.9 281.2 5655.2 11.2 
2001 82.8 16.8 5761.7 1.9 
2002 28.0 -66.2 6317.2 9.6 
2003 51.9 85.4 7665.3 21.3 
2004 292.0 462.6 9295.5 21.3 
2005 172.0 -41.1 10390.2 11.8 
2006 214.8 24.9 11922.3 14.7 
2007** 334.1 55.5 15734.6 32.0 
2008** 181.5 -45.7 17567.6 11.6 
Mean 94.26 6868.37 
SD 100.90 4463.37 
CV 1.07 0.65 
Minimum 0.30 2510.62 
Maximum 334.1 17567.6 
CAGR 27.0 11.7 
t-ratio 6.01 
Note: * refers Data for January to December 
** refer Figures are Provisional 
*** significant at 10% level 
Source: Compiled from Various issues of SIA Newsletter (FDI Data Cell) DIPP, Ministry of Commerce & 
Industry. Government of India. New Delhi. 
Handbook of Statistics on Indian Economy, RBI. 2009 
Department of Pharmaceutical. Annual Report 2009-10, Ministry of chemical & Fertilizes. Government of 
India, New Delhi 
Rajya Sabha question number 615 tabled in Rajva Sabha on 25-1 1-2009 by Mr. Joytiraditya Scindia MOS- 
MOCL. New Delhi. 
C%IIL "Industry Financial Aggregates and Ratio (Various years). 
Bulk Drub= Manufacturing Association (India) Statistics. Hyderabad. 
FDWl & Total production figures in rupees, they have been converted to USS by using average exchange 
rates fur relevant financial years obtained from RBI Handbook ofStatistics on Indian Economy. 2009 
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Figure: 5.3  
Total Production of Pharmaceutical industry and inflow of FDI (1991 -2008). 
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Table-5.613: Regression estimates of Pharmaceutical Total Production against the 
FDI Inflows. 
Constant FDIPI Profit Investment Export 
Coefficient 2195.74 0.777 0.646 0.05 2.24 
t-ratio 6.71*** 0.237 0.743 0.07 3.94*** 
R-squared 0.984 
F(o.os) (4,13) 195.5 
d(Durbin-Watson test) 0.479 
*** significant at 10% level. 
5.7 Export of Pharmaceutical Industry and the FDI Inflows: 
Now, we can represent a profile of export of the pharmaceutical sector in terms of 
amounts. The increasing trend is noticeable (Table-5.7A). In 1991 the export of the 
industry was only USS564.4million and through a gradual increase it reached at the 
amount of USS6257 million in 2008, which is nearly eleven times that of the 1991 figure. 
The average takes a value of US$ I862.2million. The SD is however quite impressive to 
an amount US$ 1758.7 million. The t-ratio is 5.84 to indicate that the mean is statistically 
significant at 10% level. The CV is equally high 0.94 suggest that the estimate observes 
the fair extent of instability (Table-5.7A). An enquiry into the export of the 
pharmaceutical industry seems relevant as to whether it depends on the flow of FDI in the 
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industry. A similar kind of multivariate regression that has been followed in the earlier 
discussion is invoked to explain the nature of the empirical relation. 
'hahle-5.7A: Statement of Export of Pharmaceutical Industry and Inflow of F DI 
(1991-2008). 
(In USS million & %) 
Years FOE Inflow in Pharmaceutical industry 
Growth 
Rate 
Pharmaceutical 
Ex ort Growth Rate  
1991 0.3* - 564.4 - 
1992 11.1* 3600.0 544.5 -3.5 
1993 9.8* -11.7 567.3 4.2 
1994 51.9 429.6 695.8 22.6 
1995 59.5 14.6 525.0 -24.5 
1996 34.4 -42.2 705.8 34.4 
1997 60.0 74.4 824.1 16.8 
1998 23.1 -61.5 822.3 -0.2 
1999 18.6 -19.5 910.4 10.7 
2000 70.9 281.2 1069.4 17.5 
2001 82,8 16.8 1198.0 12.0 
2002 28.0 -66.2 1519.7 26.9 
2003 51.9 85.4 2105.0 38.5 
2004 292.0 462.6 2751.9 30.7 
2005 172.0 -41.1 3261.9 18.5 
2006 214.8 24.9 3691.9 13.2 
2007** 334.1 55.5 5505.3 49.1 
2008** 181.5 -45.7 6257.0 13.7 
Mean 94.26 1862.21 
SD 100.90 1758.67 
CV 1.07 0.94 
Minimum 0.30 544.5 
Maximum 334.1 6257.0 
CAGR 27.0 16.0 
t-ratio 5.84*** 
Note: * refers Data for January to December 
** refer Figures are Provisional 
***significant at10%% level 
Source: Compiled from Various issues of SIA Newsletter (1;DI Data Cell) DIPP, Ministry of Commerce & 
Industry, Government of India. New Delhi. 
Handbook of Statistics on Indian Economy, R131. 2009 
Department of Pharmaceutical. Annual Report 2009-10, Ministry of chemical & Fertilizes, Government of 
India. New Delhi 
Rajyya Sahha question number 615 tabled in Rajya Sabha on 25-11-2009 by Mr. Joytiraditya Scindia MOS- 
NIOCI_, New Delhi. 
C\IIF -Industry Financial Aggregates and Ratio (Various years). 
Bulk Drug Manufacturing Association (India) Statistics. I-Iyderabad. 
FDIPI & export figures in rupees. they have been converted to US$ by using average exchange rates for 
relevant financial years obtained from RBI handbook of Statistics on Indian Economy, 2009. 
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Figure:5.4 
Export of Pharmaceutical Industry and Inflow of FDI (1991-2008). 
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Annual growth rate shows a fluctuating trend and highest in the year 2007 (49%). It is 
important to note that during the period under consideration the pharmaceutical export 
performance was much better as compared to domestic pharmaceutical production. Many 
reasons are behind this which have been explained in the earlier chapters. CAGR of 
pharmaceutical export is 16% whereas 27% for FDI inflow in pharmaceutical industry. 
Table (5.7B) represents the regression estimates of the amount of export of the 
pharmaceutical industry against the FDI inflow, total production, profit and investment. 
The F-statistic seems quite impressive to suggest that the regression is statistically 
significant at 5% level. The coefficient of determinants is impressive too to have 
explained as much as 0.99 or 99% of the variation in the export of pharmaceuticals. 
However among the coefficient of slopes only total production and investment are 
statistically significant at l0% and 5% level respectively. The coefficient of FDl flows in 
the pharmaceutical industry fails to demonstrate any significant relation towards the 
promotion of export of the industry. However Durbin-Watson test indicates the positive 
serial correlation amongst the variables. It is indicated that only total production and 
investment is positively significant for pharmaceutical export. 
Model-3: Export =a+13,FDIPI+I32total production+03profit+34investment+µf-- (3) 
Export=-342.26+(-0.0868)FDIPI+0.243total production+(-0.003)profit+0.533 investment 
+ At 
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Table-5.7B: Regression estimates of Pharmaceutical Export aaaiust the FDI Inflows. 
Constant FDIPI Total Production Profit Investment 
Coefficient -342.26 -0.0868 0.243 -0.003 0.533 
t-ratio -1.656 -0.080 3.94*** -0.009 2.675** 
R-squared 0.989 
Fioo» (4,13) 281.7 
d(Durbin-Watson test) 0.744 
•* significant at 50/s level 
*1' significant at 10% level. 
5.8 	Profitability of Pharmaceutical and the FDI Inflows: 
The profit figure plays a key role in attracting the FD[ inflows. It can he observed that the 
profit figures increased throughout the period under study to a considerable extent. In 
1991 it was only US$14.1 million and in 2008 it reached the level of USS1356 million. 
The increase is by an extent of around ninety-six times. The increase in the profit figure 
is indeed surprising and that deserves attention, One of the reasons attributed to the 
increase is that the number of firms has also increased during the period. It has increased 
from 5156 units in 1979-80 to 20053units in 1999-00. However, it is indicated that during 
1995 to 1997 the profit trend was declining. The industry faced a stiff competition during 
the late nineties hacked by regional as well as global recession in the same year that must 
have contributed to the adversities in the profit performance. Input prices have also been 
increased globally during that period coupled with high market campaigning expenses. 
The statistical description shows that the mean profit is USS 577.5 million with the SD 
587.6 million. The t-ratio is 7.32 which indicates that the mean although is statistically 
significant at 10% level. The CV is as high as 1.02 that indicates instability in the nature 
of the variable (Table-5.8A). 
The growth rate shown a fluctuating trend both in positive and negative rates and highest 
in the year 1992 (389.4%). The CAGR of phatnaceutieal profit is 24.4% and 27% for 
FDI inflows in pharmaceutical industry. 
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Tahle-5.8A: Statement of Net Profit (Profit after Tax) of Pharmaceutical Industry 
and FDI Inflows (1991-2008). 
(In USS million & %) 
Years FDI Inflow in Pharmaceutical industry Growth Rate 
Pharmaceutical 
Profit (after tax) 
Growth 
Rate 
1991 0.3* - 14.1 - 
1992 1 1.1 * 3600.0 69.0 389.4 
1993 9.8* -11.7 132.0 91.3 
1994 51.9 429.6 242.2 83.5 
1995 59.5 14.6 236.9 -2.2 
1996 34.4 -42.2 179.4 -24.3 
1997 60.0 74.4 121.8 -32.1 
1998 23.1 -61.5 123.2 1.2 
1999 18.6 -19.5 206.5 67.6 
2000 70.9 281.2 321.3 55.6 
2001 82.8 16.8 495.0 54.0 
2002 28.0 -66.2 536.7 8.4 
2003 51.9 85.4 772.3 43.9 
2004 292.0 462.6 844.4 9.3 
2005 172.0 -41.1 1136.7 34.6 
2006 214.8 24.9 1650.3 45.2 
2007** 334.1 55.5 1956.9 18.6 
2008** 181.5 -45.7 1356.0 -30.7 
Mean 94.26 577.48 
SD 100.90 587.56 
CV 1.07 1.02 
Minimum 0.30 14.1 
Maximum 334.1 1956.9 
CAGR 27.0 24.4 
t-ratio 7.32*** 
Note: * refers Data for January to December 
** refer Figures are Provisional. 
***significant at10% level 
Profit after tax = [ 100*(profit. surplus after tax - prior period and extra-ordinary income ± prior period 
extra-ordinary expenses)] sales. 
Source: Compiled from Various issues of S1A Newsletter (FDI Data Cell) DIPP, Ministry of Commerce & 
Industry, Government of India, New Delhi. 
Handbook of Statistics on Indian Economy, RBI. 2009 
Department of Pharmaceutical. Annual Report 2009-10. Ministry of chemical & Fertilizes, Government of 
India, New Delhi 
Rajya Sabha question number 615 tabled in Rajya Sabha on 25-11-2009 by qtr. Joytiraditya Scindia M1OS- 
NIOCL. New Delhi, 
C'\i([ "Industry Financial Aggregates and Ratio (Various years). 
Bulk Dru!, Nlanufacturini Association (India) Statistics. IIvderabad. 
FDIPI & Profit figures in rupees. they ha\e been converted to USS by using average exchange rates for 
relevant financial years obtained from 8131 Handbook of Statistics on Indian I:conomy, 2009. 
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Figure: 5.5 
Profit after "lax of Pharmaceutical Industry and FDI Inflows in the Industry (1991-2008) 
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Efforts have been made to explore the functional relation between the two variables of 
the profitability in the pharmaceutical industry and the FDI inflows in the industry. It has 
been argued that the hypothesis can be of either direction, profit may be the function of 
FDI inflow, or may be the FDI inflow is the function of the profit figures. In the former 
case, it is assumed that the profit of the industry depends on the FDI inflows. In the later 
case it is because of the profit in the sector which attracts foreign investment in the 
industry. In the regression analysis, both the functional relations will be taken under 
consideration. 
The first regression assumes that profit in the sector of pharmaceuticals depends on the 
FDI flows. In addition to the FDI flows there are other independent variables like earlier 
discussion on total production, export and investment. The F-statistic suggests that the 
null hypothesis of untrue regression relation cannot be rejected at 5% level. It is shows 
that the regression demonstrates an impressive regressive fit in terms of R-square. The 
coefficient of determinants shows that 0.908 or 91% of the variation in the profit figures 
could have been explained by the regression function. Among the independent variables 
FDIPI is the only variable which is statistically significant at 1% level. However, Durbin-
Watson test indicates the positive serial correlation. It is indicated that FDIPI and total 
production has significantly positive impact on pharmaceutical profit (Table-5.8B). 
Model-4: Profit =a+(iFDIPI+ I32total production+p3export+34investment+µr---(4). 
Profit--121.37+1.87FDtPl+0.063tota1 production+(-0.002)export+0.09investment+ g, 
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Table-5.8B: Regression estimates of Pharmaceutical Profit against the FDI Inflows. 
Constant FD 11'! Total Production Export Investment 
Coefficient -121.37 1.87 0.063 -0.002 0.09 
t-ratio -0.57 2.11 * 0.743 -0.009 0.393 
R-squared 0.908 
Flo) (4.13) 32.0 
d(Durbin-Watson test) 1.59 
*~igniticant at 1% level 
Now regression assumes that FDIPI depends on the profitability. Table 5.8C represents 
the regression parameters of the multivariate form of regression of FDI flows in 
pharmaceutical against the profitability of pharmaceutical, total production, export and 
investment variables of the FDI inflows. It can be observed that the F-statistic is 10.98 to 
indicate that the regression function is a true functional relation. Coefficient of 
determinant demonstrated the 0.772 or 77.2% of the variation in the FDI flows has been 
explained by the profit figures of the industry. Among the independent variables only 
profit variable happened to have a statistically significant at 1% level to suggest that it 
may be that the profit figure of the industry is a representative one in consideration to the 
decision making of the FDI in Indian pharmaceutical sector. However, the coefficients of 
slopes are not statistically significant in general and the Durbin-Watson test shows the no 
first-order auto correlation. 
Model5: FDIPI =a+131profit+li,total production+B3export+l34investment+per (5). 
FDIPI=-7.26-0.14profit+0.006total production+(-0.006)export+(-0.005)investment+ p, 
Table-5.8C: Regression estimates of FDI Inflows against the Pharmaceuticals Profit. 
Constant Profit 
Total 
Production Export Investment 
Coefficient -7.26 0.14 0.006 -0.006 -0.005 
t-ratio -0.12 2.1 1 * 0.237 -0.080 -0.071 
IZ-squared 0.772 
F )) (4.13) 10.98 
d(Durbin-Watson test) 2.5 
**significant at 1°0 level. 
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5.9 	Employment and FDf Inflows in Pharmaceutical Industry: 
There is an old debate that foreign investment in India might jeopardize the employment 
opportunities due to the adaptation of automation especially in technology intensive 
sector like pharmaceuticals. Bearing in mind a comparison between employment 
generation and FDI inflows seems relevant. It can be seen from the table (fable-5.9A) 
that the employment figure of the industry remained almost static despite the FDI flows. 
The stagnant nature of employment in pharmaceutical industry is mainly attributed to the 
utilization of high automation to reduce the operating costs. It has been observed that 
technological advancement has created a few direct job opportunities. The reason for this 
opening up of the service providing facilities by the firms with latest technology that 
requires fewer workers. The same is evidential from the fact that during the last few years 
most of the firms have opened their service stations throughout the country. The 
employment increased from 181497 employees in 1995 to 353692 in 2008. The mean 
figure of employment in pharmaceutical industry is 243872.2 with a SD of only 51406.6 
leading to a t-ratio 3.91 significant at 10% level. The CV is only 0.21 which is amazing 
and suggesting the stable nature of the variable. One of the main reasons behind such 
impressive statistics is that the period under consideration has severely been constrained 
by the availability of data. The data were available from 1995-2008. 
The relation between employment in pharmaceutical industry and FDI in the industry are 
provided in the table 5.9B. The dependent variable is the employment. The independent 
variables are the FDTPI, total production, export and investment. It has been hypothesized 
that changes in the employment in pharmaceutical depends on the FDI inflows in the 
industry. The regression parameters are not however very satisfactory. In F-statistic was 
significant to indicate that the null hypothesis of untrue relation can he rejected at 5% 
level. Regarding the coefficient of determinants shows highly significant as 97% of the 
variations could have been explained by the ordinary regression. Among independent 
variables the coefficient of total production and export are significant at 5% level. 
However, Durbin—Watson test indicates no first-order auto correlation among them. 
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Table-5.9A: Statement of Employment of Pharmaceutical Industry and FDI Inflows 
(1995-2008). 
(In numbers & %) 
Years 
FDI Inflow in 
Phartnaceutical 
industry 
Growth 
Rate 
No. oCEmployees in 
Pharmaceutical Sector 
Growth 
Rate 
1991 0.3* - NA - 
1992 111* 3600.0 NA - 
1993 9.8* -11.7 NA - 
1994 51.9 429.0 NA - 
1995 59.5 14.6 181497 - 
1996 34.4 -42.2 204609 12.7 
1997 60.0 74.4 211614 3.4 
1998 23.1 -61.5 189295 -10.5 
1999 18.6 -19.5 213999 13.1 
2000 70.9 281.2 
16.8 	- 
243410 
--- 	233704 
13.7 
2001 82.8 -4.0 -~ 
2002 28.0 -66.2 226416 -3.1 
2003 519 85.4 223556 -1.3 
2004 292.0 462.6 240791 7.7 
2005 172.0 -41.1 265396 10.2 
2006 214.8 24.9 290021 9.3 
2007** 334.1 55.5 336211 15.9 
2008** 181.5 -45.7 353692 5.2 
Mean 94.26 243872.2 
SD 100.90 51406.6 
CV 1.07 0.21 
Minimum 0.30 181497 
Maximum 334.1 353692 
CAGR 27.0 4.0 
t-ratio  3.91*** 
Note: * refers Data for January to December 
+r refer Figures are Provisional 
++^ significant at 100/, level 
Source: Compiled from Various issues of SIA Newsletter (FDI Data Cell) DIP?. Ministry of Commerce & 
Industry. Government of India- New Delhi. 
Handbook of Statistics on Indian Economy, RBI. 2009 
Department of Pharmaceutical Annual Report 2009-10, Ministry of chemical & Fertilizes, Government of 
India, New Delhi 
Rajya Sabha question number 615 tabled in Rajya Sabha on 23-11-2009 by Mr. Joytiraditya Scindia MOS- 
MOCL, New Delhi. 
CMIE Industry Financial Aggregates and Ratio (Various years). 
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Figure: 5.6 
Employment of Pharmaceutical Industry and FDI Inflows 
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Employment= 36246.1+ (-24.61) FDIPI +55.38+ (-111.33) export+ (-9.18) profit + 
14.53investment + p, 
Table-5.9B: Regression Estimates of Employment in Pharmaceuticals against FDI 
Inflow. 
Constant FDIPI 
Total 
Production 
Export Profit Investment 
Coefficient 36246.1 -24.61 55.38 -111.33 -9.18 14.53 
t-ratio 0.73 -0.44 3.14** -2.74** -0.58 1.12 
R-squared 0.971 
F oos) (5,8) 53.8 
d(Durbin-Watson test) 2.17 
**: Significant at 5% level. 
5.10 Conclusion: 
Efforts have been made in the present chapter to explore the role of FDI in the 
pharmaceutical sector. It has been noticed that there has been ample opportunity for the 
concentration of FDI in the sector particularly export and profitability of the sector. It 
revealed that 97% of pharma investment variation can be explained by the regression 
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equation. Amongst the independent variables it is only export which is statistically 
significant to pharma investment. However d-test indicated positive auto correlation 
amongst the variables. Similarly 98% of variation in pharma total production can he 
attributed by the regression equation. Among the independent variables only export is 
statistically significant while `d' test indicated positive auto correlation amongst the 
variables. 99% of variation in pharma export can be explained by regression equation and 
total production and investment are statistically significant with positive d' test 
correlation amongst the variables. As far as FDIPI and pharma profitability are 
concerned, it indicated that 91% of variation in profit can be attributed by regression 
equation. It is noticeable that only FD[PI is only statistically significant and 'd' test 
indicated positive correlation amongst the variables. Besides 97% of variation in pharma 
employment can be explained by the regression equation. It is only total production that 
is statistically significant butd' test shows negative correlation. It is mainly due to 
pharma sector being highly technology based sector. However employment opportunities 
are created in allied services due to pharma sector. 
The rate of return in the sector during the period under study observed a tremendous 
increase. The classical theory suggests that FDI seeks high returns. Based on that theory, 
there should be an influx of foreign investment in Indian pharmaceutical sector. But there 
has been limited statistical observation in support of this view. This indicates that 
structural constraints still play a crucial role in the inflow of FDI in India. The economy 
is yet to create the investment climate required for the increased inflow of the FDI. 
Besides, it has been noticed by empirical studies, that most of the variables of the 
pharmaceutical sector are not functionally related with the FDI inflow in the 
pharmaceutical sector. However, FD[ inflow in the pharmaceutical sector is attracted 
because of high rate of return. All these evidence indicated the imperfections of the 
market that must be the greatest hindrance of India shining to shine in the global arena. 
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Conclusion, Recommendations and Suggestions 
6.1 	Introduction: 
The sweeping changes introduced since 1991 mark a radical departure from the past 
and reflect a positive approach towards foreign investment. The changes provide 
freedom to foreign investors to enter the Indian economy. In terms of openness to 
FD[ entry, the prevailing Indian policy is favourably placed in tents of 
competitiveness with other major FDI receiving countries in Asia. 
The new industrial policy resolution, initiated economic reforms in July 1991. The 
industrial policy reforms 1991 have substantially reduced the industrial licensing 
requirement, removed restrictions on expansion and facilitated easy access to direct 
foreign investment. One of the key focus areas of our reforms is the redefinition of 
the respective roles of the public and private sector, within the private sector the 
contribution of foreign investment. There is recognition that the private sector 
including foreign investors has a significant role to play in raising the standard of 
living and infrastructure services in the country. Therefore due to 1991 reforms the 
flow of private capital in the form of FDI enhanced. The inflow of FDI in India has 
experienced considerable growth but compared to other developing nations, India 
has lagged behind. Whereas China could attract around one-fourth of the global 
foreign investment, India attracts only about 2% of FDI inflows. This indicates that 
India, despite being 10th largest economy with economic liberalization, has failed to 
attract sufficient amount of FDI during the period under study. 
From my study, it is evident that FDI is considered to be an important vehicle for 
economic development in India. It impacts the country's trade balance, improving 
labour standards and skills, transfer of technology and innovative ideas and the 
general business climates. It also provides opportunities for technological transfer 
and up-gradation, access to global managerial skills and practices, optimal utilization 
of human capabilities and natural resources, making indigenous industry 
internationally competitive, opening up exports markets, access to international 
quality goods & services and augmenting employment opportunities. 
In addition it is also obvious that although FDI is beneficial for an economy yet, its 
effectiveness depends upon its meaningful use and it's directing to the areas/ sectors 
where shortage of domestic capital investment is felt. More specifically from the 
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development point of view FDI process is related to export oriented areas. •Fhis 
process not only provides financial resources managerial expertise, technologies and 
entrepreneurial skills through the channel of NMNCs. The FDI policy has to be 
constantly reviewed towards this end and necessary steps should be taken to make 
India a most favourable destination for FDI. The focus of FDI should be to maximize 
its contribution to India's development and welfare rather than maximizing the 
magnitude of inflows. 
However, the presence of FDI in Indian economy in general and pharmaceuticals 
industry in particular does not mean automatic positive effects. It depends on the 
development of the domestic firms and the endeavors of domestic firms to invest in 
learning and imitation. Therefore, the benefits from FDI don't accrue automatically 
and evenly across the country and sectors. In order to reap the maximum benefits 
from FDI, there is a need to establish a transparent broad and effective enabling 
policy environment for investment and to put in place appropriate framework for 
their implementation. Such an environment must provides incentives for innovations 
and improvement of skills and contribute towards improved competitiveness. The 
cumulative amount of FDI inflows during August 1991 to February 2011 is 
US$145249 million. 
From the previous chapters. it can also be deduced that since the liberalization policy 
of 1991, the FDI approvals have increased but the actual inflows have been 
comparatively less. This is because of the intentions of the foreign investors having 
not matched with the performance. It may also be attributed to lack of political 
stability, inability of the political decisions, improper unanimity between the centre 
and the states government, conflict in political parties' ideologies regarding FDI and 
corruption etc. 
The study concluded that FDI inflows and economic development have shown 
significant growth during post-reform period (since 1991 onwards). The CAGR of 
actual FE)] inflows during 1991-2008 comes out to be as high as 24.28% as 
compared to 19.05% during pre-reform period. Similarly the GDP growth rate which 
had collapsed to 0.5% in 1991-92 rebounded to more than 9% during 2005-08 and 
8.4% during 2010-11. Other important macroeconomic indicators also improved i.e. 
Gross Domestic Savings had increased from 22% in 1991-92 to 32.3% in 2010-I I. 
Similarly Gross Domestic Capital Formation had raised 22.5% to 35.1% during the 
same period of time. Besides that India has also improved considerably on the 
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external sector front such as the current account balance, capital account, foreign 
exchange reserves and overall improvement in BOPs during post retbrm period. 
Sector-wise break-up of FDI inflow during Post reform period revealed that the most 
leading sector is the services sector which received an approval of USS23995.7 
million. This was shared 20.35% of total amount approved. Computer and IT sector 
has also registered a good share of 3.52%. Infrastructure sector including 
communication housing & real estates posted a growth of 794%, 7.13% and 6.90% 
respectively. Together they accounted for more than 50% of the total FDI approved 
in India. While in the pre-reform period, the top five sectors which have attracted the 
bulk of FD[ were chemicals, industrial machinery, mechanical engineering, electrical 
& electronics and metallurgy and together they accounted for about 68% of total FDI 
inflows. However, pharmaceutical sector which was at 8 h` place during 1991-2007 
declined to 12 h` place after 2007 mainly due to impact of the new patent law and 
global recession. But the position has now improved. 
The total amount of FDI inflow in India comes from these major countries. Mauritius 
tops the list with a percentage of 45.12%. Singapore is the second country having an 
approval of 10.04% followed by the USA (9.92%), 12K (5.79%) and Germany 
(3.32%). These top five countries concentrate nearly 75% of the total approval of 
FDI during the period under consideration. 
Similarly the largest source of FDI in India's pharmaceutical industry is Mauritius 
(56.4%). Singapore is the second largest source (11.2%) followed by the USA (5.8), 
UAE (4.7%), and Canada (4%), together they accounted for more that 80% of FDI 
in this sector during 2008-09. The state-wise FDI trends reveals that Maharashtra 
tops the list with a percentage share of 35.24% followed by New Delhi with a share 
of 20.50%, Karnataka (6.26%), Gujarat (5.79%) and Tamil Nadu (4.91%). Together 
they accounted more than 70% of the total FDI inflows during 2000-10. It is 
important to note that 75% of pharmaceutical manufacturing production is done by 
these states Maharashtra, Gujarat, Tamil Nadu, Andhra Pradesh, Karnataka, West 
Bengal and Goa. This may he attributed to their better resources, good infrastructure 
and investor friendly policies. It is further observed that FDI inflows have positive 
impact on the Indian economy in general and pharmaceutical in particular. It is 
observed that though larger FDI inflows in these states have had a favourable impact 
on the economy and pharmaceutical sector, but it has also led to wider regional 
disparities. 
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Furthermore, while analyzing FD1 in Leans of country-wise, sector-wise and state-
wise, it may also be concluded that although there has been an impressive growth in 
the magnitude of PDI inflows but they are still small when compared to the potential 
of India in terms of its investment opportunities and need. The present time is the age 
of borderless world, a world where physical distances has no matter. The need of 
time is not to reverse the process of globalization and FDI but to take bold steps to 
solve the problem created by the process of globalization. There is only one way 
forward i.e. more interactions, more interrelation, more coordination and cooperation 
between domestic and foreign investment. "therefore, well thought strategy and 
cautions approach should be adopted, so that Indian and foreign companies 
contribute to the economy simultaneously. 
The statistical analysis of the study revealed that in the year 1991 the actual amount 
of FDI inflow in India was only US$165 million and but over the period it observed 
an increasing trend to take a figure of US$2733 Imillion in 2008, which is almost 166 
times that of the figure of 1991. However, during the period under consideration it 
has experienced some fluctuations with going down to the minimum of IJS$165 
million to the maximum of US$ 27331 million. The growth rate also indicates 
considerable fluctuations both in positive and negative rates. it was highest in 2006 
(184%). This demonstrates that the inflow is dictated by the external sources rather 
than internal factors, The average Fill takes a value of US$5919 million with a SD 
of USS8042.5 million. The t-ratio suggests that the estimate is statistically significant 
at 10% level. The CV as high as 1.36 suggest the fluctuating nature of the variable. 
The CAGR is 24.3% during 1991-2008. 
While FDl inflow in Indian pharmaceutical was only US$0.3 million and over the 
period it also observed an increasing trend and reach highest US$334.1 million in 
2007 and thereafter it declined to US$181.5 million in 2008, which is 605 times that 
of the figure of 1991. The growth rates indicates considerable fluctuations both in 
positive and negative rates and highest was in 1992 (3600%). The share of 
pharmaceutical industry FDI in total FDI was 2.05% on an average. The inflow in 
pharmaceutical takes a mean of USS94.3 million and a SD of US$ 100.9 million. 
The fluctuation is demonstrated by the CV of 1.07. The growth rate is 27% during 
period of consideration. One of the reasons behind such high growth rate is the big 
difference between the minimum and maximum value of FDI inflows in 
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pharmaceutical industry. However, the Durbin-Watson test shows the positive 
correlation between these two variables i.e. total FDI and FDIPI. 
It has been observed that the pharmaceutical investment was US$ 38.4 million in 
1991 and it gradually increased to [ USS41 17. I million in 2009, which is almost 107 
times that of 1991 figures. The inflow of FD1 in Pharmaceutical sector was only 
h'SSO.30 million in 1991 and increased to USS 181.5  million in 2008. The share of 
FD1 in total investment of pharmaceutical industry was 11.8% on an average. The 
mean of pharmaceutical industry investment is USS 1027.4 million with a SD of USS 
1282.5 million. The mean of the FDI flows in the pharmaceutical industry is USS 
94.3 million with a SD of US$ 100.9 million. The t-ratio is statistically significant at 
10% level. The CV is 1.24 in case of the investment in pharmaceutical industry and 
1.07 in case of the FDI inflows to demonstrate the unstable nature of FDI inflows in 
the industry. 
It has been further observed that the regression function takes an F-value of 117.8 
which is statistically significant at 5% level. It seems that functional relation 
assumed by the empirical regression line is true that the investment in 
pharmaceutical industry is explainable by the FDI inflows in the industry. The 
coefficient of determinants shows that 97% of the variation of the dependent variable 
could have been explained by the fit. However the coefficients of slopes are not 
statistically significant in general. 
Most of the coefficients of independent variables are not statistically significant 
except for export which statistically significant at 5% level. The FDI inflow in the 
pharmaceutical industry fails to explain the variation in the investment of the 
industry. However the value of d' (Durbin-Watson test ) is significant as 0.957 and 
indicates the positive serial correlation amongst the variables. It is indicated that 
whereas export and profit are important positive significant variables for enhancing 
the level of investment in pharmaceutical sector while FDIPI has not. 
The total production figures indicate that in 1991 the figure was US$2510.6 million, 
where as it increased to USS 17567.6 million in 2008 which is seven times higher 
than that of the 1991. The mean of the variable is USS6868.4 million and the SD is 
USS 4463.5 million. The t-ratio is 6.01 suggesting that the mean is statistically 
significant at 10% level. The variable is considerably stable as is demonstrated by a 
comparatively low coefficient of variance of 0.65. 
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It can be noticed that the regression gives a good fit. The F-statistic suggests that the 
null hypothesis of untrue relation should be rejected at 5% level. The coefficient of 
determinant is as high as 0.98 to indicate 98% of the variation in the production of 
pharmaceutical industry could have been explained by the regression equation. 
Durbin-Watson test indicates the positive serial correlation among the variables. 
Among the independent variables only the export is statistically significant at 10% 
level whereas FDI inflow is not statistically significant to indicate that the production 
in the pharmaceutical industry could not be explained by the FDI inflow in the 
industry. However, it is indicated that the export, FDIPI and profit are positively 
significant for the improvement of phannaceutical total production. 
In 1991 the export of the industry was only US$564.4million and through a gradual 
increase it took the amount of t7S$6257 million in 2008, which is nearly eleven 
times that of the 1991 figure. The average lakes a value of US$ 1862.2million. The 
SD is however quite impressive at an amount of US$ 1758.7 million. The t-ratio is 
5.84 to indicate that the mean is statistically significant at 10% level. The CV is 
equally high at 0.94 suggesting that the estimate observes the fair extent of 
instability. 
The F-statistic suggests that the regression is statistically significant at 5% level. The 
coefficient of determinants is as high as 0.99 or 99% of the variation in the export of 
pharmaceuticals. However among the coefficient of slopes only total production and 
investment are statistically significant at 10% and 5% level respectively. The 
coefficient of FDI inflows in the pharmaceutical industry fails to demonstrate any 
significant relation towards the promotion of export from the industry. However 
Durbin-Watson test indicates that there is a positive serial correlation amongst these 
variables. It is indicated that only total production and investment is positively 
significant for pharmaceutical export.. 
The amount of earned profit plays a key role in attracting the FDI inflows. It can be 
observed that the profit in pliarma increased throughout the period under 
consideration, whereas in 1991 it was only USS14.1 million but by 2008 it reached to 
a level of US$135G million. The increase is around ninety-six times. One of the 
reasons attributed to this is that the number of firms has also increased during the 
period. However, it is indicated that during 1995 to 1997 the profit trend was 
declining. The industry faced a stiff competition during the late nineties backed by 
regional as well as global recession in the same year of that must have contributed to 
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the adversities in the profit performance. Input prices also increased globally during 
that period coupled with high market campaigning expenses. 
The statistical description shows that the mean profit is US$ 5775 million with the 
SD 587.6 million. The t-ratio is 7.32 which indicate that the mean is statistically 
significant at 10% level. The CV is as high as 1.02 which indicates instability in the 
nature of the variable. 
The F-statistic suggests that the null hypothesis of untrue relation can he rejected at 
5% level. The coefficient of determinants shows that 0.908 or 91 % of the variation in 
the profit figures could have been explained by the regression function. Among the 
independent variables FDIPI is the only variable which is statistically significant at 
1% level. However, Durbin-Watson test indicates the positive serial correlation. It is 
indicated that FDIPI and total production has significantly positive impact on 
pharmaceutical profit. It can be observed that the F-statistic is 15.8 to indicate that 
the regression function is a true functional relation. Coetfieient of determinant 
demonstrated the 0.772 or 77.2% of the variation in the FIJI flows can be explained 
by the profit of the industry. Among the independent variables only profit variable 
happened to be statistically significant at 1% level. This suggests that it may be the 
profit of the industry which is the main consideration in the decision making of the 
FDl in Indian pharmaceutical sector. However, the coefficients of slopes are not 
statistically significant in genera]. and the Durbin-Watson test shows the no first-
order auto correlation. 
The employment increased from 181497 employees in 1995 to 353692 in 2008. The 
mean figure of employment in pharmaceutical industry is 243872.2 with a SD of 
only 51406.6 leading to a t-ratio 3.91, significant at 10% level. The CV is only 0.21 
which is amazing and suggesting the stable nature of the variable. One of the main 
reasons behind such impressive statistics is that the period under consideration has 
severely been constrained by the availability of data. The data were available only 
from 1995-2008. The regression parameters are not however very satisfactory. The 
F-statistic was significant to indicate that the null hypothesis of untrue relation can 
be rejected. Regarding the coefficient of determinants it is highly significant as 97% 
of the variations could have been explained by the ordinary regression. Among 
independent variables the coefficient of total production and export are significant at 
5% level. However, Durbin—Watson test indicates no first-order auto correlation 
among them. 
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6.2 	Suggestions and Recommendation: 
The FDI inflow in India in absolute figure is quite impressive, but when compared to 
global flows, it is far from satisfaction. Thus, India at the moment needs a well-
balanced strategy for enhanced FDI inflows. 
In the context of the importance of FDI inflows in the Indian economy as a whole and 
phamtaceutical sector in particular. We propose the following measures to attract FDI 
in India. 
6.2.1 	Strategies and Implication for FDI in Indian Economy: 
Legal and Regulatory Framework and FDI Policy: 
Indian government has enacted laws for regulation FD[ from time to time 
keeping in view both national and international business environment. Before 
1991, FERA was constituted in 1973 for regulation of foreign investment. 
Nowadays a newly formulated FEMA is taking care of foreign investment 
regulation. But, the real problem is that all these Acts and different bodies 
constituted by the government are playing a regulatory role. The need of the 
hour is to enact a law which should play a promotional role apart from 
regulation. The government should now emphasis the national investment of 
FDI and takes care of such sensitive issues like double taxation, single point 
clearance tar investors, eliminating separate clearance at central and states 
level. 
As the volume of FDI is increasing significantly there are also many fold 
increase in the problems faced by the foreign investors. The procedures for 
getting government clearance are very complex especially for the first time 
investors. So taking in consideration these problems, a non-governmental 
society or council should be setup with help and encouragement from the DIPP 
for helping out these investors. These council/societies should operate on a 
non-profit basis and supply information, approval and clearance services to the 
foreign investors. 
Economic conditions are critical for attracting FDI, but investor friendly 
policies and facilitation centers that reduce the transaction costs of planning 
and engaging with regulatory compliance are also critical. Ilowever, sometimes 
policies are over friendly to FDI while transaction costs (including tax and 
202 
Chapter -6 
other regulatory issues) of investment remain high for domestic players and this 
can be counter-productive. Such asymmetric treatment of domestic and foreign 
investment can lead to `round-tripping' i.e. where domestic investors route 
their investment through a foreign country to avail the policy benefits of FDI. 
India has seen significant "round-tripping" activity. Since 2000 Mauritius share 
in FDI inflows to India has been very high and it can be safely argued that a 
significant portion of FDI originating out of Mauritius is of the `round-tripping' 
variety. So it is a trade-off between rigid and liberal regulatory framework. The 
government should check it carefully. 
➢ State Infrastructure Law and FDI Policy: 
For a long time it has been emphasized, the key to economic development apart 
from economics is the infrastructure development. Because a well developed 
infrastructure will play a vital role in attracting FDI. In the light of this different 
states should consider framing special laws directing investment first in 
infrastructure and then to other sectors of the economy, covering both domestic 
as well as foreign investment. Some states have already initiated this process of 
enacting law for infrastructure development. Andhra Pradesh and Karnataka are 
the two states which have taken the lead in this; others like Maharashtra, Tamil 
Nadu, Gujarat are in line. 
There should be a joint effort both by central and state government and some 
kind of coordination committee should be constituted to take up critical issues, 
which sometimes create problems between states and central government. For 
example, recently in the case of FDI approval in multiple retail sector was 
severely opposed by the states. Besides issues such as environmental clearance. 
industrial relation etc. members from corporate should also be included for 
broader acceptability. 
➢ Institutional Changes and Policy for FDI: 
The DIPP plays a pivotal role in regulating FDI, with the help from FIPB, SIA 
and FIIA and recently CCI (Competition Commission of India). The FIPB 
which works out the modalities before the approval stage and appraises the 
proposal should be empowered to grant central level registration, excise 
registration and income tax registration and DGFI registration, custom excise 
registration. This will augment the process approvals of FDI proposals. 
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The FIIA should he given freedom to frame business rules so that it can fix the 
time frame tor investment proposals both at central and state levels. The role of 
cabinet committee should be curtailed in assessment of proposals and FIIA 
should be empowered which will reduce approval time. A registration cell 
related to FDI should be set up so that data base can he maintained of FDI 
projects. It will ensure accelerated approvals of FDI. 
- Raising FDI Sectoral Caps and other Allied Issues: 
Attracting FDI is a major issue for India for the overall development of the 
economy. But there are many barriers attached which restrict the smooth inflow 
of FDI. The sectoral limits which are enforced should be properly evaluated in 
an explicit manner and should be justified. Otherwise, the sectoral caps which 
are not properly justified should be removed. 
Reduction in Transaction Costs and Improvement of Infrastructure: 
More than any FDI policy it is the level of business comfort and profitability of 
operation that attract FDI. Transaction costs of operating business in India 
remain prohibitive and infrastructure and logistical support is too weak. India 
first must become a competitive production base where people would want to 
invest. Implementation of trade facilitation reforms will lead to stronger trade 
linkages with rest of the world. 
Decentralization of Administration Process: 
India's FDI policy process still remains highly centralized in New Delhi and 
that is another major impediment in effective competition between states and 
efficacy in administration of FDI initiatives in many parts of India. Although 
thing have improved in terms of decentralization but, the entire FDI policy 
environment still remains in centered around New Delhi and not the state 
capitals where they should he given the diversity of India's economic 
prospects. 
Reduce Overly Bureaucratic Facilities: 
India's bureaucratic setup maintains several investment and trade promotion 
bodies that work at cross purposes. There are too many 'single windows' and 
investment development commissions working at the same time. There is also a 
lack of policy consistency. There needs to be a real `single window' that draws 
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from the sectoral expertise of the different ministries and more importantly the 
private sector. 
➢ Proper Coordination between Centre and States: 
While many policy barriers have been removed on FDI in India, results have at 
Limes been disappointing due to administrative harriers at the state level as well 
as lack of coordination between the central and state governments. There need 
to be greater coordination between the centre and states to ensure that the 
substantial foreign interest in investing in India gets translated into actual 
investment flows to the state. An example of this is the proposed USS 12 
billion investment, India's single largest FDI investment by South Korean steel 
giant Posco. Posco signed an agreement in June 2005 to set up a steel plant in 
Orissa but as on March 2008, the steel plant is yet to be start construction, let 
alone any operations. The government should check above kind of problems 
which foreign investor faced. 
Y Need for Simple and Transparent FDI Facilitation Structure: 
Currently, in India the FDI facilitation structure is quite complex. The IIC 
(Indian Investment Centre) which was originally mandated to pursue these 
objectives is almost defunct now. Till 1991, the Department of Economic 
Affairs was the nodal department that dealt with foreign investment policy and 
regulated the flow of FDI. But the SIA, which accepted and approved foreign 
investment application, functioned in the ministry of industries. Post 1991, the 
subject of foreign investment policy has been with the D[PP but SIA, as it is 
now known is no longer the secretariat for FIPB. The finance secretary chairs 
the FIPB and all foreign investment cases arc processed in the finance ministry. 
The process has been further complicated by the establishment of FIIA in 1999, 
to facilitate quick translation of FDI approvals into implementation, provide a 
proactive one-stop aftercare service to foreign investors. The FIIA has created 
FTCs (Fast Track Committees) in 30 ministries/departments in the central 
government. The constitution of FIIA is almost the same as the FIPB. Whereas 
the secretariat for FIPB is in the finance ministry, that of the FIIA is DIPP. It is 
clear that by creating two distinct bodies. FIPB and FI[A the system has now 
become more complex and confusing. Further currently, CCI has empowered 
to regulate the Brownfield investment in the pharmaceutical industry. Thus, it 
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is suggested that one stop department or agency should be established which 
should take care of the whole process of FDI in India. 
➢ Investment Opportunities in North-Eastern Region: 
The North-East which has got its definite entity due to its peculiar physical, 
natural, economic, social and cultural characteristics and is the poorest and 
remotest part of the country is yet to enjoy significant share of the benefits of 
liberalized process due to one or other factors. Though India has become one of 
the power magnate of FDI in Asia (after. China), the inflows of it in the North-
East is quite meager. A unique competitive advantage of the region is its 
strategic location. Almost 98% of its boarders from India's international 
boundaries as well as most attractive tourist destinations are found here. 
It is deduced in the chapter 3rd that almost half of the FD] is received by only 
few developed states like Maharashtra. Delhi, Gujarat. Karnataka and Tamil 
Nadu due to better infrastructure and a more developed industrial and financial 
sector. That is FDI has been concentrated in relatively developed states where 
large amount of public investment has been made and transportation and 
communication facilities are more developed. Keeping in view the strategic 
importance of North-East region, it is suggested that the economic development 
of this extremely backward regions should not be left. Public investment has to 
be increased to ensure that adequate infrastructure is created in this region to 
provide the pre condition for private investors to come forward and make 
investment in future and to ensure that regional disparities do not widen too 
much in India. 
➢ Liberalization in Exit Barriers: 
An exit policy needs to be formulated so that firms can enter and exit freely 
from the market. While the reforms implemented so far have helped remove the 
entry barriers, the liberalization of exit barriers has yet to take place. This is a 
major deterrent to large volumes of FDI flowing to India. While it would be 
incorrect to ignore the need and potential merit of certain safeguards, it is also 
important to recognize that safeguards if wrongly designed and/or poorly 
enforced would turn into barriers that may adversely affect the health of the 
firm. 
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➢ Need for more Flexible Labour Laws: 
In India large firms are not allowed to retrench or layoff any workers or close 
down the units without the permission of the state government. While, the law 
was enacted with a view to monitor unfair retrenchment and layoff, in effect it 
has turned out to he a provision for job security in privately owned large firms. 
This is very much in the line with the job security provided to public sector 
employees. Labour-intensive manufacturing exports require competitive and 
flexible enterprises that can vary their employment according to changes in 
market demand and changes in technology, so India remains an unattractive 
base for such production in part because of the continuing obstacles to flexible 
management of the labour force. 
➢ Reduction in Tariff and Corporate Tax Rates: 
India's tariff rates are still among the highest in the world, and continue to 
block India's attractiveness as an export platform for labour-intensive 
manufacturing production. Much greater openness is required which among 
other things would include further reduction of tariff rates. Most importantly, 
tariff rates on imported capital goods used for export, and on imported inputs 
into export production, should be duty free. 
Presently corporate tax rate in East Asia are generally in the range of 10 to 25% 
compared with a rate of 42.02% (tax rate of 40% plus surcharge of 2% plus 
cess of 3%) for foreign companies in India. High corporate tax rate is definitely 
a major disincentive to foreign corporate investment in India. Therefore, it is 
suggested that the tax policy should he rationalized and rates should be such 
that it gives makes international investor's investment a profitable one. 
➢ Stability in Macro-Economic Fundamentals: 
Rationalization and liberalization of FDI policy may be necessary but not 
sufficient for expanding FD[ inflows. The overall macro-economic 
performance continues to exercise a major influence on the magnitude of FDI 
inflows by acting as a signaling device for foreign investors about the growth 
prospect for potential host economy. Hence, paying attention to macro-
economic pertorntanec indicators such as growth rates of industry through 
public investments in socio-economic infrastructure and other supportive 
policies and creating a stable and enabling environment would crowd-in FDI 
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inflows. Studies have shown those policies that facilitate domestic investment 
also pull in FDI inflows. While investment incentives may not be very 
efficient, active promotion of FDI. by developing certain variable projects and 
getting key MNEs in them, could be useful in attracting investments in 
desirable directions. 
➢ Reduce Level of corruption: 
The high corruption in India is another important impediment in FDI inflows. It 
is an intractable problem. Corruption in India is a consequence of the nexus 
between bureaucracy, politics and criminals. Indian administrate on is tainted 
with scandals and the country is at 95 h` place with score 3.1 out of 178 
countries where corruption is rampant as per the 'Corruption Perception Index 
2011" released by Transparency International India (in this index scored ranges 
from 0 to 10 where 10 refer to highly clean and 0 refers to highly corrupt). 
The effect of corruption on FDI shows in context of the costs of doing business. 
Since foreign investors have to pay extra, costs in the form of bribes in order to 
get licenses or government permits to conduct investment, it raises costs of 
investment. Moreover corruption increases uncertainty because these kinds of 
agreements are not enforceable in the courts. It has negative impact on level of 
investment and economic growth, quality of infrastructure and on the 
productivity of the public investment, healthcare and education. All these 
factors are found to be important determinants of FDI. 
For checking corruption full proof laws should be made so that there is no 
room for discretion for politician and bureaucrats. The role of the politician 
should be minimized. Application of the evolved policies should be left in the 
hands of independent commission and authority in each area of public interest. 
Local bodies, independent of the government like Lok-pals, Lok-adalats and 
Central vigilance commission should be formed 
6.2.2 	Strategies and Implication for FDI in Indian Pharmaceutical 
Industry: 
Over a period of time the IPI has promoted, integrated, and induced self-
sustained growth of the Indian economy. However, there is a pressing need to 
lift up the sector as an impetus of industrial growth and employment and to 
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achieve a high degree of value addition in the country. IPI is currently 
recognized as global pharmacy of developing world and has distinction of 
providing quality healthcare at affordable cost. The IPI is currently divided 
into three-tier structure. Large MNCs operates as originator drug companies, 
generic companies along with large Indian generic companies and medium 
and small scale industries. Pharmaceutical industry contributed nearly 12% of 
India's manufacturing sector GDP and around 2% of the country's GDP 
during 2008-09. Besides this drugs & pharmaceuticals, have been consistently 
5'" largest exported principal commodity of the country for the last several 
years. In terms of trade balance it is the only Indian sector after apparels that 
have consistently given positive trade balance and it growing around 1.5-1.6 
times of country GDP growth rate. Furthermore it is a net earner of foreign 
exchange and this kept increasing throughout the years since 1991. Its 
turnover also witnessed a tremendous growth over the past few years i.e. from 
US$2857.14 million in 1990-91 to US$20787.40 million in 2009-10 i.e. raised 
more than seven-folds. From simple headache pills to sophisticated antibiotics 
and complex cardiac compounds, almost every type of medicine is now made 
indigenously. 
At the global arena WI ranks very high and is placed third in the world in 
terms of technology, quality and range of medicines manufactured. The 
country now ranks third world-wide by volume of production also and 14ih by 
value of production. Globally it ranks 4 h` in terms of generic production and 
3'a largest bulk drugs producers in the world it ranks 17'h in terms of export 
value of bulk drugs & formulations. India account for over one-third of DMFs 
in USA and 30% of all approved ANDAs in the US. Even in patent challenges 
India ranks 2"d only next to USA with a share of 21% of patent challenges. 
The 1990s witnessed the strongest performance of the IPI on several fronts. 
Not only did the industry exceed its output expansion of the previous decades, 
but it actually became a net foreign exchange earner. This performance 
followed the changes in the policy orientation of the Indian economy that took 
place in 1991. Industry thus took advantages of the unshackling of the 
industrial sector during the 1990s from the controls imposed by the 
government. the rapid opening up of what had been largely an insulated 
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economy to international trade and investment brought about a swill response 
from the leading firms in the pharmaceutical industry. 
The production of bulk drugs rose from US$396.5 million in 1991 to 
US$3503.2 million in 2008 showing a CAGR of 14.4% during 2006-08. The 
production of formulation on the other hand increased from USS2114.5 
million to US$ 15390.8 million during the same period of time with CAGR of 
23.6%. A noteworthy feature of the analysis is that during 2005-08 the CAGR 
of bulk drugs production was nearly half as compared to the growth rate of 
formulations production. It is indicated that formulation production increases 
at a faster rate as compared to the bulk drugs production. This reveals that IPI 
is shifting from the production and trading of less value added goods (bulk 
drugs) to high value added goods (formulations) during post-reform period. 
Similarly the export performance of the pharmaceutical industry is also very 
remarkable given that it has been the only amongst the major industrial sector 
to have consistently generated trade surplus irrespective to global crisis. Indian 
pharmaceutical export increased from USS 564.4 million in 1991 to USS 
6257.0 million in 2008. 'trade balance also increased US$ 320.1 million to 
US$4286.5 million during the same period of time. As a result this sector 
contributes nearly 5% of India's total manufactured exports. India's share in 
world pharmaceutical export also improved from 0.9% in 1992 to 1.4% in the 
year 2008. 
The pharmaceutical industry is severely technological and capital intensive 
and India is one of the very few developing countries that has comparative 
advantages in the industry. However despite the impressive growth of this 
sector and low costs production there are several concerns which needs to be 
addressed. Like accessibility and affordability of medicines by the common 
man, instituting standards of quality, strengthening the fragmented regulatory 
system, sustaining growth of generic etc. 
The IN responded to economic reforms in many different ways. Firms like 
Cipla. Zydus and Lupin etc improved their manufacturing efficiency and 
established large production facilities. While firms like Sun pharma, Torrent 
and Wockhdardt etc re-structured and shifted their technology focus, product 
basket and market focus. Special emphasis was given to marketing and 
distribution networks by almost all leading firms during this time. Besides, 
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domestic leaders substantially increased their in-house R&D investment and 
implemented new approaches of drug/product development. 
Furthermore moving the value chain of R&D in year 2000 process 
development account 65%, NODS 30% and NCEs 5%, where in 2005 it was 
35%, 35% and 30% respectively. 
The presence of foreign firms boosts the competitive environment in the 
pharmaceutical sector and spillover effects are generated through the 
elimination of insufficient firms and faster adoption of technology. It will be 
further increased in near future due to TRIPs implementation. Besides the 
MNCs invest a lot in training and positive externalities in the form of human 
capital development seem to be generated. Further, the MNCs are highly 
aware of quality standards for products and production processes which seem 
to have positive impact to the domestic industry to improve their products 
quality, continually in the future due to new patent law and enhanced 
investment climate. Currently, domestic firms have invested more in R&D 
than they did in pre-reform period and this competition in terms of R&D can 
stimulate further competition and growth in the industry. 
Therefore the impact of FDI on IPI manifolds. With the new WTO patent 
regime the foreign players have found greater security in operating in the 
India. Due to the spillover effects of a competitive environment the domestic 
players have substantially increased their productivity, profitability and are on 
stronger footing with the incoming pharmaceutical firms. In facts domestic 
players have started challenging MNCs in their own country. 
The development of Indian talent and adoption of managerial techniques by 
domestic firms has made India a preferred destination of FDI. This is a 
positive spiral of the spillover effects of FDI. Due to earlier FDI infusions the 
human capital has been upgraded which in turn is attracting more FDI. Hence 
the spillover effects are evident in increasing the productivity of the IPl and 
have resulted in India gaining respect as a global player. 
FDI in the IPI is mainly market-seeking. India's advantage for MNCs in the 
pharmaceutical industry is first of all the large domestic market, with a more 
than one billion population. Wide disease pattern, relatively cheap manpower 
and skilled labour are other factors that attract foreign investors. English is 
widely spoken language, which makes communication easy for foreign 
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investors. The production of pharmaceuticals is also relatively cheap in India 
as there is a strong production base in the country. It is easy to get good 
quality bulk drugs, which is attractive for foreign firms. Because of India's 
focus on reverse engineering and the development of production processes, it 
has high technical competence in production in the pharmaceutical industry, 
which makes this industry attractive to foreign investors. The industry is also 
highly competitive among suppliers which give the MNCs a good bargaining 
position. India has many advantages for foreign investors and consequently 
the country has future potential to become an attractive destination for out-
sourcing in drugs discovery and clinical trials. 
From the analysis of FDI in pharmaceutical industry it has been observed that 
the share of pharmaceutical industry's FDI in total FDI inflows was 2.05% on 
an average during the period under consideration. 
In order to promote PDI and maximize further spillover effects, polices should 
be investor friendly, with a clear developing strategy. The policies in India 
should encourage domestic firms  to invest more in R&D and technology up-
gradation and human resources by providing suitable fiscal and financial 
incentives. 
SMEs (Small and Medium Enterprises) contribute 42% of total 
pharmaceutical production and 62% of total employment. Government should 
ensure that the SSI grows at a healthy rate as it is employment intensive 
sector. Lack of awareness in the area of patenting of technology, GMP, GCP 
and GLP is an issue with SMEs. Government with the help of BDMA and 
IDMA can conduct awareness camps for SMEs. This will not only help these 
units to match the expectations of developed market but also help in retaining 
or bringing back our talent abroad as specialists in this area. Further, schemes 
to promote compliance of schedule Ni, improvement in quality by adopting 
international regulatory standards and technology upgradation with special 
focus on the SSis. 
Currently, corporate players in this sector including the MNCs whose costs are 
prohibitively high are looking at the pharmaceutical SMEs in India to out-
source their production and research programmes. This has opened up a big 
opportunity for SMEs pharmaceutical. But they face one major impediment in 
grabbing this opportunity. Their research facilities do not match with the 
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western standards, although their manufacturing capabilities are excellent. 
Indian SMEs are finding it difficult to keep up with the pace of R&D in 
technologically advanced countries. The prime reason for the Indian SMEs 
lagging behind the developed countries is the severe shortage of fund they are 
facing. To overcome this problem, the Indian SMEs pharmaceutical can adopt 
the CRAMS practice. This time-tested business is practiced elsewhere in the 
world and can provide a highly effective financial boost to SMEs in India. 
Since R&D in pharmaceutical is a highly risky venture, there is dire need to 
give incentive through tax concession on a permanent basis. It is suggested 
that the tax holidays should be at least 20-25 years because the development of 
any molecule takes at least 15-20 years. 
The level of FDI in all industry is an important factor for possible spillover 
effects. When the level of FDI is relatively low in an industry it can lead in 
insignificant result. This is also the case in the IPI. This should be enhanced by 
providing more investor friendly policies. 
Government at various levels should take active part in disseminating 
knowledge about the IPRs and the possible strategies that can be adopted by 
the industry. Lesson should he drawn from the Chinese experience where 
systematic efforts were taken to educate the bureaucrats, policy makers and 
the industry about the WTO and product patent in pharmaceutical industry. 
India will have to strengthen the patent examination process and speed up the 
processing procedures. Besides, a strong institutional and judicial framework 
will have to be set up for monitoring the price, to prevent infringement and 
trade dress cases of patent products respectively. 
Emphasize also has to be given to the macroeconomic policies, such as the 
monetary policy, fiscal policy, foreign trade policy, the exchange rate policy 
and FDI policy so that they are in tune with the requirement of the growth of 
the pharmaceutical sector. 
With India emerging as a major hub for Contract Research particularly clinical 
trials it is important to ensure good clinical practices in the country. 
Animal testing is essential in drug discovery. Effective solution is needed for 
undertaking NCEs based discovery research to solve the difficulties 
encountered in conducting toxicity studies in bigger animals, The approval 
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process for animal imports, animal experiment protocol, needs to be 
streamlined and expedited. 
Spurious drugs are a sensitive issue affecting not only the level of FDI but also 
health of the people as well as the prestige of the country's pharmaceutical 
trade interest. Steps should be taken by the government to counter threat of 
spurious drugs. 
Price regulation is another major impediment for FDI inflows in Indian 
pharmaceutical sector. Focus on price monitoring rather price control is 
required. Apart from this resolution of data exclusivity law will help in 
increasing confidence among foreign companies. 
It may be noted that reforms are required at regulatory/policy level too. 
Presently both central and state governments regulate pharmaceutical sector. 
While states regulatory authorities are responsible for regulating 
manufacturing, sales and distribution of drugs, the central regulation approves 
new drugs, clinical trials, control imports of drugs and also coordinates among 
the states bodies. Hence, drug regulation and price control should be with the 
same agency so that an integrated regulatory system exists in the economy. 
Strengthening the regulatory system is also required in the context of new 
patent regime. There is a need to simplify procedures and shorten the time line 
for various approvals. Strengthening of regulatory system with respect to data 
protection is also crucial. These measures will help in attracting more FDI 
particularly in R&D in India. 
Technological cooperation with the MNCs stimulates growth in the 
manufacturing and R&D spaces of the domestic industry. Recently, with the 
fear that if MNCs take over Indian companies it will lead to an oIigopolistic 
market situation and increasing drug price (However various studies have 
shown that drug prices almost stable currently). Due to this now FDI upto 
100% in Greenfield projects will remain under automatic route but in the 
Browntirld projects it will need to go via government approval route. The 
same approval which is presently done the FIPB but in future it will be by the 
CCI. Movement to restrict FDI in this way will a retrogressive step in the 
financial reform process in the country, adversely affecting FDI not only in the 
pharmaceutical sector but possibly tar beyond it. ]fence, the Government 
should rethink in this matter. 
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6.3 	Direction for Further Research: 
The present study has dealt with the role of the FDI in pharmaceutical industry for the 
period from 1991-2008. Performance appraisal of pharmaceutical industry has been 
done in terms of examining the trends in production, investment, export and 
employment in pharmaceutical sector. The same parameters have been taken to assess 
the role of FDI viz-a-viz production, investment, export and employment. 
However, the study has not taken the segment-wise analysis of FDI inflows in 
pharmaceutical industry i.e. bulk drugs and formulations. Since India is the third 
largest bulk drug manufacturer there is scope for the research in future in these 
segments. 
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Appendix-I: Sector-specific policy for FDI- At a glance. 
In the following sectors/activities, FDI is allowed up-to the litnit indicated below 
subject to other conditions as indicated (31 March 2008).Sectorgl limits on FDI 
(2008). 
Sr. 
No. Q 
Q 
— W >.  
c 
v°¢ v'  
I Agriculture 
1.  Floriculture, Autom 
Horticulture, 100% atic 
Development of Seeds, 
Animal 	Husbandry, 
Pisciculture, 	Aqua- 
culture 	and 	Cultivation 
of 	Vegetables 	& 
Mushrooms 	under 
controlled conditions and 
services related to agro 
and allied sectors. 
Note: Besides the above, 
FDI is not allowed in any 
other agricultural 
sector/activity _ 
2.  Tea Sector, 	including Subject to divestment of 26% 
tea plantation 100% FIBP equity in favour of Indian 
partner/lndian public within 5 
Note: Besides the above, years and prior approval of 
FDI is not allowed in any State Government concerned 
other 	plantation in 	case of any change in 
sector/activity future land use. 
II Industry 
li A Mining 
3. Mining covering Subject to Mines & Minerals 
exploration and 100% Autom (Development & Regulation) 
mining of diamonds & ado Act, 1957 www.minesnic.in 
precious stones; gold, Press 	Note 	18 	(1998) 	and 
silver and minerals. Press Note 1 (2005) are not 
applicable 	for 	setting 	up 
100% owned subsidiaries in 
so far as the mining sector is 
concerned, 	subject 	to 	a 
declaration from the applicant 
that he has no existing joint 
venture for the same area and 
/or the particular mineral. 
xix 
4. Coal 	& 	Lignite mining Subject to provisions of Coal 
for captive 100% Autom Mines (Nationalization) Act, 
consumption by 	power atic 1973 
projects, www.coal.nic.in 
and iron & steel, cement 
production 	and 	other 
eligible 	activities 
permitted under the Coal 
Mines 
(Nationalization) 	Act, 
1973. 
5. Mining 	and 	mineral Subject 	to 	sectoral 
separation 	of 	titanium 100% FIPB regulations 	and 	the 	Mines 
bearing 	minerals 	and and Minerals (Development 
ores, 	its 	value 	addition & Regulation) Act, 1957 and 
and integrated activities, the following conditions- 
Note: 	FDI 	will 	not 	be 
allowed 	in 	mining 	of i. value addition facilities are 
"prescribed 	substances" set up within India along with 
listed in Government of transfer of technology; 
India 	notification 	No. ii. disposal of tailing during 
S.O. 61(E) dt. 	18.1.2006 the mineral 	separation shall 
issued by the Department be carried out in accordance 
of Atomic Energy under with 	regulations 	framed by 
the Atomic Energy Act, the 	Atomic 	Energy 
1962. Regulatory 	Board 	such 
Atomic 	Energy 	(Radiation 
Protection) Rules 2004 and 
the 	Atomic 	Energy 	(Safe 
Disposal 	of 	Radioactive 
Wastes) Rules 1987. 
II B Manufacturing 
6. Alcohol- 	Distillation & 100% Autom Subject 	to 	license 	by 
Brewing atic appropriate  authorit 
7. Cigars 	& 	Cigarettes- 100% FIPB Subject to industrial 	license 
Manufacture under 	the 	Industries 
(Development & Regulation) 
Act, 1951 
8. Coffee& 	Rubber 100% Autom 
processing & atic 
warehousing  
9. Defence production 26% FIPB Subject 	to 	licensing 	under 
Industries 	(Development 	& 
Regulation) 	Act, 	1951 	and 
guidelines 	on 	FOE 	in 
production 	of arms 	& 
a11111111n1tion. 
xx 
10.  Hazardous chemicals. 100% Autom Subject to industrial license 
viz.. hydrocyanic acid atic under 	the 	Industries 
and its derivatives: (Development & Regulation) 
phosgene and its Act, 1951 and other sectoral 
derivatives; and regulations 
isocyanatcs and 
diisocyantes of 
hydrocarbon. 
11.  Industrial explosives - 100% Autom Subject 	to 	industrial 	license 
Manufacture atic under Industries 
(Development & Regulation) 
Act, 	1951 	and 	regulations 
under Explosives Act, 1898 
12.  Drugs & 100% Autom 
Pharmaceuticals atic 
including those 
involving use of 
recombinant DNA 
technology 
11 C Power 
13, Power 	including 100% Autom Subject to provisions of the 
generation 	(except atic Electricity 	Act, 	2003 
Atomic energy); www.00wermin.nic.in 
transmission, distribution 
and Power Trading. 
III Services 
14. Civil Aviation Sector 
(i)  Airports- 
a. Greenfield projects 	100% Autom Subject 	to 	sectoral 
atic regulations 	notified 	by 
Ministry 	of Civil 	Aviation 
www civilaviation.nic. in 
h. Existing projects 100% FIPB Subject 	to 	sectoral 
beyond regulations 	notified 	by 
74% Ministry 	of Civil 	Aviation 
www.civilaviation.nic. in 
(ii)  Air Transport Services including Domestic Scheduled Passenger Airlines; 
Non-Schedules Airlines; Chartered Airlines: Cargo Airlines; Helicopter and 
Seaplane Services 
C. Scheduled Air Transport 49%- Autom Subject 	to 	no 	direct 	or 
Services/ 	Domestic FD[; atic indirect 	participation 	by 
Scheduled 	Passenger 100%- foreign airlines and sectoral 
Airline for regulations. 
NRI 
investme 
fit 
Xxi 
d.  Non-Scheduled 	Air 	74°- Autom Subject 	to 	no 	direct 	or 
Transport Service 	Non- 	FDI atic indirect 	participation 	by 
Scheduled 	airlines. 	l00° - t()reign 	airlines 	in 	Non- 
Chartered 	airlines, 	and 	ti)r NRIs Scheduled 	and 	Chartered 
Cargo airline~ 	 investme airlines. 	Foreign airlines are 
nt allowed to participate in the 
equity 	of 	companies 
operating 	Cargo 	airlines. 
Also 	subject 	to 	sectoral 
regulations. 
e.  Helicopter 100% Autom Foreign airlines are allowed 
Services/Seaplane atic to participate in the equity of 
services 	requiring companies 	operating 
DGCA approval Helicopter 	and 	seaplane 
airlines. 	Also 	subject 	to 
sectoral regulations. 
(iii) Other services under Civil Aviation Sector 
f.  Ground 	Handling 74%- Autom Subject 	to 	sectoral 
Services FDI atic regulations 	and 	security 
100%- clearance. 
for NRIs 
investme 
lit 
g.  Maintenance and Repair 100% Autom 
organizations, 	flying atic 
training 	institutes; 	and 
technical training 
institutions 
15.  Asset 	Reconstruction 49% FIPB Where 	any 	individual 
Companies (only investment exceeds 10% of 
FDI) the 	equity, 	provisions 	of 
Section 	3(3)(t) 	of 
Securitization 	and 
Reconstruction 	of Financial 
Assets and Enforcement of 
Security 	Interest Act, 	2002 
should 	be 	complied 	with. 
www.finmin.nic.in 
16.  Banking - Private sector 74% Autom Subject 	to 	guidelines 	for 
(FDI+FII atic setting 	up 	branches 	/ 
subsidiaries of foreign banks 
issued 	by 	RBI. 
17. Broadcasting 
a.  FM Radio FDI +FII FIPB Subject to Guidelines notified 
investme by Ministry of Int'Ormation & 
nt Broadcasting. 
up to www.mib.nic.in 
20% 
b.  Cable network 49% FIPB Subject to Cable Television 
(FDI+FII Network 	Rules 	(1994) 
Notified 	by 	Ministry 	of 
Information & Broadcasting. 
www.mib.nic.in 
c.  Direct-To-Home 49% FIPB Subject to guidelines issued 
(FDI+FII by Ministry of Information & 
Broadcasting. 
Within www.mib.nic.in 
this 
limit, 
FDI 
compone 
nt not to 
exceed 
20% 
d.  Setting up 49% FIPB Subject to Up-linking Policy 
hardware facilities (FDI+FII notified 	by 	Ministry 	of 
such as up-linking, ) Information & Broadcasting. 
HUB, etc www.mib.nic.in 
e.  Up-linking a News 26% FIPB Subject to guidelines issued 
& Current Affairs FDI+FII by Ministry of Information & 
TV Channel Broadcasting. 
www.mib.nic.in 
f.  Up-linking a Non- 100% FIPB Subject to guidelines issued 
news & Current by Ministry of Information & 
Affairs TV Broadcasting. 
Channel www.mib.nic.in 
18. Commodity Exchanges 49%(FD FIPB FII 	purchases 	shall 	be 
I+FII) restricted 	to 	secondary 
Investme market only. 
nt by No 	foreign 	investor/entity, 
Register including persons 	acting 	in 
ed FII concert, will hold more than 
under 5% of the equity in 	these 
PIS will companies. 
be 
limited 
to 23°,'0 
and 
investme 
nt under 
FDI 
canying packages, 
parcels and other items 
which 	do not 	come 
within the ambit of the 
Indian Post Office Act, 
1898. 
21. Credit Information 
Companies 
Scheme 
limited 
to 26%. 
19. Construction 100% Autom 
Development 	projects, atic 
including 	housing, 
commercial 
premises, 	resorts, 
educational 
institutions, 	recreational 
facilities, 	city 	and 
regional level 
infrastructure,  
townships. 
Note:: 	FDl 	is 	not 
allowed in Real 	Estate , 
Business i 
Subject to conditions notified 
vide Press Note 2 (2005 
Series) including: 
a. minimum capitalization of 
US$ 10 million for wholly 
owned subsidiaries and i.S$ 
5 million for joint venture. 
The funds would have to be 
brought within six months of 
commencement of business 
of the Company. 
b. Minimum area to be 
developed under each 
project- 10 hectares in case of 
development of serviced 
housing plots; and built-up 
area of 50,000 sq. mts. in 
case 	of 	construction 
development project; and any 
of the above in case of a 
combination project. 
[Note 1: For investment by 
NRls. 	the 	conditions 
mentioned in Press Note 2 
2005 are not applicable. 
Note 2: For investment in 
SEZs, Hotels & Hospitals, 
conditions mentioned in Press 
Note 2(2005) are not 
Subject to existing laws and 
exclusion of activity relating 
to distribution of letters, 
which is exclusively reserved 
for 	the 	State. 
www.indiapost. gov.in 
49 % 	FIPB Foreign Investment in CIC 
(FDI+FII 	will be subject to Credit 
Information 	Companies 
lnvestme 	(Regulation) Act, 2005. 
Lit by Flt investment will be subject 
Register 	to the conditions that 
ed FII (a) No single entity should 
under 	i 	directly or indirectly hold 
PIS will more than 10% equity 
he (b) Any acquisition in excess 
limited of 	1% 	will 	have 	to 	be 
to 24% reported to RBI as a reporting 
only in requirement; and 
the CICs (c) Flls 	investing 	in 	CICs 
listed at shall 	not 	seek 	a 
the representation on the Board 
Stock of Directors based upon their 
Exchang shareholding. 
es within 
the 
overall 
limit of 
49% 
foreign 
investme 
nt. 
22. Industrial Parks both 100% Autom Conditions 	in 	Press 	Note 
setting up and in atic 2(2005) 	applicable 	for 
established Industrial construction 	development 
Parks projects 	would 	not 	apply 
provided the Industrial Parks 
meet 	with 	the 	under- 
mentioned conditions- 
i. it 	would 	comprise 	of a 
minimum of 10 units and no 
single unit shall occupy more 
than 50% of the allocable 
area; 
ii. the minimum percentage 
of the area to be allocated for 
industrial activity shall not be 
less than 66% of the total 
allocable area. 
23. Insurance 26% Autom Subject to licensing by the 
atic Insurance 	Regulatory 	& 
Development Authority 
www.irda.nic.in 
24. Investing 	companies 	in 100% FIPB Where there is a prescribed 
infrastructure / 	services cap for foreign investment, 
sector (except telecom only 	the 	direct 	investment 
sector) will be considered for the 
prescribed 	cap 	and 	foreign 
investment 	in 	an 	investing 
company will not be set off 
against this cap provided the 
foreign direct investment in 
such investing company does 
not 	exceed 	49% 	and 	the 
xxv 
management of the investing 
tympany is with the Indian 
owners. 
Non-Banking Finance Companies 25. 
Merchant 100% Autom Subject to: 
i) Banking atic a. 	minimum 	capitalization 
norms for fund based NBFCs 
ii) Underwriting 	portfolio - 	USS 	0.5 	million 	to 	be 
Management Services brought upfront for FDI up to 
iii) Investment Advisory 51%; US$ 5 million to be 
Services brought 	upfront 	for 	FDI 
iv) Financial Consultancy above 51% and up to 75%; 
and US$ 50 million out of 
v) Stock Broking which US$ 7.5 million to be 
brought 	upfront 	and 	the 
vi) Asset balance in 24 months for FD[ 
Management beyond 75% and up to 100%. 
vii) Venture Capital 
it 	minimum 	capitalization 
viii) Custodial Services norms 	for 	non-fund 	based 
NBFC 	activities- 	US$ 	0.5 
ix) Factoring million. 
x) Credit Rating c. foreign investors can set up 
Agencies 100% operating subsidiaries 
xi) Leasing & Finance without 	the 	condition 	to 
disinvest a minimum of 25% 
xii) Finance of its equity to Indian entities 
subject to bringing in US$ 50 
xiii) Housing million 	without 	any 
Finance restriction 	on 	number 	of 
xiv) Forex Broking operating subsidiaries 
without 	bringing 	additional 
xv) Credit card capital. 
Business 
xvi) Money d. 	joint 	venture 	operating 
changing business NBFC's that have 75% or 
xvii) Micro credit less 	than 	75% 	foreign 
Rural credit investment 	will 	also 	be 
xiii) allowed to set up subsidiaries 
for undertaking other NBFC 
activities 	subject 	to 	the 
subsidiaries 	also 	complying 
with the applicable minimum 
capital inflow. 
e. 	compliance 	with 	the 
guidelines of the RBI. 
xxvi 
f. 	The 	minimum 
capitalization 	norms 	would 
apply 	would 	be 	applicable 
where the foreign holding in 
a 	NBFC(both 	direct 	and 
indirect) 	exceeds 	the 	limits 
indicated at (a) above 
26 	 j Petroleum & Natural Gas sector 
a.  Refining 49% in FIPB Subject to Sectoral policy 
case of (in case www.pctroleum.nic.in and no 
PSUs of divestment 	or 	dilution 	of 
100% in PSUs) domestic 	equity 	in 	the 
case of Autom existing PSUs. 
Private atic 
compani (in case 
es of 
private 
compa 
hies) 
b.  Other than 100% Autom Subject 	to 	sectoral 
Refining and atic regulations 	issued 	by 
including market Ministry 	of 	Petroleum 	& 
study and Natural Gas 
formulation; www.petroleum.nic.in 
investment/ 
financing; setting 
up infrastructure 
for marketing in 
Petroleum & 
Natural Gas 
sector. 
27. Print i'ledia 
a.  Publishing of 26% FIPB Subject to Guidelines notified 
newspaper and by Ministry of Information & 
periodicals Broadcasting. 
dealing with www.mib.nic.in 
news and current affairs 
b.  Publishing of 100% FIPB Subject to guidelines issued 
scientific by Ministry of Information & 
magazines/ Broadcasting. 
specialty www.mib.nic.in 
journals,  
periodicals 
28. Telecommunications 
u. Basic and 74% Autom Subject to guidelines notified 
cellular, Unified (Includin atie in the PN 3(2007) 
Access Services, g up to 
National/ F. FTI, 49%. 
International NRI. FIPB 
Long Distance, FCCBs, beyond 
V-Sat, Public ADRs, 49%. 
Mobile Radio GDRs, 
Trunked converti 
Services ble 
(PVTRTS), preferen 
Global Mobile ce 
Personal shares, 
Communications and 
Services proportio 
(GMPCS) and - 
other value nate 
added telecom foreign 
services equity in 
Indian 
promoter 
si 
Investing 
Compan 
b. ISP with 74% Autom Subject 	to 	licensing 	and 
gateways, radio- atic security requirements notified 
paging, end-to- up to by 	the 	Dept. 	of 
end bandwidth. 49%. Telecommunications. 
FIPB www.dotindia.com 
beyond 
49%. 
C. (a) ISP without 100% Autom Subject to the condition that 
gateway, atic such companies shall divest 
(b) infrastructure up to 26% of their equity in favour 
provider 49%. of Indian public in 5 years, if 
providing dark FIPB these companies are listed in 
fibre, right of way,duct beyond other parts of the world. Also 
space,tower (Category 1); 49%, subject 	to 	licensing 	and 
(c) electronic security requirements, where 
mail and voice required. 
mail www.dotindia.com 
d. Manufacture of 100% Autom Subject 	to 	sectoral 
telecom atic requirements. 
equipments www.dotindia.com 
29. 	Trading 
a.  Wholesale/cash 100% Autom 
& catry trading atic 
b.  Trading for 100% 
exports Autom 
die 
c.  Trading of items 100% Subject to the condition that 
sourced from small scale the test marketing approval 
sector FIPB will be for a period of two 
years 	and 	investment 	in 
setting 	up 	manufacturing 
d.  Test marketing 100% facilities 	eomonrences 
of such items for which a simultaneously 	with 	test 
company 	has 	approval FIPB marketing. 
for manufacture 
Subject to guidelines for FDI 
in 	trading 	issued 	by 
c. Single Brand 51% Department 	of 	Industrial 
product retailing Policy & Promotion vide 
FIPB Press Note 3 (2006 Series). 
30. Satellites - 74% FIPB Subject to Sectoral guidelines 
Establishment issued 	by 	Department 	of 
and operation Space'ISRO 
www.isro.org 
31. Special 100% Autom Subject to Special Economic 
Economic Zones atic Zones 	Act, 	2005 	and 	the 
and Free Trade Foreign Trade Policy. 
Warehousing www.sczindia.nic.in 
Zones covering 
setting up of these Zones 
and setting up units in 
the Zones 
Source :Gnvernnunt of India, Mini. try of Commerce & Industry, Department of Industrial Policy & 
Promotion, SIA(FC Section), Press Note 7 2t 0081 
Appendix-II: Top Ten Pharmaceutical Companies with R&D Investment of the 
World (2009). 
In USS Billion and % 
S.1o. Company Global 
R&D 2008 Top Selling drug  Expenditure 
Pfizer 44.2 7.9 Liptor-12.4 
(USA) (5.7) (17.9) Lyrica-2.6 Celebrax-2.5 
GSK 43.0 5.2 Serctide/Advair-6.0 2  Valtrex-1.7 (UK) (5.6) (12.1) Lamictal-1.4 
Sanoti Aventis 38.7 6.5 Lovenox-39 
3' (France) (5.0) (16.8) Plavix-3.7 Lantus-3.5 
Novartis 36.0 7.2 DiovaniCodiovan-5.7 4. (Switzerland) (4.7) (20.0)  Gleevec/Glivec-3.7 Zometa- 1.4 
Astra Zeneca 31.6 5.1 Nexium - 5.2 
5' (UK) (4.1) (16.1) Seroquel -4.5 Crestor-3.6 
Johnson & Remicade-3.7 
6. Johnson 24.6 5.1 Topamax- 2.7 
(USA) (3.2) (20'7) Procrit - 2.5 
Merck 23.6 4.8 Singulair 4.4 
7' (USA) (3.1) (20.3) Cozaar/Hyzaar 3.6 Fosamax 1.6 
Roche 21.0 7.2 Mabthera/Rituxan 5.6 8.  (Switzerland) (2.7) (34.3) Avastin 4.9 Herceplin 4.8 
Zyprexa - 4.7 
9.  Eli Lilly (.) (19g)  Cy nbalta 2.7 
Gemzar - 1.6 
Wyeth 19.0 3.4 Effexor 3.9 10.  (USA) (2.5) (17.9) Prevnac 2.7 Enbrel 2.6 
Note: Figure are in parenthesis are in percentage are getting on the total global sales 
in 2008 ($773 billion) 
Source: 	http//www.scribed.com/doc/21016515/top-5pharmaceutical companies 
pharm-exec 
xxx 
Appendix-I11: Some Major Potential Patent Expirations (2009-2011). 
Brand Name Company indication 2008 Sales (USS million) 
2009 
vacid Novartis Ulcers.  Gastroesopha.el reilux disease 
X948  
` 
Topamax Ortho-McNeil Seizure disorders, nmig;raine, headache 2356 
Valtrex GSK Viral infections 2020 
Adderall XR Shire Attention deficit hyper activity disorder 1585 
Ambien CR Sanofi Aventis In somhia 986 
Pulmicort 
Res pules AstraZeneca Asthma 876 
Cell Cept Roche "Trans plant rejection 777 
Clarinex Sherin  Allergies 251 
Fosamax Plus D Merck Osteoporosis 240 
Casodex AstraZeneca Prostate cancer 228 
Prandin Novo Nordisk Type 2 diabetes 153 
2010 
Effexor XR \Vycth Depression, anxiety panic disorder 2791 
Flomax Boehringer Inglheim Benigin Prostatic Hypertrophy 1318 
Cozaar Merck High Blood Pressure 731 
Arimidex Astra Zeneca Breast Cancer 617 
Hyzaar Merck High Blood Pressure 548 
Aldara Graceway Actinic Keratosis genital warts, skin cancer 375 
Mirapex Boehringer In elheim Restless legs Syndrome 344 
Differin Galderana Acne 282 
Astelin Meda Allergic rhinitis 273 
Ra amune Wyeth Transplant rejection 136 
2011 
Li 	itor Pfizer High Cholestrol 6392 
Actos Takeda Type I1 diabetes 2569 
Zyprexa Lilly Schizophrenia, Bipolar Disorder 1853 
Leva uin Ortho-McNeil Bacterial infections 1719 
Arice t Eisai Al zheimers disease 1224 
Xalatan Pfizer Glaucoma, Ocular hypertension 494 
Caduct Pfizer High Blood Pressure 418 
Patanol Alcoa Allergic Conjuctivitis 256 
Ternodar Schering Brain Cancer 224 
Tazorac  Alloran Acne 109 
Accolate Astra Zeneca Asthma . 44 
Note: Ranked by US Sales 
Source: Meed Cos 2009 Drug 'Trend Report 
Appendix-I\': Major NCEs Pipeline of Indian Companies. 
Company with code 	 Indication 	 Status 
Dr. Reddv's Lab 
DRL I "422 Dyslipidemia, atherosclerosis and 
associated cardiovascular diseases. Phase I 
DRF 2593 Diabetes Licensed out to Rheoscience in 2004, 
now in Phase III 
DRF 1042 Oncology Abandoned after partner Clintech 
couldn't raise fund for Phase 11 
DRF 10945(Perlecan) Metabolic disorder Phase I completed —showed little 
progress so was abandoned 
DRL 11605 Metabolic disorder Preclinical abandoned in 2007 
DRL 16536 Metabolic disorder Preclinical abandoned in 2007 
DRF 4848 Anti-inflammatory Preclinical abandoned in 2003 
DRF 3188 Cancer. viral infections and immuno 
stimulation 
Preclinical abandoned in 2003 
DRF 4158 Insulin sensitizer for type 2 diabetics Out-licensing partner Novartis 
suspended clinical trials in Jan. 2002 
DRF 2725 Insulin sensitizer for type 2 diabetics Out-licensing partner Novo Nordisk 
suspended clinical trials in 2002 
Glenmark 
GRC 3886 	 Chronic obstructive pulmonary 	Trials on COPD proved inconclusive. 
disease, asthma 	 Test are on for asthma 
GRC 8200 Diabetes type 2 Phase II completed 
GRC 6211 Osteoarthritic pain, incontinence. 
neuropathic pain 
Out-licensing partner Eli Lilly 
suspended clinical trials in early 
October 2008. 
GRC 4039 Rheumatoid arthritis, multiple 
sclerosis 
Phase I completed 
GRC 10693 Neuropathic pain, osteoarthritis and 
other inflammatory pain 
Phase I completed 
GRC 15300 Pain In phase I trials 
GBR 500 Sclerosis, inflammatory disorder In phase I trials 
GBR 600 	 Anti platelet, adjunct to PCU acute 	In phase I trials 
coronary syndrome 
Lupin 
LL 4858 Anti-TB In phase 11 	trials 
LL 3348 Anti 	soriasis In phase II trials 
LL 4218 Anti- psoriasis In phase II trials 
LL 2011 Anti-migraine In phase III trials 
Piramal Healthcare 
P 276 Mantle cell lymphoma, malignant 
melanoma, multiple myeloma and 
head and neck cancer 
In phase 11 	trials 
P 1446 Once logy In phase I trials 
P1736 Type 2 diabetes In phase I trials 
IIPS 31807- I HF* Rheumatoid and psoriasis Phase 11 completed 
IIPH 30907* Dermatology Phase II completed 
1IPB 00105-Ber-A01 * Chronic myeloid leukemia In phase 1 11 
PP 9706642* Herpes Preclinical development 
P 3914 Non-steroidal anti-inflammatory drug Preclinical development 
PM 181104 Methicillin-resistant staphylococcus 
aureus \"ancuHrvem-resistant 
Preclinical development 
cnterococcu 
Ranbaxv 
RBX 11160 Malaria In phase ill 
RX 9341 Urinary incontinence Phase I completed 
RBX 7796 Allergic rhinitis and asthma phase 11 clinical trial 
RBX 10558 ll slipidemia phase II clinical trial 
RBX 2258 Benign prostatic hyperplasia Triials suspended by out-licensing 
partner Schwarz phurma in Nov. 2004 
RBX 7644 Anti-bacterial Development suspended during phase 
II in 2003 
RBX 9001 Benign prostatic hyperplasia Development suspended during 
reclnical development in 2003 
REX 6198 Benign prostatic hyperplasia 	Development suspended during 
preclinical develo meet in 2003 
Wockhardt 
WCK 771 Antibiotic Phase 11 clinical trial 
WCK 1152 Respiratory infection Phasc I clinical trial 
WCK 2349 Respiratory infection Phase I clinical trial 
WCK 4873 Toxicity Pre-clinical stage 
Zvdus 
Cadilahealthcare 
ZYHI Dysli idemia In phase lii 
ZYH2 Diabetes In phac I 
ZYH7 D sli idemia In phase 
ZY1400 	 Inflammation and pain 	 In haseI 
Sun Pharma 
SUN 1334H Allergic rhinitis perennial rhinitis 
urticaria 
Going on in phase III 
SUN 44 CNS related disorder Pre-clinical stage 
SUN 09 Muscles asticity Pre-clinical stage 
SUN 461 Asthma Pre-clinical stage 
Now 	This list is not exhaustive, numbers of other NCL are at various stages of development by Indian 
Companies Details are not available in annual report on web sites. 
• Refer to herbal drugs 
Source: Compiled from Company amival report and websites. 
Appendix-V: Statistical Description. 
Model 1: OT S, using observations 1991-2008 (T = 18) 
Dependent variable: Investment 
Coefficient 	Sid. Error 	t-ratio p -value 
const -326.059 	237.91 	-1.3705 0.19373 
FDIPI -0.0860531 	1.20843 	-0.0712 0.94431 
Export 0.666618 	0.2492 	2.6750 0.01908 ** 
TotalProductio 0.00675118 	0.102077 	0.0661 0.94827 
Profit 0.127784 	0.324877 	0.3933 0.70045 
Mean dependent var 1027.372 	S.D. dependent var 1282.483 
Sum squared resid 750567.8 	S.E. of regression 240.2831 
R-squared 0.973157 	Adjusted R-squared 0.964897 
F(4, 13) 117.8226 	P-value(F) 4.49e-10 
Log-likelihood -121.2848 	Akaike criterion 252.5696 
Schwarz criterion 257.0215 	llannan-Quinn 253.1835 
rho 0.520709 	Durbin-Watson 0.957345 
Model 2: OLS, using observations 1991-2008 (T = 18) 
Dependent variable: Total Production 
Coefficient 	Std. Error 	t-ratio p-value 
const 2195.74 	327.421 	6.7062 0.00001 	*** 
FDIPI 0.776981 	3.27639 	02371 0.81624 
Profit 0.645916 	0.869542 	0.7428 0.47080 
Investment 0.0498239 	0.753328 	0.0661 0.94827 
Export 2.24207 	0.569116 	3.9396 0-00169 	*** 
Mean dependent var 6868.367 	S.D. dependent var 4463.493 
Sum squared resid 5539213 	S.E. of regression 652.7582 
R-squared 0.9S3645 	Adjusted R-squared 0.978613 
F(4, 13) 195.4665 	P-value(F) 1.Sle-II 
Log-likelihood -139.2738 	Akaike criterion 288.5476 
Schwarz criterion 292.9995 	Hannan-Quinn 289.1615 
rho 0.677381 	Durbin-Watson 0.479206 
xxxv 
Model 3: OLS. using observations 1991-2008 (T = 18) 
Dependent variable: Export 
Coca//icient 	Sc]. Error 	t-ratio p-value 
-342.258 	206.743 	-1.6555 0.12176 
-0.0868289 	1.08006 	-0.0804 0.9371 5 
0.242714 	0.0616095 	3.9396 0.00169 	*** 
-0.0026928 	0.292105 	-0.0092 0.99278 
0.532576 	0.199091 	2.6750 0.01908 	** 
1862.207 	S.D. dependent var 1758.673 
599646.1 	S.E. of regression 214.7711 
0.988596 	Adjusted R-squared 0.985086 
281.7254 	P-value(F) 1.74e-12 
-119.2644 	Akaike criterion 248.5288 
252.9807 	Hannan-Quinn 249.1427 
0.567258 	Durbin-Watson 0.743543 
const 
FDIPI 
Total Productio 
Profit 
Investment 
Mean dependent var 
Sum squared resid 
R-squared 
F(4, 13) 
Log-likelihood 
Schwarz criterion 
rho 
Model 4: OLS, using observations 1991-2008 (T = 18) 
Dependent variable: Profit 
Coefficient 	Sid. Error 	1-ratio p-value 
const -121.372 	213.363 	-0.5689 0.57915 
FDIPI 1.86564 	0.885687 	2.1064 0.05516 
Investment 0.0920361 	0.233991 	0.3933 0.70045 
Export -0.00242762 	0.263339 	-0.0092 0.99278 
Total Productio 0.0630374 	0.084862 	0.7428 0.47080 
Mean dependent var 577.4833 	S.D. dependent var 587.5560 
Sum squared resid 540593.6 	S.E. of regression 203.9219 
R-squared 0.907886 	Adjusted R-squared 0.879544 
F(4, 13) 32.03255 	P-value(F) 1.28e-06 
Log-likelihood -118.3314 	Akaike criterion 246.6627 
Schwarz criterion 25I.1 146 	Hannan-Quinn 247.2766 
rho 0.125665 	Durbin-Watson 1.594459 
xxxvi 
Model 5: OLS. using observations 1991-2008 (T = 18) 
Dependent variable: FDIPI 
Coe%f cient 	Std. furor 	t-ratio p-vahte 
const -7.26783 	58.3691 	-0.1245 0.90281 
Export -0.00572278 	0.0711855 	-0.0804 0.93715 
Total Productio 0.00554371 	0.0233768 	0.2371 0.81624 
Investment -0.00453121 	0.0636308 	-0.0712 0.94431 
Profit 0.136394 	0.0647511 	2.1064 0.05516 
Mean dependent var 94.26111 	S.D. dependent var 100.9064 
Sum squared resid 39521.88 	S.E. of regression 55.13751 
R-squared 0.771676 	Adjusted R-squared 0.701423 
F(4, 13) 10.98416 	P-value(F) 0.000407 
Log-likelihood -94.78903 	Akaike criterion 199.5781 
Schwarz criterion 204.0299 	Hannan-Quinn 200.1919 
rho -0.279627 	Durbin-Watson 2.498313 
Model 6: OLS, using observations 1995-2008 (T = 14) 
Dependent variable: Employment 
Coefficient 	Std. Error 	t-ratio Jp-i'altre 
36246.1 	49611.3 	0.7306 0.48587 
-24.6071 	56.4256 	-0.4361 0.67429 
-111.332 	40.6183 	-2.7409 0.02541 	** 
55.3844 	17.6482 	3.1382 0.01384 	** 
-9.1821 	15.7628 	-0.5825 0.57626 
14.531 	13.008 	1.1171 0.29638 
243872.2 	S.D. dependent var 51406.62 
9.93e+08 	S.E. of regression 1 1 138.87 
0.971 107 	Adjusted R-squared 0.953049 
53.77695 	P-value(F) 6.07c-06 
-146.4026 	Akaike criterion 304.8052 
308.6395 	1-lannan-Quinn 304.4502 
-0.114040 	Durbin-Watson 2.173104 
const 
FDIPI 
Export 
Total_Productio 
Profit 
Investment 
Mean dependent var 
Sum squared resid 
R-squared 
F(5, 8) 
Log-likelihood 
Schwarz criterion 
rho 
